Longevity Wiki - User contributions [en-GB]

Gotu Kola

2021-10-27T08:20:38Z

Schulzm: Added Draft Banner

{{Draft-article}}

Gotu kola (also known by its scientific name ''Centella asiatica'') is an herb in the parsley family used in traditional Chinese and Ayurvedic medicine (two forms of complementary and alternative medicine).<ref name=":0">Gohil, K., Patel, J., & Gajjar, A. (2010). Pharmacological review on Centella asiatica: A potential herbal cure-all. ''Indian Journal of Pharmaceutical Sciences, 72''(5), 546. <nowiki>https://doi.org/10.4103/0250-474X.78519</nowiki></ref><ref name=":1">''Gotu kola: Overview, uses, side effects, precautions, interactions, dosing and reviews.'' (n.d.). Retrieved June 8, 2021, from <nowiki>https://www.webmd.com/vitamins/ai/ingredientmono-753/gotu-kola</nowiki></ref><ref>''What is Ayurveda?'' (n.d.). WebMD. Retrieved June 8, 2021, from <nowiki>https://www.webmd.com/balance/guide/ayurvedic-treatments</nowiki></ref><ref>''What is traditional Chinese medicine?'' (n.d.). WebMD. Retrieved June 8, 2021, from <nowiki>https://www.webmd.com/balance/guide/what-is-traditional-chinese-medicine</nowiki></ref>

Gotu kola is native to tropical and subtropical parts of Asia, and it should not be confused with kola nut, as it does not contain caffeine and has not been shown to have stimulant properties.<ref name=":0" /><ref name=":2">''Gotu kola: Health benefits and side effects.'' (2020, March 10). <nowiki>https://www.medicalnewstoday.com/articles/gotu-kola-benefits</nowiki></ref> It is used to treat burns, poor circulation, schistosomiasis, atherosclerosis, and many other conditions.<ref name=":1" /><ref name=":2" /> Some also claim that gotu kola can benefit the brain and nervous system, increasing attention span and concentration, and improving memory.<ref name=":0" /><ref name=":2" /> However, scientists have not yet performed sufficient research to justify these uses of gotu kola, with the exceptions of second-degree burns, varicose veins, and venous insufficiency.

Gotu kola does appear to accelerate the healing process when applied to second-degree burns, and taking gotu kola (or Centellase, an extract of it) by mouth seems to improve blood circulation and reduce swelling in people with poor blood circulation in the legs. Its effect on blood circulation and swelling lets it serve as a treatment for varicose veins (a vein condition causing itchy skin, swelling, and aching in the legs, which becomes more likely as patients age) and venous insufficiency (in which veins have problems moving blood from the legs to the heart).<ref name=":1" /><ref>''The basics of varicose veins.'' (n.d.). WebMD. Retrieved June 12, 2021, from <nowiki>https://www.webmd.com/skin-problems-and-treatments/understanding-varicose-veins-basics</nowiki></ref><ref>''Venous insufficiency: Medlineplus medical encyclopedia.'' (n.d.). Retrieved June 12, 2021, from <nowiki>https://medlineplus.gov/ency/article/000203.htm</nowiki></ref>

It should be noted that science has not found evidence ''against'' gotu kola's effectiveness against other conditions; it simply has not found evidence ''for'' gotu kola's effectiveness. An exception is radiation dermatitis (a type of skin damage), as some research has shown that a cream containing gotu kola extract does not reduce the severity of radiation dermatitis from breast cancer treatments.<ref name=":1" />

== Citations ==
<references />

Handbook:Content Writer Meetings

2021-10-19T11:48:27Z

Schulzm: 19/10/21 Meeting Notes

== 19/10/2021 ==

=== 🧍 Attending ===
*Jack Harley
*Ben Wu
*Lindsay Ciocco
*Lara Milwid
*Maximilian Schulz

=== 📣 Updates ===

* Updates on Pillar Articles:
** Introductory Article: Max Schulz wants to contribute starting November (but first version is done)
** COVID and Aging Article (Ben): Wants it to be reviewed by Max Schons (for example)
** Epigenetic Repgoramming: Ben is just fixing the last grammar errors and wants to put it up for review then
** Biomarkers of Healthspan: Max Schons wrote a first version on Google Docs, Max Schulz should reach out and review the docs
** Aging and Neurodegeneration: Only sections that Habakuk wrote in Google Docs should be migrated to the wiki article, then ready for review
* Lara Milwid started writing about Negligible senescence and Telomeres, shared questions around citations and diagrams (see action items)
* We talked about ways to access scientific papers:
** [https://pubmed.ncbi.nlm.nih.gov/ PubMed] often has open access
** [https://sci-hub.se/ Sci-Hub] and [https://libgen.is/ Library Genesis] together give access to most papers (preferred search via DOI number)
* We agreed that Max Schulz and Jack Harley will reach out to content writers next week
* We discussed that we should evaluate to move the content writer meeting to the weekend to give more people access (should be decided via a poll)

{| class="wikitable"
|
===✅ Action Items===

*Give some guidance on how and where to cite sources in articles (e.g. citing at the end of a paragraph if the whole content is from one source) (Jack)
*Remove the warning in the handbook that states we should not use any external figures. It was clarified that as a non-profit, educational organization we can include any figure as long as we cite the source and remove it upon request by the original author. (Jack)
*Follow-up with content writers and create a poll to check if we should move the meeting to weekends
*
|}
== 21/09/2021 ==

===📓Preparation Notes===
''Max Schulz:''

* New process for draft articles created (see [https://en.longevitywiki.org/wiki/Handbook:Handbook#:~:text=The%20Contribute%20menu-,Create%20a%20page,-%5Bedit%5D Handbook], to be shared at the next content writer meeting as well):
**[[Template:Draft-article|Draft Article banner template]] should be added to beginning of article via <nowiki>{{ Draft-article }}</nowiki> (without spaces), automatically adding a banner and the "Drafts" category (maybe in the future add automatically for new pages/articles?)
**Moved some (non-glossary) articles into Drafts that were very obvious ([https://en.longevitywiki.org/wiki/Articles#:~:text=Risk%20Factor-,Drafts,-%5Bedit%5D Articles Drafts Section])
**Note: The DPL Extensions on the Articles page take a while to update the lists when articles are moved between categories ([[mediawikiwiki:Topic:Qdku9ow0v2z2krrv|MediaWiki Topic]] | [https://phabricator.wikimedia.org/T13685 Related Issue])
*Proposal: New category of articles (Category: "Ethics")
**We distinguish between "Scientific" (Category: Longevity, should be changed) and "Ethical" articles on longevity
**No planned articles yet, should come from the community
**Ethical articles should also conform to a Wiki standard, presenting both sides of an argument and trying to be as objective as possible (compared to more biased articles, e.g. from Lifespan.io.

=== 🧍 Attending ===
*Jack Harley
*Ben Wu
*Stuart McWhinny
*Lindsay Ciocco
*Sharon Wong
*Robin Howlett
*Andreas Lie Massey
*Timothy Porterfield

=== 📣 Updates ===
''Jack Harley:''

* The Trello board is the key organizational hub for content creation
* Articles in progress should be assigned a Trello card with a link to the Wiki page.
* The [[Handbook:Handbook|Handbook]] is the centralized knowledge base - for any questions, refer to this resource
* Content writers may ask for assistance in the 'content writers' channel of Discord
* Has begun work on ''Aging and Neurodegeneration'' article which will be completed in 1-2 weeks' time
* Jack and Ben Wu are happy to assist with researching content for the Wiki
* Content writers can feel free to suggest new topics in the 'unassigned' tab of the Trello board
* Ethical articles should be less biased, as per Max's point
* Content writers meetings will be at this same time (10.30 am London time / 9.30 am GMT / 11.30 am CET / 7.30 pm AEST / 5.30 am ET) every ''two weeks''. The next meeting will be on the 5th of October.

''Sharon Wong:''

* Has created a translation guide, which has been posted in the Discord server. Is seeking feedback and advice before it is added to the Handbook.

''Andreas Lie Massey:''

* Will resume working on the ''Fisetin'' article once exams have concluded.

''Stuart McWhinny:''

* Is beginning work on ''Blue Zones'' article
* Is managing the [https://discord.gg/JrXv42jUyS Discord server] and encouraged feedback for the server to be directed to him for implementation. The goal is to ensure the server is welcoming to new volunteers.
* Encouraged content writers not to be shy, as the Wiki is an ongoing, collaborative process and mistakes can be corrected as the content is expanded.

''Ben Wu:''

* Noted that the '<nowiki>{{ Draft-article }}</nowiki> ' text required to be added to the beginning of an article to categorise it as a 'draft' ''must be copied and pasted'', and cannot be typed.

''Timothy Porterfield:''

* Has completed two articles, on ''Gotu Kola'' and ''Mitochondrial Dysfunction.'' Wanted to know whether he should post Google Docs content on the Wiki. It was decided that all content should be drafted and edited on the Wiki itself.

''Robin Howlett:''

* Seeking assistance for 'Longevity and Equality' article. Ben, Stuart and Jack provided links and references on this topic.

== 07/09/2021 ==

===📓Preparation Notes===
''Max Schulz:''

*'''Proposed Content writer meeting process'''
** Introductions by new members (short, 1 min / person):
***Name & where you are based
***Background & interest in longevity
***What topics you want to contribute to
**Meeting notes writer?
**Content writer manager (Max) sharing process & technology updates
**Going through pillar articles updates (content, reviews, contributions)
**Round table: Unblocking writers - suggestions what to write on, asking for reviews etc.
* '''Proposed Trello board process'''
** Article writing is organized on the Trello board: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]
** Three kind of articles: "Pillar Articles" (Expert Knowledge), "General Articles" (Open to anyone) and "Glossary" (2-3 sentences description from a longevity perspective) | [[Articles]] page is now organised accordingly
***On Trello: Pillar articles are labeled (as well as the introductory article)
*** Categories to use when saving articles: "Pillar Articles", "Longevity", "Glossary" '''(handbook has to be updated accordingly)'''
**Trello board organisation:
***Unsassigned for article ideas
***Assigned when someone wants to write an article
***Once working on a draft: In progress
*** When finished with a first draft: In Review (merged past columns)
***When reviewed by at least one other writer in the group: Completed
** Articles are never '''really''' done, as science progresses, so if you want to add something meaningful - please do so and share your idea both on Trello and this meeting!
**Feel free to add ideas about the processes & tools either in these meetings or on the Trello column "Feedback for tooling & organisation"!
**Non-structured contributions: Just get started writing on topics that interest you - the Trello board is to synchronise your efforts with the team and share your work!
*'''Process for creating drafts directly on Wiki:'''
**I think it would be great if we also wrote the drafts directly into the wiki; Instead of creating local google docs
**References from Wikipedia: [[wikipedia:Wikipedia:Drafts|Draft Namespace]] | [[mediawikiwiki:Draft_namespace|MediaWiki Draft Discussions]]
**Possibilities: change title, e.g. "[DRAFT] Biomarkers of healthspan", use Draft Namespace or Category, or simply add a template banner at the start of an article and/or section (used like this <nowiki>{{ Draft-article }}</nowiki>)
**Max simple proposal (for now): Add template banner and discuss directly on the draft, adding comments with the comment feature of the editor (see source)
*'''Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021'''
*Kindly ask all writers to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
*Meeting slot not set in stone, will send out a doodle again with more choice after this meeting (with ~10 days response deadline)

===🧍 Attending===

*Maximilian Schulz
*Jack Harley
*Ben Wu
*Joly Ghanawi
*Habakuk Hain
*Lindsay Ciocco
*Sharon Wong
*Robin Howlett

===📣 Updates===

*Introductions of all participants, newcomers:
**Habakuk Hain: Graduate with an MD and something like a Master’s in Molecular Biology from the University of Göttingen in 2022 - interested in contributing to Neurodegeneration article
**Robin Howlett: Non-technical background, interested in writing about the ethical implications of longevity
*Process updates shared, see Preparation Notes - in addition discussed:
**'''Drafting process: Draft Banner (using templates), Category "Draft" and using Editor comments to discuss'''
**It was brought up that we should make discussion pages visible to have discussions on existing articles as well
*Updates on pillar articles:
**Overview Article: Max Schulz and Ben to collaborate on this
**Rapamycin (Ben): Completed to a high standard, ready to share
**Epigenetic reprogramming (Ben & Lindsay): Requires a few additions, that are currently being worked on
**Aging and Neurodegeneration (Jack): Draft for aging and neurodegeneration article can be completed by the end of September. Habakuk could collaborate?
**COVID-19 and Aging (Ben): Max Schons can begin work on this after completing the biomarkers of healthspan piece (additional perspective of infectious disease research)
*Other longevity articles:
**References need to be added for calorie restriction article - will be done by Joly
*New writers can contribute to ‘unassigned’ topics, in particular drugs purported to extend lifespan. The rapamycin article can be used as a ‘template’ – specifically the subheadings (Note: process should be added to handbook)
*Sharon Wong: Will put together a table to summarise main challenges and points to note for the translation efforts
*In addition to the Wiki itself, discussions for specific articles can also be had in the ‘content writers chat’ channel on Discord - but the wiki is preferred whenever possible.

{| class="wikitable"
|
===✅ Action Items===

*Enable drafting process & document in the handbook (Max Schulz)
*Enable discussion pages on Wiki (Max Schulz)
*
|}

Negligible senescence

2021-10-19T09:49:18Z

Schulzm: Added comment about naked mole rats

== Definition ==
Negligible senescence refers to an absence of gradual deterioration with age, specifically an absence of:

# age-related increases in disease incidence and associated death rate;
# decrease in reproductive capability; and
# deterioration in physiological capacity, such as strength, mobility and sensory acuity.

It should be noted that negligible senescence is not synonymous with immortality. An organism that displays negligible senescence - i.e. no gradual deterioration - can still die of a sudden process, whether internal or external, such as predator attack, accident, starvation, exposure to adverse environmental conditions, disease or semelparity.

== Examples of animals considered negligibly senescent ==

==== Naked mole rat (Heterocephalus glaber) ====

The naked mole rat<ref>Buffenstein, R. (2008). Negligible senescence in the longest living rodent, the naked mole-rat: insights from a successfully aging species. ''Journal of Comparative Physiology B'', ''178''(4), 439-445.

</ref> is the only mammal known to meet all three criteria of negligible senescence:

''1. No age-related increases in disease incidence and associated death rate:''

In the first two months of life babies are at increased risk of death from inadequate maternal care, cannibalism by siblings and poor inoculation of gastrointestinal flora and fauna. However, after this initial period the rate of death by natural causes is distributed randomly among all age groups rather than showing any age-related increase, except towards the end of the maximum species life span (i.e. the longest a member of the species has been observed to live), when there is believed to be a sudden increase in death rate.

''2. No decrease in reproductive capability:''

Breeding females show no menopause or decline in fertility, even after age 30. In fact, litter size tends to increase with age, although the pups born to older breeders are at greater risk of dying before weaning, possibly because of inadequate milk supply or because of greater disturbance to the larger colonies where these older breeders tend to be found.

The long lifespan of breeding females casts doubt on most evolutionary theories of aging, which generally propose that there is a trade-off between fecundity and lifespan, as energy invested in reproduction is not invested in repairing and maintaining the body.

3. ''No deterioration in physiological capacity, such as strength, mobility and sensory acuity:''

Body composition is maintained from age 2 to age 24.

Naked mole rats have low susceptibility to disease. Notably, neoplasm has never been observed in this species.

=== Aldabra giant tortoise ===
Maximum observed life span: 255 years

=== Rougheye rockfish (Sebastes aleutianus) ===
Maximum observed lifespan: 205 years

=== Lobster ===
Scientists do not currently have a way of establishing the age of lobsters with certainty, but it has been estimated<ref>https://cdnsciencepub.com/doi/abs/10.1139/f99-116</ref> that male European lobsters in the wild have an average life span of 31 years and a maximum of 42 ± 5, while females have an average life span of 54 years and a maximum of 72 ± 9.

=== Lake sturgeon (Acipenser fulvescens) ===
Maximum observed life span: 152 years

=== Ocean quahog (Arctica islandica) ===
Bivalve molluscs <ref>Stenvinkel, P., & Shiels, P. G. (2019). Long-lived animals with negligible senescence: clues for ageing research. ''Biochemical Society Transactions'', ''47''(4), 1157-1164.</ref>provide the widest range of lifespans available for interspecies comparisons. The maximal lifespan in different populations of bivalve molluscs ranges from 36 for the Atlantic surfclam (Spisula solidissima) to >500 years for the ocean quahog (Arctica islandica), despite the similar size and living conditions. (Age is counted by growth rings on the shell).

=== Sea urchin ===
Sea urchins<ref>Bodnar, A. G. (2015). Cellular and molecular mechanisms of negligible senescence: insight from the sea urchin. Invertebrate reproduction & development, 59(sup1), 23-27. </ref> are widely used as model organisms for scientific research, part of their value being their close phylogenetic relationship to humans.

Sea urchins grow throughout their lives and can regenerate damaged appendages. Neoplasm is rare in these animals.

Some species of sea urchins show negligible senescence, and among these species there is a wide variation in maximum life span, ranging from 4 years (Lytechinus variegatus) to 100 years (Strongylocentrotus franciscanus).

Comparison between sea urchin species that show negligible senescence and those that do not and between species with different maximum life spans provides a useful opportunity to investigate factors affecting both aging and life span.

Studies of negligibly senescent sea urchins, of various species and with a range of maximum life spans, have shown maintenance of:

* telomeres;
* antioxidant and proteasome enzyme activities;
* cellular pathways involved in energy metabolism, protein homeostasis and tissue regeneration

They have also shown a lack of major age-related accumulation of oxidative cellular damage.

The findings suggest that negligible senescence relies on the maintenance of mechanisms that sustain tissue homeostasis and regenerative capacity.

== Strategies for engineered negligible senescence (SENS)<ref>Zealley, B., & De Grey, A. D. (2013). Strategies for engineered negligible senescence. Gerontology, 59(2), 183-189. </ref> ==
Achieving (‘engineering’) negligible senescence in humans would not necessarily require damage to be prevented; rather, it would entail repairing damage as it occurs, rapidly and effectively enough that the functioning of the whole organism is not compromised – just as a vintage car can be kept in good working order if wear and tear is regularly repaired.

=== Where in the aging process to intervene in order to engineer negligible senescence ===
Aging can be modelled as a three-stage process:

# '''Metabolism:''' Metabolic processes produce toxins, some of which are not completely removed by the body’s repair mechanisms.
# '''Damage:''' As the toxins accumulate, they cause damage.
# '''Pathology:''' The damage caused by the toxins drives age-related pathologies

Negligible senescence could be engineered by interrupting one of these stages.

Stage 1 (metabolism) and stage 3 (pathology) are difficult to intervene in because they are dynamic processes where an intervention can set off a cascade of results.

Stage 2 (damage) is a simpler target for intervention. This is because although damage itself can also cause dynamic reactions, ''removing'' damage is unlikely to do so. Furthermore, acting on stage 2 does not require an in-depth understanding of stages 1 and 3.

Intervening in stage 2 requires identifying types of damage for which intervention might be needed. As such damage is age-related, a useful way to identify it is to compare the damage found in young people with that found in older people.

Such damage appears to fall into seven categories:

# Cell loss
# Cell death resistance
# Cell overproliferation
# Intracellular ‘junk’
# Extracellular junk
# Tissue stiffening
# Mitochondrial defects

Efforts to develop strategies for engineered negligible senescence therefore focus on methods for mitigating each of the above types of damage, using either existing biotechnology or plausible extensions of it.

=== Why engineer negligible senescence? ===

# Compassionate motives: age-related deterioration has a negative impact on quality of life.
# Economic motives: resources have to be dedicated to supporting those suffering from age-related deterioration. The deterioration also compromises their ability to carry out productive work.

== Implications of deploying anti-senescence technologies widely ==
Widespread deployment of anti-senescence technologies would cause populations to surge. <ref><nowiki>https://www.sciencedirect.com/science/article/pii/S0040162515001985</nowiki> </ref>

==== Advantages ====

* The labor force would be larger and, on average, healthier, which would boost economic growth.

==== Disadvantages ====

* The cost of implementing the anti-senescence technologies could still outweigh the resulting economic growth in some countries.
* In order to finance citizens’ longer lives, governments would have to restructure their financing.
* It might be necessary to eliminate retirement.
* There would be much greater pressure on the environment.

<references />
[[Category:Longevity]]

Handbook:Meeting Minutes

2021-10-06T13:23:03Z

Schulzm: Adding notes for 06/10/21

== 06/10/2021 ==

=== 🧍 Attending ===
*Jack Harley
*Marc Smeehuijzen
*Maximilian Schulz
*Ben Wu
*Andreas Melhede
*Stuart McWhinney

=== 📣 Updates ===
''Jack Harley''

* Aging and Neurodegeneration article is almost complete (Draft found here: [[Aging and Neurodegeneration]])
* Not many attendees at yesterday's content writer meeting. Unsure if it's because it wasn't announced beforehand via mail & Discord
** We should understand the value of the meetings
* We should think about how to create incentives to contribute: Intrestingly enough though, Wikipedia seems to work quite fine without "special incentives"
* It should be a goal of the project to have tight collaborations with the [https://www.reddit.com/r/longevity/ longevity subreddit] (where Ben is the moderator) such that new information and Q&A is also added to the Wiki by community members
* Max Schons sent his article ("Biomarkers of healthspan") to Jack as a google docs (should be added to the Wiki)
* It is not clear if the "pillar articles" or "general articles" will be more relevant to readers, we should measure this after lunch to direct our efforts
* We need to get the message accross that the Wiki is open access. We could add a banner at regular intervals to motivate more contributions
* We need a launch plan; who to contact, what channels to use. The main people for this should be Marc, Andreas and Ben
** '''Specific launch date that should be announced: 15th of December 2021!'''

''Marc Smeehuijzen''

* It is currently not clear to a general audience what "pillar articles" mean, it should be clearly described in the articles section

''Ben Wu''

* "Epigenetic reprogramming" article is almost complete
* EyeWiki can be a good reference for acknowledging authors which are shown at the top of an article ([https://eyewiki.org/Glaucoma_Drainage_Devices example])

''Max Schulz''

* We may consider thinking about a process to promote general articles to pillar articles that have an "expert reviewer"

''Stuart McWhinney''

* On Fandom, there is a sidebar with most popular articles and recent updates that helps users navigate the content

{| class="wikitable"
|
===✅ Action Items===

* Jack: Schedule launch discussion in 2 weeks on 20th of October
* Max: Follow-up with content writers for onboarding and checking up on their involvement
* Andreas: Brainstorm about incentives for writers on the Wiki
* Stuart: Finalizing Discord badges, checking w/Max with regards to content writers
* Marc: Add explanations to the article page to be clear about what pillar articles represent
* Marc: Look into how to show the main authors of an article (minimal author profile with background on top of page)
* Marc: Talk with Bogdan to showcase launch date on website
*
|}
== 15/09/2021 ==

=== 🧍 Attending===
*Jack Harley
*Bogdan Dziewierz
*Maximilian Schulz
*Ben Wu
*Andreas Melhede
*Stuart McWhinney

===📣 Updates===
'''Change in meeting cadence:''' From now on, cross organisational meeting will only be every first Wednesday of the month. Separate meetings for engineering and content writer tasks.

''Bogdan''

*Engineering team has divided tasks on Jira and is working on them

''Maximilian Schulz''

*Will change all seperate board invitations to organisation invitations: [https://trello.com/invite/longevitywiki/46e20cd2037ee4cf6e326277218f8286 Trello invite link]
*Content writer meetings set up again: [[Handbook:Content Writer Meetings]]
**Created doodle for upcoming content writer meetings: [https://doodle.com/poll/pp9uysigaw66ddes Doodle Link]
**Started reaching out to interested people in the past for 1:1 onboarding. Content writer onboarding checklist (initially created by Jack): [https://docs.google.com/document/d/15pdBEzUpfEakZ4A-lSRAyfitRRQCUkQ5jR1779P4Y8E/edit Google Docs] (moved in the future)
**Sharing the process updates in the Content Writer meeting minutes instead
** On vacation with limited internet access 20/09 - 03/10. Jack Harley will lead the next content writer meeting
**The drafting & review process is quite simplistic and won't work in the future, we are aware that we need to work on this
*There seem to be quite many people interested in the ethical aspects of longevity research (e.g. recently Robin Howlett, check the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU/edit#gid=2043094641 Volunteer Survey responses]), however it's not part of the currently defined topics ([[Handbook:Handbook#Mission]]); Shall we add it? Does it fit to "wiki-style" content?
**Agreed that we distinguish between "Scientific" and "Philosophical/Ethical" articles on the topic
**No planned articles yet, can come from the community
**Consensus that there is a need for ethical articles that are objective to a Wiki standard (compared to more biased articles, e.g. from Lifespan.io)
*There are many lists on longevity managed by individuals, such as Karl Pfleger ([https://agingbiotech.info/diagnostics/ Diagnostics Example]) - I think it would make so much more sense to manage them in a community like Longevity Wiki, and also good to offer the primary source for these.
**Bogdan shared that he is already looking into the Semantic Wiki extension also as a data source for the life extension tool
*Not discussed in the meeting and followed up upon separately:
** Process for next organisational meeting should also include reviewing the Trello board
**Created public google calendar for LW Meetings, inviting everybody who manages meetings: [https://calendar.google.com/calendar/u/0?cid=NDA4YnV2MjhrNmk2aHU2ODhtZ29nZnBnbG9AZ3JvdXAuY2FsZW5kYXIuZ29vZ2xlLmNvbQ Calendar Link]
**It might make sense to look into the plugins Sam Voigt recommends such as the "Structured Discussions" Extension (see associated [https://trello.com/c/YQpe82tv/33-enable-discussion-forums-on-articles Trello Card])
''Stuart''

* It is currently difficult for newcomers to understand who to contact for what contributions, he along with Andreas Melhede will assign roles to the relevant people

{| class="wikitable"
|
===✅ Action Items===

* Bogdan: Meeting invitation is changed to first Wednesday of the month
*Max: Update Wiki to allow for "Philosophical Articles" as well
*Jack: Give Stuart admin access on Discord to assign roles
*
|}
==08/09/2021==
===🧍 Attending===
* Jack Harley
*Blake Delaney
* Marc Smeehuijzen
*Bogdan Dziewierz

===📣 Updates===
''Blake Delaney''

*Introduction: hedge fund manager, with programming, and bioscience background. Previously created a longevity wiki but did not gain traction at the time

* Wikipedia doesn't have the highest quality on longevity and cryonics topics as those with higher override capability often prevent a thorough review of the topic
*Media Wiki has the functionality for authors to be notified when their articles are updated - this can be applied to our project
*Created a 'Cryonics' page on the Wiki - should we keep it on the Wiki? Consensus was yes.
*Social funding could be used to raise funding for the Wiki
*Suggest he can fund AWS infrastructure
*Create a Lifespan.io project and pitch our organization to them to attract funding
*Crowdfunding on the Discord server
*Interested in joining the engineering team and will try to make it to this week's meeting
*Can support a member to create an application to register for a US charity
*There is significant work involved in maintaining charity status
*Alternatively, operate as an LLC and avoid most tax liability by spending as much as you earn
*Some US states have very minimal reporting requirements for LLCs.

''Marc''

*How should we provide feedback to each other's article?

*Discussion page makes sense for feedback to specific articles
* Benefit of our Wiki is that it allows for more speculative topics than Wikipedia, such as longevity science and cryonics

''Jack''

*Provided update on content writers meeting
*Block updates to 'Pillar' articles once completed to avoid vandalism
* Can keep the 'cryonics' page on the Wiki, though, pending reaching out to science and medical organizations for content writing

''Sharon Wong''

*Have a header that says, 'version active as of (date)' on multilingual pages to overcome the issue of translated articles requiring frequent updates
*Having issues uploading the image on the rapamycin article - @Bogdan to investigate
*Style and standardising translating terms into Chinese requires a standard glossary
*There is a need to stipulate the translation tool for those who are translating the wiki (e.g. DeepL)
*Need for the 'how to contribute' page on the Wiki Handbook to be updated with translation tasks.
*Higher bar for 'tax deductible status' in Australia. It's a good reason to avoid this for now, to avoid excessive paperwork.

''Bogdan''

*Will have to create 'drafts' namespace
*'Discussion' page associated with pages on the Wiki is currently active
*Discussion page can foster more discussion amongst non-Discord users of the Wiki
*Cryonics discussion brings up an interesting point - what is the included scope of the Wiki? Consensus was that anything 'life-span extending' related should be included. In particular topics that Wikipedia doesn't cover well.
*Updated the onboarding guide for new developers
*Life extension tool in-progress
*Sam Voigt has previously volunteered to pursue the pros and cons of registering as a non-for-profit - @Jack to get in touch
*UK may have a separate charity status to receive money if no goods or services (business-like activities)

==01/09/2021==

===🧍 Attending===

*Jack Harley
*Ben Wu
* Sharon Wong
*Marc Smeehuijzen
* Andreas Melhede

===📣 Updates===
''Jack Harley''

* Begun ''Aging and Neurodegeneration'' brainstorm and write-up. References and comments welcome.
*Collaborated with Max to create process for content writers (discussed below)
*Kindly ask all Wiki members to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
*[https://agingpharma.org/ ARDD Conference] has begun - good opportunity for Wiki members to learn more about the field - videos should be uploaded to the website for free viewing in the coming weeks.
*Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021

''Sharon Wong''

* Noted that the translation for the Rapamycin article was updating while
*Found it difficult to quickly copy content and formatting to a new page - Bogdan may able to assist with this
*Noted that it's probably not worth translating references
*Recommended deepl.com as the 'gold standard' for translating of articles. Produces more simplistic sentence structures compared to Google Translate.

''Ben Wu''

*Summary of EARD conference - mentioned Tina Woods' talk on lobbying UK government to increase funding towards aging research, and recognising biology of aging as a critical healthcare mission. Also mentioned that emphasis on healthspan seems more effective in communication than emphasis on lifespan.

''Marc''

*Bi-weekly content writers meetings could be structured around a review process whereby writers provide helpful feedback on other writers' articles. Maybe writers with journalistic/editor experience know of an effective review process similar to how people work at a newspaper/magazine/journal.
*We should prevent information being copied across various parts of the website because this makes maintenance harder. E.g. the 'About us' information is now both on the About us page and in the Handbook. He suggests removing the 'About Us' content from the Handbook, and replace it with a link to the 'About us' page.
* The handbook contains much valuable information for contributors but is not that interesting for most wiki visitors who just visit the wiki for longevity related information. He suggests to show only some high level 'how to contribute' information on the 'How to contribute' page so we don't overwhelm visitors (basically just asking people to contact us if they want to help) and then add a prominent link to the Handbook for if they want to dive into all the details. 

Andreas Melhede:

*Discussed Discord Role Management on Discord with Stuart McWhinney.
** It is very close to finished and ready to be implemented on our server.

''Max Schulz:''

*Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
***Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
***Using ''Organisational'' board to manage weekly core meetings
***Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
***Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
**''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
***Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
***I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
***Proposed board usage:
****Future ideas for clearly far in the future (months)
****Backlog for tasks to do soon (weeks)
****Todo for tasks agreed to be done next, or you want to work on next
****Once task is worked on -> Move to In Progress
****If you want someone to review -> Move to In Review
****If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
***Meaningful task definitions
***Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
*Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
**Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
**Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
* Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
** Should be filled out by all team members so we have an overview.

==25/08/2021==

===🧍 Attending ===

*Jack Harley
* Bogdan Dziewierz
*Marc Smeehuijzen
*Ben Wu
*Andreas Melhede
*Heye Groß
*Max Schons
*Stuart

===📣 Updates===
*Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
*Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
*Max Schons working on risk factors, subjective vs objective measures of health, various major disease
*Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
*Heye planning on engaging with EA community at conferences and talking about the Wiki
*Technical meeting bimonthly with Bogdan, Mac, Stuart
*Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
===✅ Action Items===

* Continue working on core articles
*
|}

==18/08/2021 ==

===🧍 Attending===
*Jack Harley
*Bogdan Dziewierz
*Max Schulz
*Andreas Melhede
*Sam Voigt
*Marc Smeehujizen
*Heye Groß

===📣 Updates Roundtable===
Jack Harley

*India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

*More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

*Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

*Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

*Custom namespace "Handbook" created on the Wiki
*Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

*Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
*Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
*Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

*Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

*Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
**Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
*Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
**5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
**In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
**Open calendar links for meetings would be good (also are there other meetings to know of...?)
*How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
*There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
**Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
*What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
*Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
*Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

*Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
===✅ Action Items===

*Jack: There is a need for volunteers to help with on-boarding new contributors

*Bogdan: We need to make it more prominent and visible in the menu
*Bogdan: How to contribute menu item needs to be replaced with Handbook
*Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
*Jack: Let’s try to organise symposium or conference once we get funding.
*Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

==11/08/2021 ==

===Purpose===
Regular weekly meeting

=== 🧍 Attending===

*Jack Harley, Co-Founder
*Bogdan Dziewierz, Co-founder & Head of Engineering
*Max Schons, Content Writer
*Max Schulz, Engineering Team Member and Organisational Consultant
*Ben Wu, Head of Content
*Andreas Melhede, Head of Marketing
*Sharon Wong, Content Translator

===📣 Updates Roundtable===

#Name: Max Schulz
##Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
##Discussed platforms for hosting the Handbook, such as Confluence.
#Name Bogdan
##Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
##Life extension tool is a work in progress.
#Name Jack
##Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
#‍Name Max Schons
##Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
##Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
#Name Ben
##Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
#Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
#Name Andreas
##Provided updates on social media accounts.
##Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
===✅ Action Items===

*Bogdan to create namespace for Handbook, and Handbook landing page
*Jack follow up on Max’s organizational wiki suggestions
*Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
*Bogdan to organize an Engineering team spring meeting
*Jack to create and share a document of organizational processes
*Max Schulz to forward exemplary handbook to Jack
*Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021==

===🧍 Attending===

*Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
*Marc Smeehuijzen, Head of UX
*Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

===📣 Updates Roundtable===

#Name: Bogdan
##Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
##Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
##Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
##There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
##Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
##New marketing expert is interested in joining the project, could work alongside Andreas
##Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
##Looking for someone who can manage the content writers.
#‍Name Marc
##Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
##Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
#Name Andreas
##Made some social media posts on the 5 key articles that we’re working on.
##Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items===

* Ben looks for famous professor as co author for India Times article
*Jack follow up on Maximillian’s organizational wiki suggestions
*Jack looks for someone to manage the content writers
*Jack to assign organizational document writing to other members
*Marc joins the engineering team and moves his Trello cards to Jira
|}

==29/07/2021==

===🧍 Attending===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

===🙌 Celebrate wins ===

*New software developer, Mark Whitlock, will join the IT team to help develop the technical side
*Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

===💬 Discussion Topics ===

*Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

===📣 Updates Roundtable ===

#Name: Jack
##A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
##We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
##Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
#Name Ben
##Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

#We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

#Name Andreas
##Clarifying the target audience as primarily those who are non-specialists
##Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
===✅ Action Items===

*Jack meeting with Max Shulz to discuss further collaboration ideas
*Ben to add list of drugs of interest to lifespan extension tool database
*Ben to add relevant sources to the database for content writers - E.g. ITP
*Assign content writers / other team members with science background to assist with completing data for the life extension tool
*Andreas to create Discord channel for meeting minutes
*Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Content Writer Meetings

2021-09-17T14:24:00Z

Schulzm: /* 📓Preparation Notes */ Add proposal of ethical articles

== xx/09/2021 ==

===📓Preparation Notes===
''Max Schulz:''

* New process for draft articles created (see [https://en.longevitywiki.org/wiki/Handbook:Handbook#:~:text=The%20Contribute%20menu-,Create%20a%20page,-%5Bedit%5D Handbook], to be shared at the next content writer meeting as well):
**[[Template:Draft-article|Draft Article banner template]] should be added to beginning of article via <nowiki>{{ Draft-article }}</nowiki> (without spaces), automatically adding a banner and the "Drafts" category (maybe in the future add automatically for new pages/articles?)
**Moved some (non-glossary) articles into Drafts that were very obvious ([https://en.longevitywiki.org/wiki/Articles#:~:text=Risk%20Factor-,Drafts,-%5Bedit%5D Articles Drafts Section])
**Note: The DPL Extensions on the Articles page take a while to update the lists when articles are moved between categories ([[mediawikiwiki:Topic:Qdku9ow0v2z2krrv|MediaWiki Topic]] | [https://phabricator.wikimedia.org/T13685 Related Issue])
*Proposal: New category of articles (Category: "Ethics")
**We distinguish between "Scientific" (Category: Longevity, should be changed) and "Ethical" articles on longevity
**No planned articles yet, should come from the community
**Ethical articles should also conform to a Wiki standard, presenting both sides of an argument and trying to be as objective as possible (compared to more biased articles, e.g. from Lifespan.io)

== 07/09/2021 ==

===📓Preparation Notes===
''Max Schulz:''

*'''Proposed Content writer meeting process'''
** Introductions by new members (short, 1 min / person):
***Name & where you are based
***Background & interest in longevity
***What topics you want to contribute to
**Meeting notes writer?
**Content writer manager (Max) sharing process & technology updates
**Going through pillar articles updates (content, reviews, contributions)
**Round table: Unblocking writers - suggestions what to write on, asking for reviews etc.
* '''Proposed Trello board process'''
** Article writing is organized on the Trello board: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]
** Three kind of articles: "Pillar Articles" (Expert Knowledge), "General Articles" (Open to anyone) and "Glossary" (2-3 sentences description from a longevity perspective) | [[Articles]] page is now organised accordingly
***On Trello: Pillar articles are labeled (as well as the introductory article)
*** Categories to use when saving articles: "Pillar Articles", "Longevity", "Glossary" '''(handbook has to be updated accordingly)'''
**Trello board organisation:
***Unsassigned for article ideas
***Assigned when someone wants to write an article
***Once working on a draft: In progress
*** When finished with a first draft: In Review (merged past columns)
***When reviewed by at least one other writer in the group: Completed
** Articles are never '''really''' done, as science progresses, so if you want to add something meaningful - please do so and share your idea both on Trello and this meeting!
**Feel free to add ideas about the processes & tools either in these meetings or on the Trello column "Feedback for tooling & organisation"!
**Non-structured contributions: Just get started writing on topics that interest you - the Trello board is to synchronise your efforts with the team and share your work!
*'''Process for creating drafts directly on Wiki:'''
**I think it would be great if we also wrote the drafts directly into the wiki; Instead of creating local google docs
**References from Wikipedia: [[wikipedia:Wikipedia:Drafts|Draft Namespace]] | [[mediawikiwiki:Draft_namespace|MediaWiki Draft Discussions]]
**Possibilities: change title, e.g. "[DRAFT] Biomarkers of healthspan", use Draft Namespace or Category, or simply add a template banner at the start of an article and/or section (used like this <nowiki>{{ Draft-article }}</nowiki>)
**Max simple proposal (for now): Add template banner and discuss directly on the draft, adding comments with the comment feature of the editor (see source)
*'''Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021'''
*Kindly ask all writers to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
*Meeting slot not set in stone, will send out a doodle again with more choice after this meeting (with ~10 days response deadline)

===🧍 Attending===

*Maximilian Schulz
*Jack Harley
*Ben Wu
*Joly Ghanawi
*Habakuk Hain
*Lindsay Ciocco
*Sharon Wong
*Robin Howlett

===📣 Updates===

*Introductions of all participants, newcomers:
**Habakuk Hain: Graduate with an MD and something like a Master’s in Molecular Biology from the University of Göttingen in 2022 - interested in contributing to Neurodegeneration article
**Robin Howlett: Non-technical background, interested in writing about the ethical implications of longevity
*Process updates shared, see Preparation Notes - in addition discussed:
**'''Drafting process: Draft Banner (using templates), Category "Draft" and using Editor comments to discuss'''
**It was brought up that we should make discussion pages visible to have discussions on existing articles as well
*Updates on pillar articles:
**Overview Article: Max Schulz and Ben to collaborate on this
**Rapamycin (Ben): Completed to a high standard, ready to share
**Epigenetic reprogramming (Ben & Lindsay): Requires a few additions, that are currently being worked on
**Aging and Neurodegeneration (Jack): Draft for aging and neurodegeneration article can be completed by the end of September. Habakuk could collaborate?
**COVID-19 and Aging (Ben): Max Schons can begin work on this after completing the biomarkers of healthspan piece (additional perspective of infectious disease research)
*Other longevity articles:
**References need to be added for calorie restriction article - will be done by Joly
*New writers can contribute to ‘unassigned’ topics, in particular drugs purported to extend lifespan. The rapamycin article can be used as a ‘template’ – specifically the subheadings (Note: process should be added to handbook)
*Sharon Wong: Will put together a table to summarise main challenges and points to note for the translation efforts
*In addition to the Wiki itself, discussions for specific articles can also be had in the ‘content writers chat’ channel on Discord - but the wiki is preferred whenever possible.

{| class="wikitable"
|
===✅ Action Items===

*Enable drafting process & document in the handbook (Max Schulz)
*Enable discussion pages on Wiki (Max Schulz)
*
|}

Handbook:Handbook

2021-09-17T14:20:21Z

Schulzm: /* Bi-weekly content writer meetings */ Add process discussed in last meeting

== About the Handbook==
The Longevity Wiki Handbook is the 'source of truth' for the Wiki organisation. It currently contains our mission and strategy, the roles we are looking for, links to our communication platforms and some editing advice. Like the Wiki itself, it's all publicly accessible and transparent and will likely grow and change over time.
== Mission==
Longevity Wiki is an open-access project to create the go-to platform for the science of longevity. The wiki was borne from the need for high quality scientific content on aging and longevity to be freely available and accessible. The Wiki ultimately aims to cover the following topics in detail:

*Longevity drugs and the evidence supporting them
*Personal longevity strategies/advice
*Hallmarks of aging/biology of aging
*Animal models of aging
*Laboratories working in geroscience, and their focus
*Longevity biotech (companies, development pipeline)
*Biology of aging + diseases of aging connection

More information about us can be found on our [[About]] page.

==Strategy==
Instead of producing as much content as possible, we’re going to focus on creating 5 pillar articles written by experts on the topic. These articles will demonstrate the knowledge and quality of our initiative, and then we will build out the wiki from there. These are the pillar articles:

#'''Epigenetic reprogramming'''
#'''Aging and Neurodegeneration'''
#'''Rapamycin'''
#'''Biomarkers of healthspan'''
#'''COVID-19 and Aging'''

In conjunction with these articles, we are going to create a Glossary page of key terms in the longevity space, along with a short (2-3 sentence definition).

== Available Roles and Projects for the Wiki ==
Longevity Wiki is an open access, collaborative project and we invite all volunteers to contribute! The goal of the Wiki is to create a trusted, high quality platform of longevity science content.

This section lists the current projects we are working on, and how you can get involved. If you're interested, please complete our [https://forms.gle/P1huKGcDiPLnRAB17 Volunteer Survey Form] and we will follow up with you by email.

===Pillar article writing===
'''Role: Senior content writer'''

'''Minimum requirements: Masters or PhD training, ideally in a relevant field to content being written'''

We are seeking those with strong scientific backgrounds to help our initial offering of 5 ‘pillar’ articles that will form the initial content on the Wiki.

These articles are designed to be long-form (1.5-2.5k words) articles summarizing the relevant literature as it pertains to aging biology. The style we are aiming for is similar to a literature review, but with a simplified writing style that is accessible to non-specialist readers.

An example is our article on [[Rapamycin]], however, the style and structure of the article may vary by topic.

The following topics have been selected:

*'''Epigenetic reprogramming'''
*'''Aging and Neurodegeneration'''
*'''Rapamycin'''
*'''Biomarkers of healthspan'''
*'''COVID-19 and Aging'''

===Glossary expansion===
'''Role: Junior content writer'''

'''Minimum requirements: High school level biology'''

We are building a glossary of relevant terminology to expand the scope of the Wiki. The glossary will be accessible from an article through the use of so called ‘hovercards’ which makes it possible to display the meaning of a difficult term without leaving the article page.

The list of glossary terms is being populated based on the pillar articles. A full list of glossary terms can be found here (ADD LINK).

To contribute to the glossary, simply choose a term that has not yet been defined, and write a concise, and scientifically accurate definition.

Some guidelines:

*All references should be cited using APA referencing

*All links to internal articles should be linked
*Definitions should be clear and comprehensible to non-specialist audiences
*Definitions can be up to 270 characters in length

An example of a glossary term (ADD LINK).

===Life extension tool database===
'''Role: Researcher'''

'''Minimum requirements: Undergraduate biology, ability to comprehend the longevity data and research'''

We are creating a ‘life extension tool’ that provides an up to date overview of the life extension achieved for different animals with different interventions.

A [https://zpl.io/bePZGJl sample of the tool] can be viewed on our design platform Zeplin.

In order to populate data for the tool, we require assistance in reviewing the literature to identify the lifespan extension associated with different drugs and species, and the original publication in which this was published.

Our current database: [https://docs.google.com/spreadsheets/d/14OLhV4WWSUGomEY-3zko1o8zHHrJwt5YipGbjxhracM/edit?usp=sharing Life Extension Tool Data].

===Software engineering support===
'''Role: Engineer'''

'''Minimum requirements: Interest in software engineering'''

As the wiki grows, we need to ensure that the automation and infrastructure develops. We are especially looking for people with the following abilities:

* AWS reliability engineering/DevOps (people to manage infrastructure and deploy apps)
* PHP
* Front-end development
* Technical product ownership
* A scrum master/iteration manager

===Marketing===
'''Role: Based on experience and performance'''

'''Minimum requirements: Past experience in marketing, splendid communicator and creative individual who is eager to learn'''

Our marketing department is expanding. If you are a creative individual who loves communicating, you could get a lot of significant responsibilities.

=== Graphic design ===
'''Role: Illustrator, data visualization'''

'''Minimum requirements: Experience with graphic design'''

We are looking for individuals with graphic design skills to help us create and re-work pictures, scientific diagrams and graphs to communicate information to non-technical audiences. You will work closely with our content writers to produce high-impact, engaging visuals to accompany the written content.

=== Other roles ===
'''Role: Translator'''

We are looking for individuals with language skills to translate articles into other languages to reach a broader audience - particularly languages spoken commonly around the world. This will be done with the assistance of tools such as Google Translate.

'''Role: UX specialist'''

We are seeking expertise in user experience (UX) to help us design an intuitive and engaging platform. The goal is to create a satisfying experience for our users. You will work with the Head of UX in this role.

== Our communication platforms ==
Besides this Handbook we use a few other platforms for communicating and sharing resources. We're committed to being an open-access platform, and as such, we share all information possible, such as meeting minutes.

Non-engineering tasks are organised in Trello for now, use [https://trello.com/invite/longevitywiki/46e20cd2037ee4cf6e326277218f8286 this invitation link] to get access to the organisation.

=== Discord Server ===
We mostly communicate via the [https://discord.gg/UDKmjcnjye Longevity Wiki Discord Server]. It serves as a day-to-day message board, as well as the host of our meetings. Meetings take place every week at 08:30 GMT.

=== Google Drive ===
Our [https://drive.google.com/drive/folders/19Ol2wcRd2IWUt_gOC5j5Ff7FjSzPVuBf Drive folder] is used for sharing many useful documents, such as draft ideas, spreadsheets, or useful non-wiki resources.

===Organisational monthly meetings===

* Organisanional task management: [https://trello.com/b/0u9pSclR/organisational Trello Board]
* [https://en.longevitywiki.org/wiki/Handbook:Meeting_Minutes Meeting minutes]

Monthly meeting on general organisational topics and as a synchronization between engineering and content writing.

==== Trello process ====
* Future ideas for clearly far in the future (months)
* Backlog for tasks to do soon (weeks)
* Todo for tasks agreed to be done next, or you want to work on next
* Once task is worked on -> Move to In Progress
* If you want someone to review -> Move to In Review
* If task is done -> Move to Done, can then be shared in the next weekly meeting and archived

=== Bi-weekly content writer meetings ===

* Organisanional task management: [https://trello.com/b/mfwbyEB6/content-creators Trello Board]
* [[Handbook:Content Writer Meetings|Meeting minutes]]

==== Agenda ====

* Introductions by new members (short, 1 min / person):
** Name & where you are based
** Background & interest in longevity
** What topics you want to contribute to
* Designate Meeting notes writer
* Content writer manager sharing process & technology updates
* Going through pillar articles updates (content, reviews, contributions)
* Round table: Unblocking writers - suggestions what to write on, asking for reviews etc.

==== Trello process ====
The process for tracking article progress with Trello cards is as follows:

* Unsassigned for article ideas
* Assigned when someone wants to write an article
* Once working on a draft: In progress
* When finished with a first draft: In Review (merged past columns)
* When reviewed by at least one other writer in the group: Completed

==== General remarks ====

* Articles are never really done, as science progresses, so if you want to add something meaningful - please do so and share your idea both on Trello and this meeting!
* Non-structured contributions: Just get started writing on topics that interest you - the Trello board is to synchronise your efforts with the team and share your work!

===Engineering Team===

*Source code: [https://github.com/longevitywiki Github]
*Task management: [https://longevitywiki.atlassian.net/jira/software/projects/LW/boards/1 Jira]
*Documentation & roadmap: [https://longevitywiki.atlassian.net/wiki/spaces/LW/overview Confluence]

==How to edit the Wiki==
All articles, no matter what categories they are tagged with, are found on the [[Special:AllPages|All Pages]] site.

===Let us know first===
If you want to edit the wiki, please [[Contact|contact us]] first, so we can help you get started.

===MediaWiki===
Longevity Wiki uses the [[mediawikiwiki:MediaWiki|MediaWiki]] platform - the same as Wikipedia. This is the software that makes it possible to store all content, edit articles, track changes and more.
[[File:Account menu.png|thumb|100x100px|The Account menu]]

===Create an account ===
If you want to edit the wiki, it's a good idea to create an account first. That way it's easier to keep track of your work and you get some extra functionality. To create an account, in the menu click the Account icon on the right (the 'little person') and click '''Create account''' and follow the instructions. Creating an account is not mandatory however for editing.
[[File:Contribute menu.png|thumb|198x198px|The Contribute menu]]

===Create a page===
To create a new article on the wiki, go to the menu and click '''Contribute''' and then '''Create new page'''. You will then be prompted to select a title for your article. After that, the Edit toolbar appears at the top and you can start writing. The Edit toolbar provides you with standard edit functions like making headings, bold text, insert links, insert images and much more.

[[File:Editor Options Menu.png|thumb|198x198px|Editor Options Menu]]

The articles are categorized into four kinds, each with an associated category that should be added by using the '''Categories''' Option in the menu within the editor. (See "Editor Options Menu")

*'''Pillar Articles:''' Described in the [[Handbook:Handbook#Strategy|Strategy]] section, need expert knowledge equivalent to having a post-grad (MSc, Ph.D., MD) in a related area, currently managed by the core group. (Category: Pillar Articles)
*'''Longevity Articles:''' All articles about longevity, traditional wiki development and open for everyone to contribute. Should be created as draft first and reviewed by others in the community. (Category: Longevity)
*'''Glossary:''' Key terms in the longevity space, along with a short 2-3 sentence definition, no draft necessary. (Category: Glossary)
*'''Drafts:''' Articles that haven't been reviewed yet and finalized to a certain stage. (Category: Drafts)
These articles are all shown on the website on the [[Articles]] page.

====Drafts====
When creating a new page, the [[Template:Draft-article|Draft Article banner template]] should be added to beginning of article via <nowiki>{{ Draft-article }}</nowiki> (without spaces), automatically adding a banner and the "Drafts" category.

Drafts will not be actively mantained, but the core team might ask authors sometimes if they are still working on the article. The process for now is simple: Write a draft, have others in the community review it, finalise it and remove the draft banner '''(Work in Progress)'''.

For the review process we encourage to use our Discord server and write comments with the comments feature of the editor; text that is written in the editor but not shown on the published page.

===Edit a page===
To edit an existing article, lookup the article, go to the menu and click '''Contribute''' and then (under 'This page...') click '''Edit'''. Then the Edit toolbar will open at the top, and you can start writing.
[[File:Text editor.png|none|thumb|732x732px|The '''Edit''' toolbar]]

===Images===
Often it's a good idea to include images in your article. Just make sure that if you use an image of someone else, you are not violating any copyright. In general, you are free to use images with a [https://creativecommons.org/ Creative Commons] license, but don't forget to use the right [https://creativecommons.org/use-remix/ attribution]. If you need help creating an image yourself, let us know in the Images channel on our [https://discord.gg/jBR5aRcpfV Discord Server], and we can help you create a unique and copyright-free image.

===Referencing===
For referencing to external sources (e.g. a journal article), Longevity Wiki uses the [[wikipedia:APA_style|APA referencing style]] - the same as Wikipedia. To create a reference, click '''Cite''' on the Edit toolbar. There are a few useful resources for creating citations, such as [https://zbib.org/ Zoterobib].

===Writing style===
The aim of the Wiki is to create '''comprehensive''', '''scientifically accurate''' and '''accessible''' content on longevity. The writing style we are aiming for is essentially the same as Wikipedia, in balancing technical and non-technical content. Here is our '''[[Writing tips for easy reading|writing guide]]''' to help you get started. More information on Wikipedia's writing style can be found in [[wikipedia:Wikipedia:Manual_of_Style|Wikipedia's Manual of Style]].

==Contact information==
See our [[Contact]] page.

Handbook:Handbook

2021-09-16T07:28:34Z

Schulzm: /* Our communication platforms */ Change Trello Invitation Links

== About the Handbook==
The Longevity Wiki Handbook is the 'source of truth' for the Wiki organisation. It currently contains our mission and strategy, the roles we are looking for, links to our communication platforms and some editing advice. Like the Wiki itself, it's all publicly accessible and transparent and will likely grow and change over time.
== Mission==
Longevity Wiki is an open-access project to create the go-to platform for the science of longevity. The wiki was borne from the need for high quality scientific content on aging and longevity to be freely available and accessible. The Wiki ultimately aims to cover the following topics in detail:

*Longevity drugs and the evidence supporting them
*Personal longevity strategies/advice
*Hallmarks of aging/biology of aging
*Animal models of aging
*Laboratories working in geroscience, and their focus
*Longevity biotech (companies, development pipeline)
*Biology of aging + diseases of aging connection

More information about us can be found on our [[About]] page.

==Strategy==
Instead of producing as much content as possible, we’re going to focus on creating 5 pillar articles written by experts on the topic. These articles will demonstrate the knowledge and quality of our initiative, and then we will build out the wiki from there. These are the pillar articles:

#'''Epigenetic reprogramming'''
#'''Aging and Neurodegeneration'''
#'''Rapamycin'''
#'''Biomarkers of healthspan'''
#'''COVID-19 and Aging'''

In conjunction with these articles, we are going to create a Glossary page of key terms in the longevity space, along with a short (2-3 sentence definition).

== Available Roles and Projects for the Wiki ==
Longevity Wiki is an open access, collaborative project and we invite all volunteers to contribute! The goal of the Wiki is to create a trusted, high quality platform of longevity science content.

This section lists the current projects we are working on, and how you can get involved. If you're interested, please complete our [https://forms.gle/P1huKGcDiPLnRAB17 Volunteer Survey Form] and we will follow up with you by email.

===Pillar article writing===
'''Role: Senior content writer'''

'''Minimum requirements: Masters or PhD training, ideally in a relevant field to content being written'''

We are seeking those with strong scientific backgrounds to help our initial offering of 5 ‘pillar’ articles that will form the initial content on the Wiki.

These articles are designed to be long-form (1.5-2.5k words) articles summarizing the relevant literature as it pertains to aging biology. The style we are aiming for is similar to a literature review, but with a simplified writing style that is accessible to non-specialist readers.

An example is our article on [[Rapamycin]], however, the style and structure of the article may vary by topic.

The following topics have been selected:

*'''Epigenetic reprogramming'''
*'''Aging and Neurodegeneration'''
*'''Rapamycin'''
*'''Biomarkers of healthspan'''
*'''COVID-19 and Aging'''

===Glossary expansion===
'''Role: Junior content writer'''

'''Minimum requirements: High school level biology'''

We are building a glossary of relevant terminology to expand the scope of the Wiki. The glossary will be accessible from an article through the use of so called ‘hovercards’ which makes it possible to display the meaning of a difficult term without leaving the article page.

The list of glossary terms is being populated based on the pillar articles. A full list of glossary terms can be found here (ADD LINK).

To contribute to the glossary, simply choose a term that has not yet been defined, and write a concise, and scientifically accurate definition.

Some guidelines:

*All references should be cited using APA referencing

*All links to internal articles should be linked
*Definitions should be clear and comprehensible to non-specialist audiences
*Definitions can be up to 270 characters in length

An example of a glossary term (ADD LINK).

===Life extension tool database===
'''Role: Researcher'''

'''Minimum requirements: Undergraduate biology, ability to comprehend the longevity data and research'''

We are creating a ‘life extension tool’ that provides an up to date overview of the life extension achieved for different animals with different interventions.

A [https://zpl.io/bePZGJl sample of the tool] can be viewed on our design platform Zeplin.

In order to populate data for the tool, we require assistance in reviewing the literature to identify the lifespan extension associated with different drugs and species, and the original publication in which this was published.

Our current database: [https://docs.google.com/spreadsheets/d/14OLhV4WWSUGomEY-3zko1o8zHHrJwt5YipGbjxhracM/edit?usp=sharing Life Extension Tool Data].

===Software engineering support===
'''Role: Engineer'''

'''Minimum requirements: Interest in software engineering'''

As the wiki grows, we need to ensure that the automation and infrastructure develops. We are especially looking for people with the following abilities:

* AWS reliability engineering/DevOps (people to manage infrastructure and deploy apps)
* PHP
* Front-end development
* Technical product ownership
* A scrum master/iteration manager

===Marketing===
'''Role: Based on experience and performance'''

'''Minimum requirements: Past experience in marketing, splendid communicator and creative individual who is eager to learn'''

Our marketing department is expanding. If you are a creative individual who loves communicating, you could get a lot of significant responsibilities.

=== Graphic design ===
'''Role: Illustrator, data visualization'''

'''Minimum requirements: Experience with graphic design'''

We are looking for individuals with graphic design skills to help us create and re-work pictures, scientific diagrams and graphs to communicate information to non-technical audiences. You will work closely with our content writers to produce high-impact, engaging visuals to accompany the written content.

=== Other roles ===
'''Role: Translator'''

We are looking for individuals with language skills to translate articles into other languages to reach a broader audience - particularly languages spoken commonly around the world. This will be done with the assistance of tools such as Google Translate.

'''Role: UX specialist'''

We are seeking expertise in user experience (UX) to help us design an intuitive and engaging platform. The goal is to create a satisfying experience for our users. You will work with the Head of UX in this role.

== Our communication platforms ==
Besides this Handbook we use a few other platforms for communicating and sharing resources. We're committed to being an open-access platform, and as such, we share all information possible, such as meeting minutes.

Non-engineering tasks are organised in Trello for now, use [https://trello.com/invite/longevitywiki/46e20cd2037ee4cf6e326277218f8286 this invitation link] to get access to the organisation.

=== Discord Server ===
We mostly communicate via the [https://discord.gg/UDKmjcnjye Longevity Wiki Discord Server]. It serves as a day-to-day message board, as well as the host of our meetings. Meetings take place every week at 08:30 GMT.

=== Google Drive ===
Our [https://drive.google.com/drive/folders/19Ol2wcRd2IWUt_gOC5j5Ff7FjSzPVuBf Drive folder] is used for sharing many useful documents, such as draft ideas, spreadsheets, or useful non-wiki resources.

===Organisational monthly meetings===

* Organisanional task management: [https://trello.com/b/0u9pSclR/organisational Trello Board]
* [https://en.longevitywiki.org/wiki/Handbook:Meeting_Minutes Meeting minutes]

Monthly meeting on general organisational topics and as a synchronization between engineering and content writing.

Trello Board usage:

* Future ideas for clearly far in the future (months)
* Backlog for tasks to do soon (weeks)
* Todo for tasks agreed to be done next, or you want to work on next
* Once task is worked on -> Move to In Progress
* If you want someone to review -> Move to In Review
* If task is done -> Move to Done, can then be shared in the next weekly meeting and archived

=== Bi-weekly content writer meetings ===

* Organisanional task management: [https://trello.com/b/mfwbyEB6/content-creators Trello Board]
* [[Handbook:Content Writer Meetings|Meeting minutes]]

The process of synchronising content writing and ideas is just being set up.

===Engineering Team===

*Source code: [https://github.com/longevitywiki Github]
*Task management: [https://longevitywiki.atlassian.net/jira/software/projects/LW/boards/1 Jira]
*Documentation & roadmap: [https://longevitywiki.atlassian.net/wiki/spaces/LW/overview Confluence]

==How to edit the Wiki==
All articles, no matter what categories they are tagged with, are found on the [[Special:AllPages|All Pages]] site.

===Let us know first===
If you want to edit the wiki, please [[Contact|contact us]] first, so we can help you get started.

===MediaWiki===
Longevity Wiki uses the [[mediawikiwiki:MediaWiki|MediaWiki]] platform - the same as Wikipedia. This is the software that makes it possible to store all content, edit articles, track changes and more.
[[File:Account menu.png|thumb|100x100px|The Account menu]]

===Create an account ===
If you want to edit the wiki, it's a good idea to create an account first. That way it's easier to keep track of your work and you get some extra functionality. To create an account, in the menu click the Account icon on the right (the 'little person') and click '''Create account''' and follow the instructions. Creating an account is not mandatory however for editing.
[[File:Contribute menu.png|thumb|198x198px|The Contribute menu]]

===Create a page===
To create a new article on the wiki, go to the menu and click '''Contribute''' and then '''Create new page'''. You will then be prompted to select a title for your article. After that, the Edit toolbar appears at the top and you can start writing. The Edit toolbar provides you with standard edit functions like making headings, bold text, insert links, insert images and much more.

[[File:Editor Options Menu.png|thumb|198x198px|Editor Options Menu]]

The articles are categorized into four kinds, each with an associated category that should be added by using the '''Categories''' Option in the menu within the editor. (See "Editor Options Menu")

*'''Pillar Articles:''' Described in the [[Handbook:Handbook#Strategy|Strategy]] section, need expert knowledge equivalent to having a post-grad (MSc, Ph.D., MD) in a related area, currently managed by the core group. (Category: Pillar Articles)
*'''Longevity Articles:''' All articles about longevity, traditional wiki development and open for everyone to contribute. Should be created as draft first and reviewed by others in the community. (Category: Longevity)
*'''Glossary:''' Key terms in the longevity space, along with a short 2-3 sentence definition, no draft necessary. (Category: Glossary)
*'''Drafts:''' Articles that haven't been reviewed yet and finalized to a certain stage. (Category: Drafts)
These articles are all shown on the website on the [[Articles]] page.

====Drafts====
When creating a new page, the [[Template:Draft-article|Draft Article banner template]] should be added to beginning of article via <nowiki>{{ Draft-article }}</nowiki> (without spaces), automatically adding a banner and the "Drafts" category.

Drafts will not be actively mantained, but the core team might ask authors sometimes if they are still working on the article. The process for now is simple: Write a draft, have others in the community review it, finalise it and remove the draft banner '''(Work in Progress)'''.

For the review process we encourage to use our Discord server and write comments with the comments feature of the editor; text that is written in the editor but not shown on the published page.

===Edit a page===
To edit an existing article, lookup the article, go to the menu and click '''Contribute''' and then (under 'This page...') click '''Edit'''. Then the Edit toolbar will open at the top, and you can start writing.
[[File:Text editor.png|none|thumb|732x732px|The '''Edit''' toolbar]]

===Images===
Often it's a good idea to include images in your article. Just make sure that if you use an image of someone else, you are not violating any copyright. In general, you are free to use images with a [https://creativecommons.org/ Creative Commons] license, but don't forget to use the right [https://creativecommons.org/use-remix/ attribution]. If you need help creating an image yourself, let us know in the Images channel on our [https://discord.gg/jBR5aRcpfV Discord Server], and we can help you create a unique and copyright-free image.

===Referencing===
For referencing to external sources (e.g. a journal article), Longevity Wiki uses the [[wikipedia:APA_style|APA referencing style]] - the same as Wikipedia. To create a reference, click '''Cite''' on the Edit toolbar. There are a few useful resources for creating citations, such as [https://zbib.org/ Zoterobib].

===Writing style===
The aim of the Wiki is to create '''comprehensive''', '''scientifically accurate''' and '''accessible''' content on longevity. The writing style we are aiming for is essentially the same as Wikipedia, in balancing technical and non-technical content. Here is our '''[[Writing tips for easy reading|writing guide]]''' to help you get started. More information on Wikipedia's writing style can be found in [[wikipedia:Wikipedia:Manual_of_Style|Wikipedia's Manual of Style]].

==Contact information==
See our [[Contact]] page.

Handbook:Handbook

2021-09-16T07:26:23Z

Schulzm: /* Organisational monthly meetings */

== About the Handbook==
The Longevity Wiki Handbook is the 'source of truth' for the Wiki organisation. It currently contains our mission and strategy, the roles we are looking for, links to our communication platforms and some editing advice. Like the Wiki itself, it's all publicly accessible and transparent and will likely grow and change over time.
== Mission==
Longevity Wiki is an open-access project to create the go-to platform for the science of longevity. The wiki was borne from the need for high quality scientific content on aging and longevity to be freely available and accessible. The Wiki ultimately aims to cover the following topics in detail:

*Longevity drugs and the evidence supporting them
*Personal longevity strategies/advice
*Hallmarks of aging/biology of aging
*Animal models of aging
*Laboratories working in geroscience, and their focus
*Longevity biotech (companies, development pipeline)
*Biology of aging + diseases of aging connection

More information about us can be found on our [[About]] page.

==Strategy==
Instead of producing as much content as possible, we’re going to focus on creating 5 pillar articles written by experts on the topic. These articles will demonstrate the knowledge and quality of our initiative, and then we will build out the wiki from there. These are the pillar articles:

#'''Epigenetic reprogramming'''
#'''Aging and Neurodegeneration'''
#'''Rapamycin'''
#'''Biomarkers of healthspan'''
#'''COVID-19 and Aging'''

In conjunction with these articles, we are going to create a Glossary page of key terms in the longevity space, along with a short (2-3 sentence definition).

== Available Roles and Projects for the Wiki ==
Longevity Wiki is an open access, collaborative project and we invite all volunteers to contribute! The goal of the Wiki is to create a trusted, high quality platform of longevity science content.

This section lists the current projects we are working on, and how you can get involved. If you're interested, please complete our [https://forms.gle/P1huKGcDiPLnRAB17 Volunteer Survey Form] and we will follow up with you by email.

===Pillar article writing===
'''Role: Senior content writer'''

'''Minimum requirements: Masters or PhD training, ideally in a relevant field to content being written'''

We are seeking those with strong scientific backgrounds to help our initial offering of 5 ‘pillar’ articles that will form the initial content on the Wiki.

These articles are designed to be long-form (1.5-2.5k words) articles summarizing the relevant literature as it pertains to aging biology. The style we are aiming for is similar to a literature review, but with a simplified writing style that is accessible to non-specialist readers.

An example is our article on [[Rapamycin]], however, the style and structure of the article may vary by topic.

The following topics have been selected:

*'''Epigenetic reprogramming'''
*'''Aging and Neurodegeneration'''
*'''Rapamycin'''
*'''Biomarkers of healthspan'''
*'''COVID-19 and Aging'''

===Glossary expansion===
'''Role: Junior content writer'''

'''Minimum requirements: High school level biology'''

We are building a glossary of relevant terminology to expand the scope of the Wiki. The glossary will be accessible from an article through the use of so called ‘hovercards’ which makes it possible to display the meaning of a difficult term without leaving the article page.

The list of glossary terms is being populated based on the pillar articles. A full list of glossary terms can be found here (ADD LINK).

To contribute to the glossary, simply choose a term that has not yet been defined, and write a concise, and scientifically accurate definition.

Some guidelines:

*All references should be cited using APA referencing

*All links to internal articles should be linked
*Definitions should be clear and comprehensible to non-specialist audiences
*Definitions can be up to 270 characters in length

An example of a glossary term (ADD LINK).

===Life extension tool database===
'''Role: Researcher'''

'''Minimum requirements: Undergraduate biology, ability to comprehend the longevity data and research'''

We are creating a ‘life extension tool’ that provides an up to date overview of the life extension achieved for different animals with different interventions.

A [https://zpl.io/bePZGJl sample of the tool] can be viewed on our design platform Zeplin.

In order to populate data for the tool, we require assistance in reviewing the literature to identify the lifespan extension associated with different drugs and species, and the original publication in which this was published.

Our current database: [https://docs.google.com/spreadsheets/d/14OLhV4WWSUGomEY-3zko1o8zHHrJwt5YipGbjxhracM/edit?usp=sharing Life Extension Tool Data].

===Software engineering support===
'''Role: Engineer'''

'''Minimum requirements: Interest in software engineering'''

As the wiki grows, we need to ensure that the automation and infrastructure develops. We are especially looking for people with the following abilities:

* AWS reliability engineering/DevOps (people to manage infrastructure and deploy apps)
* PHP
* Front-end development
* Technical product ownership
* A scrum master/iteration manager

===Marketing===
'''Role: Based on experience and performance'''

'''Minimum requirements: Past experience in marketing, splendid communicator and creative individual who is eager to learn'''

Our marketing department is expanding. If you are a creative individual who loves communicating, you could get a lot of significant responsibilities.

=== Graphic design ===
'''Role: Illustrator, data visualization'''

'''Minimum requirements: Experience with graphic design'''

We are looking for individuals with graphic design skills to help us create and re-work pictures, scientific diagrams and graphs to communicate information to non-technical audiences. You will work closely with our content writers to produce high-impact, engaging visuals to accompany the written content.

=== Other roles ===
'''Role: Translator'''

We are looking for individuals with language skills to translate articles into other languages to reach a broader audience - particularly languages spoken commonly around the world. This will be done with the assistance of tools such as Google Translate.

'''Role: UX specialist'''

We are seeking expertise in user experience (UX) to help us design an intuitive and engaging platform. The goal is to create a satisfying experience for our users. You will work with the Head of UX in this role.

== Our communication platforms ==
Besides this Handbook we use a few other platforms for communicating and sharing resources. We're committed to being an open-access platform, and as such, we share all information possible, such as meeting minutes.

=== Discord Server ===
We mostly communicate via the [https://discord.gg/UDKmjcnjye Longevity Wiki Discord Server]. It serves as a day-to-day message board, as well as the host of our meetings. Meetings take place every week at 08:30 GMT.

=== Google Drive ===
Our [https://drive.google.com/drive/folders/19Ol2wcRd2IWUt_gOC5j5Ff7FjSzPVuBf Drive folder] is used for sharing many useful documents, such as draft ideas, spreadsheets, or useful non-wiki resources.

===Organisational monthly meetings===

* Organisanional task management: [https://trello.com/b/0u9pSclR/organisational Trello Board] | [https://trello.com/invite/b/0u9pSclR/0722f6126c69d1341e63765f41d23531/organisational Invitation Link]
* [https://en.longevitywiki.org/wiki/Handbook:Meeting_Minutes Meeting minutes]

Monthly meeting on general organisational topics and as a synchronization between engineering and content writing.

Trello Board usage:

* Future ideas for clearly far in the future (months)
* Backlog for tasks to do soon (weeks)
* Todo for tasks agreed to be done next, or you want to work on next
* Once task is worked on -> Move to In Progress
* If you want someone to review -> Move to In Review
* If task is done -> Move to Done, can then be shared in the next weekly meeting and archived

=== Bi-weekly content writer meetings ===

* Organisanional task management: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]
* [[Handbook:Content Writer Meetings|Meeting minutes]]

The process of synchronising content writing and ideas is just being set up.

===Engineering Team===

*Source code: [https://github.com/longevitywiki Github]
*Task management: [https://longevitywiki.atlassian.net/jira/software/projects/LW/boards/1 Jira]
*Documentation & roadmap: [https://longevitywiki.atlassian.net/wiki/spaces/LW/overview Confluence]

==How to edit the Wiki==
All articles, no matter what categories they are tagged with, are found on the [[Special:AllPages|All Pages]] site.

===Let us know first===
If you want to edit the wiki, please [[Contact|contact us]] first, so we can help you get started.

===MediaWiki===
Longevity Wiki uses the [[mediawikiwiki:MediaWiki|MediaWiki]] platform - the same as Wikipedia. This is the software that makes it possible to store all content, edit articles, track changes and more.
[[File:Account menu.png|thumb|100x100px|The Account menu]]

===Create an account ===
If you want to edit the wiki, it's a good idea to create an account first. That way it's easier to keep track of your work and you get some extra functionality. To create an account, in the menu click the Account icon on the right (the 'little person') and click '''Create account''' and follow the instructions. Creating an account is not mandatory however for editing.
[[File:Contribute menu.png|thumb|198x198px|The Contribute menu]]

===Create a page===
To create a new article on the wiki, go to the menu and click '''Contribute''' and then '''Create new page'''. You will then be prompted to select a title for your article. After that, the Edit toolbar appears at the top and you can start writing. The Edit toolbar provides you with standard edit functions like making headings, bold text, insert links, insert images and much more.

[[File:Editor Options Menu.png|thumb|198x198px|Editor Options Menu]]

The articles are categorized into four kinds, each with an associated category that should be added by using the '''Categories''' Option in the menu within the editor. (See "Editor Options Menu")

*'''Pillar Articles:''' Described in the [[Handbook:Handbook#Strategy|Strategy]] section, need expert knowledge equivalent to having a post-grad (MSc, Ph.D., MD) in a related area, currently managed by the core group. (Category: Pillar Articles)
*'''Longevity Articles:''' All articles about longevity, traditional wiki development and open for everyone to contribute. Should be created as draft first and reviewed by others in the community. (Category: Longevity)
*'''Glossary:''' Key terms in the longevity space, along with a short 2-3 sentence definition, no draft necessary. (Category: Glossary)
*'''Drafts:''' Articles that haven't been reviewed yet and finalized to a certain stage. (Category: Drafts)
These articles are all shown on the website on the [[Articles]] page.

====Drafts====
When creating a new page, the [[Template:Draft-article|Draft Article banner template]] should be added to beginning of article via <nowiki>{{ Draft-article }}</nowiki> (without spaces), automatically adding a banner and the "Drafts" category.

Drafts will not be actively mantained, but the core team might ask authors sometimes if they are still working on the article. The process for now is simple: Write a draft, have others in the community review it, finalise it and remove the draft banner '''(Work in Progress)'''.

For the review process we encourage to use our Discord server and write comments with the comments feature of the editor; text that is written in the editor but not shown on the published page.

===Edit a page===
To edit an existing article, lookup the article, go to the menu and click '''Contribute''' and then (under 'This page...') click '''Edit'''. Then the Edit toolbar will open at the top, and you can start writing.
[[File:Text editor.png|none|thumb|732x732px|The '''Edit''' toolbar]]

===Images===
Often it's a good idea to include images in your article. Just make sure that if you use an image of someone else, you are not violating any copyright. In general, you are free to use images with a [https://creativecommons.org/ Creative Commons] license, but don't forget to use the right [https://creativecommons.org/use-remix/ attribution]. If you need help creating an image yourself, let us know in the Images channel on our [https://discord.gg/jBR5aRcpfV Discord Server], and we can help you create a unique and copyright-free image.

===Referencing===
For referencing to external sources (e.g. a journal article), Longevity Wiki uses the [[wikipedia:APA_style|APA referencing style]] - the same as Wikipedia. To create a reference, click '''Cite''' on the Edit toolbar. There are a few useful resources for creating citations, such as [https://zbib.org/ Zoterobib].

===Writing style===
The aim of the Wiki is to create '''comprehensive''', '''scientifically accurate''' and '''accessible''' content on longevity. The writing style we are aiming for is essentially the same as Wikipedia, in balancing technical and non-technical content. Here is our '''[[Writing tips for easy reading|writing guide]]''' to help you get started. More information on Wikipedia's writing style can be found in [[wikipedia:Wikipedia:Manual_of_Style|Wikipedia's Manual of Style]].

==Contact information==
See our [[Contact]] page.

Handbook:Handbook

2021-09-16T06:55:22Z

Schulzm: /* Organisational weekly meetings */

== About the Handbook==
The Longevity Wiki Handbook is the 'source of truth' for the Wiki organisation. It currently contains our mission and strategy, the roles we are looking for, links to our communication platforms and some editing advice. Like the Wiki itself, it's all publicly accessible and transparent and will likely grow and change over time.
== Mission==
Longevity Wiki is an open-access project to create the go-to platform for the science of longevity. The wiki was borne from the need for high quality scientific content on aging and longevity to be freely available and accessible. The Wiki ultimately aims to cover the following topics in detail:

*Longevity drugs and the evidence supporting them
*Personal longevity strategies/advice
*Hallmarks of aging/biology of aging
*Animal models of aging
*Laboratories working in geroscience, and their focus
*Longevity biotech (companies, development pipeline)
*Biology of aging + diseases of aging connection

More information about us can be found on our [[About]] page.

==Strategy==
Instead of producing as much content as possible, we’re going to focus on creating 5 pillar articles written by experts on the topic. These articles will demonstrate the knowledge and quality of our initiative, and then we will build out the wiki from there. These are the pillar articles:

#'''Epigenetic reprogramming'''
#'''Aging and Neurodegeneration'''
#'''Rapamycin'''
#'''Biomarkers of healthspan'''
#'''COVID-19 and Aging'''

In conjunction with these articles, we are going to create a Glossary page of key terms in the longevity space, along with a short (2-3 sentence definition).

== Available Roles and Projects for the Wiki ==
Longevity Wiki is an open access, collaborative project and we invite all volunteers to contribute! The goal of the Wiki is to create a trusted, high quality platform of longevity science content.

This section lists the current projects we are working on, and how you can get involved. If you're interested, please complete our [https://forms.gle/P1huKGcDiPLnRAB17 Volunteer Survey Form] and we will follow up with you by email.

===Pillar article writing===
'''Role: Senior content writer'''

'''Minimum requirements: Masters or PhD training, ideally in a relevant field to content being written'''

We are seeking those with strong scientific backgrounds to help our initial offering of 5 ‘pillar’ articles that will form the initial content on the Wiki.

These articles are designed to be long-form (1.5-2.5k words) articles summarizing the relevant literature as it pertains to aging biology. The style we are aiming for is similar to a literature review, but with a simplified writing style that is accessible to non-specialist readers.

An example is our article on [[Rapamycin]], however, the style and structure of the article may vary by topic.

The following topics have been selected:

*'''Epigenetic reprogramming'''
*'''Aging and Neurodegeneration'''
*'''Rapamycin'''
*'''Biomarkers of healthspan'''
*'''COVID-19 and Aging'''

===Glossary expansion===
'''Role: Junior content writer'''

'''Minimum requirements: High school level biology'''

We are building a glossary of relevant terminology to expand the scope of the Wiki. The glossary will be accessible from an article through the use of so called ‘hovercards’ which makes it possible to display the meaning of a difficult term without leaving the article page.

The list of glossary terms is being populated based on the pillar articles. A full list of glossary terms can be found here (ADD LINK).

To contribute to the glossary, simply choose a term that has not yet been defined, and write a concise, and scientifically accurate definition.

Some guidelines:

*All references should be cited using APA referencing

*All links to internal articles should be linked
*Definitions should be clear and comprehensible to non-specialist audiences
*Definitions can be up to 270 characters in length

An example of a glossary term (ADD LINK).

===Life extension tool database===
'''Role: Researcher'''

'''Minimum requirements: Undergraduate biology, ability to comprehend the longevity data and research'''

We are creating a ‘life extension tool’ that provides an up to date overview of the life extension achieved for different animals with different interventions.

A [https://zpl.io/bePZGJl sample of the tool] can be viewed on our design platform Zeplin.

In order to populate data for the tool, we require assistance in reviewing the literature to identify the lifespan extension associated with different drugs and species, and the original publication in which this was published.

Our current database: [https://docs.google.com/spreadsheets/d/14OLhV4WWSUGomEY-3zko1o8zHHrJwt5YipGbjxhracM/edit?usp=sharing Life Extension Tool Data].

===Software engineering support===
'''Role: Engineer'''

'''Minimum requirements: Interest in software engineering'''

As the wiki grows, we need to ensure that the automation and infrastructure develops. We are especially looking for people with the following abilities:

* AWS reliability engineering/DevOps (people to manage infrastructure and deploy apps)
* PHP
* Front-end development
* Technical product ownership
* A scrum master/iteration manager

===Marketing===
'''Role: Based on experience and performance'''

'''Minimum requirements: Past experience in marketing, splendid communicator and creative individual who is eager to learn'''

Our marketing department is expanding. If you are a creative individual who loves communicating, you could get a lot of significant responsibilities.

=== Graphic design ===
'''Role: Illustrator, data visualization'''

'''Minimum requirements: Experience with graphic design'''

We are looking for individuals with graphic design skills to help us create and re-work pictures, scientific diagrams and graphs to communicate information to non-technical audiences. You will work closely with our content writers to produce high-impact, engaging visuals to accompany the written content.

=== Other roles ===
'''Role: Translator'''

We are looking for individuals with language skills to translate articles into other languages to reach a broader audience - particularly languages spoken commonly around the world. This will be done with the assistance of tools such as Google Translate.

'''Role: UX specialist'''

We are seeking expertise in user experience (UX) to help us design an intuitive and engaging platform. The goal is to create a satisfying experience for our users. You will work with the Head of UX in this role.

== Our communication platforms ==
Besides this Handbook we use a few other platforms for communicating and sharing resources. We're committed to being an open-access platform, and as such, we share all information possible, such as meeting minutes.

=== Discord Server ===
We mostly communicate via the [https://discord.gg/UDKmjcnjye Longevity Wiki Discord Server]. It serves as a day-to-day message board, as well as the host of our meetings. Meetings take place every week at 08:30 GMT.

=== Google Drive ===
Our [https://drive.google.com/drive/folders/19Ol2wcRd2IWUt_gOC5j5Ff7FjSzPVuBf Drive folder] is used for sharing many useful documents, such as draft ideas, spreadsheets, or useful non-wiki resources.

===Organisational monthly meetings===

* Organisanional task management: [https://trello.com/b/0u9pSclR/organisational Trello Board] | [https://trello.com/invite/b/0u9pSclR/0722f6126c69d1341e63765f41d23531/organisational Invitation Link]
* [https://en.longevitywiki.org/wiki/Handbook:Meeting_Minutes Meeting minutes]

The meetings consist of our sprint planning sessions and mid-sprint meetings, which occur on alternating weeks.

=== Bi-weekly content writer meetings ===

* Organisanional task management: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]
* [[Handbook:Content Writer Meetings|Meeting minutes]]

The process of synchronising content writing and ideas is just being set up.

===Engineering Team===

*Source code: [https://github.com/longevitywiki Github]
*Task management: [https://longevitywiki.atlassian.net/jira/software/projects/LW/boards/1 Jira]
*Documentation & roadmap: [https://longevitywiki.atlassian.net/wiki/spaces/LW/overview Confluence]

==How to edit the Wiki==
All articles, no matter what categories they are tagged with, are found on the [[Special:AllPages|All Pages]] site.

===Let us know first===
If you want to edit the wiki, please [[Contact|contact us]] first, so we can help you get started.

===MediaWiki===
Longevity Wiki uses the [[mediawikiwiki:MediaWiki|MediaWiki]] platform - the same as Wikipedia. This is the software that makes it possible to store all content, edit articles, track changes and more.
[[File:Account menu.png|thumb|100x100px|The Account menu]]

===Create an account ===
If you want to edit the wiki, it's a good idea to create an account first. That way it's easier to keep track of your work and you get some extra functionality. To create an account, in the menu click the Account icon on the right (the 'little person') and click '''Create account''' and follow the instructions. Creating an account is not mandatory however for editing.
[[File:Contribute menu.png|thumb|198x198px|The Contribute menu]]

===Create a page===
To create a new article on the wiki, go to the menu and click '''Contribute''' and then '''Create new page'''. You will then be prompted to select a title for your article. After that, the Edit toolbar appears at the top and you can start writing. The Edit toolbar provides you with standard edit functions like making headings, bold text, insert links, insert images and much more.

[[File:Editor Options Menu.png|thumb|198x198px|Editor Options Menu]]

The articles are categorized into four kinds, each with an associated category that should be added by using the '''Categories''' Option in the menu within the editor. (See "Editor Options Menu")

*'''Pillar Articles:''' Described in the [[Handbook:Handbook#Strategy|Strategy]] section, need expert knowledge equivalent to having a post-grad (MSc, Ph.D., MD) in a related area, currently managed by the core group. (Category: Pillar Articles)
*'''Longevity Articles:''' All articles about longevity, traditional wiki development and open for everyone to contribute. Should be created as draft first and reviewed by others in the community. (Category: Longevity)
*'''Glossary:''' Key terms in the longevity space, along with a short 2-3 sentence definition, no draft necessary. (Category: Glossary)
*'''Drafts:''' Articles that haven't been reviewed yet and finalized to a certain stage. (Category: Drafts)
These articles are all shown on the website on the [[Articles]] page.

====Drafts====
When creating a new page, the [[Template:Draft-article|Draft Article banner template]] should be added to beginning of article via <nowiki>{{ Draft-article }}</nowiki> (without spaces), automatically adding a banner and the "Drafts" category.

Drafts will not be actively mantained, but the core team might ask authors sometimes if they are still working on the article. The process for now is simple: Write a draft, have others in the community review it, finalise it and remove the draft banner '''(Work in Progress)'''.

For the review process we encourage to use our Discord server and write comments with the comments feature of the editor; text that is written in the editor but not shown on the published page.

===Edit a page===
To edit an existing article, lookup the article, go to the menu and click '''Contribute''' and then (under 'This page...') click '''Edit'''. Then the Edit toolbar will open at the top, and you can start writing.
[[File:Text editor.png|none|thumb|732x732px|The '''Edit''' toolbar]]

===Images===
Often it's a good idea to include images in your article. Just make sure that if you use an image of someone else, you are not violating any copyright. In general, you are free to use images with a [https://creativecommons.org/ Creative Commons] license, but don't forget to use the right [https://creativecommons.org/use-remix/ attribution]. If you need help creating an image yourself, let us know in the Images channel on our [https://discord.gg/jBR5aRcpfV Discord Server], and we can help you create a unique and copyright-free image.

===Referencing===
For referencing to external sources (e.g. a journal article), Longevity Wiki uses the [[wikipedia:APA_style|APA referencing style]] - the same as Wikipedia. To create a reference, click '''Cite''' on the Edit toolbar. There are a few useful resources for creating citations, such as [https://zbib.org/ Zoterobib].

===Writing style===
The aim of the Wiki is to create '''comprehensive''', '''scientifically accurate''' and '''accessible''' content on longevity. The writing style we are aiming for is essentially the same as Wikipedia, in balancing technical and non-technical content. Here is our '''[[Writing tips for easy reading|writing guide]]''' to help you get started. More information on Wikipedia's writing style can be found in [[wikipedia:Wikipedia:Manual_of_Style|Wikipedia's Manual of Style]].

==Contact information==
See our [[Contact]] page.

Handbook:Content Writer Meetings

2021-09-15T09:50:50Z

Schulzm: First preparation notes for 2nd September meeting

== xx/09/2021 ==

===📓Preparation Notes===
''Max Schulz:''

* New process for draft articles created (see [https://en.longevitywiki.org/wiki/Handbook:Handbook#:~:text=The%20Contribute%20menu-,Create%20a%20page,-%5Bedit%5D Handbook], to be shared at the next content writer meeting as well):
**[[Template:Draft-article|Draft Article banner template]] should be added to beginning of article via <nowiki>{{ Draft-article }}</nowiki> (without spaces), automatically adding a banner and the "Drafts" category (maybe in the future add automatically for new pages/articles?)
**Moved some (non-glossary) articles into Drafts that were very obvious ([https://en.longevitywiki.org/wiki/Articles#:~:text=Risk%20Factor-,Drafts,-%5Bedit%5D Articles Drafts Section])
**Note: The DPL Extensions on the Articles page take a while to update the lists when articles are moved between categories ([[mediawikiwiki:Topic:Qdku9ow0v2z2krrv|MediaWiki Topic]] | [https://phabricator.wikimedia.org/T13685 Related Issue])

== 07/09/2021 ==

===📓Preparation Notes===
''Max Schulz:''

*'''Proposed Content writer meeting process'''
** Introductions by new members (short, 1 min / person):
***Name & where you are based
***Background & interest in longevity
***What topics you want to contribute to
**Meeting notes writer?
**Content writer manager (Max) sharing process & technology updates
**Going through pillar articles updates (content, reviews, contributions)
**Round table: Unblocking writers - suggestions what to write on, asking for reviews etc.
* '''Proposed Trello board process'''
** Article writing is organized on the Trello board: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]
** Three kind of articles: "Pillar Articles" (Expert Knowledge), "General Articles" (Open to anyone) and "Glossary" (2-3 sentences description from a longevity perspective) | [[Articles]] page is now organised accordingly
***On Trello: Pillar articles are labeled (as well as the introductory article)
*** Categories to use when saving articles: "Pillar Articles", "Longevity", "Glossary" '''(handbook has to be updated accordingly)'''
**Trello board organisation:
***Unsassigned for article ideas
***Assigned when someone wants to write an article
***Once working on a draft: In progress
*** When finished with a first draft: In Review (merged past columns)
***When reviewed by at least one other writer in the group: Completed
** Articles are never '''really''' done, as science progresses, so if you want to add something meaningful - please do so and share your idea both on Trello and this meeting!
**Feel free to add ideas about the processes & tools either in these meetings or on the Trello column "Feedback for tooling & organisation"!
**Non-structured contributions: Just get started writing on topics that interest you - the Trello board is to synchronise your efforts with the team and share your work!
*'''Process for creating drafts directly on Wiki:'''
**I think it would be great if we also wrote the drafts directly into the wiki; Instead of creating local google docs
**References from Wikipedia: [[wikipedia:Wikipedia:Drafts|Draft Namespace]] | [[mediawikiwiki:Draft_namespace|MediaWiki Draft Discussions]]
**Possibilities: change title, e.g. "[DRAFT] Biomarkers of healthspan", use Draft Namespace or Category, or simply add a template banner at the start of an article and/or section (used like this <nowiki>{{ Draft-article }}</nowiki>)
**Max simple proposal (for now): Add template banner and discuss directly on the draft, adding comments with the comment feature of the editor (see source)
*'''Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021'''
*Kindly ask all writers to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
*Meeting slot not set in stone, will send out a doodle again with more choice after this meeting (with ~10 days response deadline)

===🧍 Attending===

*Maximilian Schulz
*Jack Harley
*Ben Wu
*Joly Ghanawi
*Habakuk Hain
*Lindsay Ciocco
*Sharon Wong
*Robin Howlett

===📣 Updates===

*Introductions of all participants, newcomers:
**Habakuk Hain: Graduate with an MD and something like a Master’s in Molecular Biology from the University of Göttingen in 2022 - interested in contributing to Neurodegeneration article
**Robin Howlett: Non-technical background, interested in writing about the ethical implications of longevity
*Process updates shared, see Preparation Notes - in addition discussed:
**'''Drafting process: Draft Banner (using templates), Category "Draft" and using Editor comments to discuss'''
**It was brought up that we should make discussion pages visible to have discussions on existing articles as well
*Updates on pillar articles:
**Overview Article: Max Schulz and Ben to collaborate on this
**Rapamycin (Ben): Completed to a high standard, ready to share
**Epigenetic reprogramming (Ben & Lindsay): Requires a few additions, that are currently being worked on
**Aging and Neurodegeneration (Jack): Draft for aging and neurodegeneration article can be completed by the end of September. Habakuk could collaborate?
**COVID-19 and Aging (Ben): Max Schons can begin work on this after completing the biomarkers of healthspan piece (additional perspective of infectious disease research)
*Other longevity articles:
**References need to be added for calorie restriction article - will be done by Joly
*New writers can contribute to ‘unassigned’ topics, in particular drugs purported to extend lifespan. The rapamycin article can be used as a ‘template’ – specifically the subheadings (Note: process should be added to handbook)
*Sharon Wong: Will put together a table to summarise main challenges and points to note for the translation efforts
*In addition to the Wiki itself, discussions for specific articles can also be had in the ‘content writers chat’ channel on Discord - but the wiki is preferred whenever possible.

{| class="wikitable"
|
===✅ Action Items===

*Enable drafting process & document in the handbook (Max Schulz)
*Enable discussion pages on Wiki (Max Schulz)
*
|}

Handbook:Meeting Minutes

2021-09-15T09:46:16Z

Schulzm: 15/09/21 Meeting Notes

== 15/09/2021 ==

=== 🧍 Attending===
*Jack Harley
*Bogdan Dziewierz
*Maximilian Schulz
*Ben Wu
*Andreas Melhede
*Stuart McWhinney

===📣 Updates===
'''Change in meeting cadence:''' From now on, cross organisational meeting will only be every first Wednesday of the month. Separate meetings for engineering and content writer tasks.

''Bogdan''

*Engineering team has divided tasks on Jira and is working on them

''Maximilian Schulz''

*Will change all seperate board invitations to organisation invitations: [https://trello.com/invite/longevitywiki/46e20cd2037ee4cf6e326277218f8286 Trello invite link]
*Content writer meetings set up again: [[Handbook:Content Writer Meetings]]
**Created doodle for upcoming content writer meetings: [https://doodle.com/poll/pp9uysigaw66ddes Doodle Link]
**Started reaching out to interested people in the past for 1:1 onboarding. Content writer onboarding checklist (initially created by Jack): [https://docs.google.com/document/d/15pdBEzUpfEakZ4A-lSRAyfitRRQCUkQ5jR1779P4Y8E/edit Google Docs] (moved in the future)
**Sharing the process updates in the Content Writer meeting minutes instead
** On vacation with limited internet access 20/09 - 03/10. Jack Harley will lead the next content writer meeting
**The drafting & review process is quite simplistic and won't work in the future, we are aware that we need to work on this
*There seem to be quite many people interested in the ethical aspects of longevity research (e.g. recently Robin Howlett, check the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU/edit#gid=2043094641 Volunteer Survey responses]), however it's not part of the currently defined topics ([[Handbook:Handbook#Mission]]); Shall we add it? Does it fit to "wiki-style" content?
**Agreed that we distinguish between "Scientific" and "Philosophical/Ethical" articles on the topic
**No planned articles yet, can come from the community
**Consensus that there is a need for ethical articles that are objective to a Wiki standard (compared to more biased articles, e.g. from Lifespan.io)
*There are many lists on longevity managed by individuals, such as Karl Pfleger ([https://agingbiotech.info/diagnostics/ Diagnostics Example]) - I think it would make so much more sense to manage them in a community like Longevity Wiki, and also good to offer the primary source for these.
**Bogdan shared that he is already looking into the Semantic Wiki extension also as a data source for the life extension tool
*Not discussed in the meeting and followed up upon separately:
** Process for next organisational meeting should also include reviewing the Trello board
**Created public google calendar for LW Meetings, inviting everybody who manages meetings: [https://calendar.google.com/calendar/u/0?cid=NDA4YnV2MjhrNmk2aHU2ODhtZ29nZnBnbG9AZ3JvdXAuY2FsZW5kYXIuZ29vZ2xlLmNvbQ Calendar Link]
**It might make sense to look into the plugins Sam Voigt recommends such as the "Structured Discussions" Extension (see associated [https://trello.com/c/YQpe82tv/33-enable-discussion-forums-on-articles Trello Card])
''Stuart''

* It is currently difficult for newcomers to understand who to contact for what contributions, he will assign roles to the relevant people

{| class="wikitable"
|
===✅ Action Items===

* Bogdan: Meeting invitation is changed to first Wednesday of the month
*Max: Update Wiki to allow for "Philosophical Articles" as well
*Jack: Give Stuart admin access on Discord to assign roles
*
|}
==08/09/2021==
===🧍 Attending===
* Jack Harley
*Blake Delaney
* Marc Smeehuijzen
*Bogdan Dziewierz

===📣 Updates===
''Blake Delaney''

*Introduction: hedge fund manager, with programming, and bioscience background. Previously created a longevity wiki but did not gain traction at the time

* Wikipedia doesn't have the highest quality on longevity and cryonics topics as those with higher override capability often prevent a thorough review of the topic
*Media Wiki has the functionality for authors to be notified when their articles are updated - this can be applied to our project
*Created a 'Cryonics' page on the Wiki - should we keep it on the Wiki? Consensus was yes.
*Social funding could be used to raise funding for the Wiki
*Suggest he can fund AWS infrastructure
*Create a Lifespan.io project and pitch our organization to them to attract funding
*Crowdfunding on the Discord server
*Interested in joining the engineering team and will try to make it to this week's meeting
*Can support a member to create an application to register for a US charity
*There is significant work involved in maintaining charity status
*Alternatively, operate as an LLC and avoid most tax liability by spending as much as you earn
*Some US states have very minimal reporting requirements for LLCs.

''Marc''

*How should we provide feedback to each other's article?

*Discussion page makes sense for feedback to specific articles
* Benefit of our Wiki is that it allows for more speculative topics than Wikipedia, such as longevity science and cryonics

''Jack''

*Provided update on content writers meeting
*Block updates to 'Pillar' articles once completed to avoid vandalism
* Can keep the 'cryonics' page on the Wiki, though, pending reaching out to science and medical organizations for content writing

''Sharon Wong''

*Have a header that says, 'version active as of (date)' on multilingual pages to overcome the issue of translated articles requiring frequent updates
*Having issues uploading the image on the rapamycin article - @Bogdan to investigate
*Style and standardising translating terms into Chinese requires a standard glossary
*There is a need to stipulate the translation tool for those who are translating the wiki (e.g. DeepL)
*Need for the 'how to contribute' page on the Wiki Handbook to be updated with translation tasks.
*Higher bar for 'tax deductible status' in Australia. It's a good reason to avoid this for now, to avoid excessive paperwork.

''Bogdan''

*Will have to create 'drafts' namespace
*'Discussion' page associated with pages on the Wiki is currently active
*Discussion page can foster more discussion amongst non-Discord users of the Wiki
*Cryonics discussion brings up an interesting point - what is the included scope of the Wiki? Consensus was that anything 'life-span extending' related should be included. In particular topics that Wikipedia doesn't cover well.
*Updated the onboarding guide for new developers
*Life extension tool in-progress
*Sam Voigt has previously volunteered to pursue the pros and cons of registering as a non-for-profit - @Jack to get in touch
*UK may have a separate charity status to receive money if no goods or services (business-like activities)

==01/09/2021==

===🧍 Attending===

*Jack Harley
*Ben Wu
* Sharon Wong
*Marc Smeehuijzen
* Andreas Melhede

===📣 Updates===
''Jack Harley''

* Begun ''Aging and Neurodegeneration'' brainstorm and write-up. References and comments welcome.
*Collaborated with Max to create process for content writers (discussed below)
*Kindly ask all Wiki members to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
*[https://agingpharma.org/ ARDD Conference] has begun - good opportunity for Wiki members to learn more about the field - videos should be uploaded to the website for free viewing in the coming weeks.
*Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021

''Sharon Wong''

* Noted that the translation for the Rapamycin article was updating while
*Found it difficult to quickly copy content and formatting to a new page - Bogdan may able to assist with this
*Noted that it's probably not worth translating references
*Recommended deepl.com as the 'gold standard' for translating of articles. Produces more simplistic sentence structures compared to Google Translate.

''Ben Wu''

*Summary of EARD conference - mentioned Tina Woods' talk on lobbying UK government to increase funding towards aging research, and recognising biology of aging as a critical healthcare mission. Also mentioned that emphasis on healthspan seems more effective in communication than emphasis on lifespan.

''Marc''

*Bi-weekly content writers meetings could be structured around a review process whereby writers provide helpful feedback on other writers' articles. Maybe writers with journalistic/editor experience know of an effective review process similar to how people work at a newspaper/magazine/journal.
*We should prevent information being copied across various parts of the website because this makes maintenance harder. E.g. the 'About us' information is now both on the About us page and in the Handbook. He suggests removing the 'About Us' content from the Handbook, and replace it with a link to the 'About us' page.
* The handbook contains much valuable information for contributors but is not that interesting for most wiki visitors who just visit the wiki for longevity related information. He suggests to show only some high level 'how to contribute' information on the 'How to contribute' page so we don't overwhelm visitors (basically just asking people to contact us if they want to help) and then add a prominent link to the Handbook for if they want to dive into all the details. 

Andreas Melhede:

*Discussed Discord Role Management on Discord with Stuart McWhinney.
** It is very close to finished and ready to be implemented on our server.

''Max Schulz:''

*Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
***Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
***Using ''Organisational'' board to manage weekly core meetings
***Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
***Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
**''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
***Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
***I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
***Proposed board usage:
****Future ideas for clearly far in the future (months)
****Backlog for tasks to do soon (weeks)
****Todo for tasks agreed to be done next, or you want to work on next
****Once task is worked on -> Move to In Progress
****If you want someone to review -> Move to In Review
****If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
***Meaningful task definitions
***Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
*Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
**Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
**Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
* Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
** Should be filled out by all team members so we have an overview.

==25/08/2021==

===🧍 Attending ===

*Jack Harley
* Bogdan Dziewierz
*Marc Smeehuijzen
*Ben Wu
*Andreas Melhede
*Heye Groß
*Max Schons
*Stuart

===📣 Updates===
*Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
*Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
*Max Schons working on risk factors, subjective vs objective measures of health, various major disease
*Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
*Heye planning on engaging with EA community at conferences and talking about the Wiki
*Technical meeting bimonthly with Bogdan, Mac, Stuart
*Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
===✅ Action Items===

* Continue working on core articles
*
|}

==18/08/2021 ==

===🧍 Attending===
*Jack Harley
*Bogdan Dziewierz
*Max Schulz
*Andreas Melhede
*Sam Voigt
*Marc Smeehujizen
*Heye Groß

===📣 Updates Roundtable===
Jack Harley

*India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

*More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

*Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

*Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

*Custom namespace "Handbook" created on the Wiki
*Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

*Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
*Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
*Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

*Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

*Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
**Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
*Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
**5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
**In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
**Open calendar links for meetings would be good (also are there other meetings to know of...?)
*How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
*There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
**Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
*What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
*Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
*Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

*Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
===✅ Action Items===

*Jack: There is a need for volunteers to help with on-boarding new contributors

*Bogdan: We need to make it more prominent and visible in the menu
*Bogdan: How to contribute menu item needs to be replaced with Handbook
*Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
*Jack: Let’s try to organise symposium or conference once we get funding.
*Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

==11/08/2021 ==

===Purpose===
Regular weekly meeting

=== 🧍 Attending===

*Jack Harley, Co-Founder
*Bogdan Dziewierz, Co-founder & Head of Engineering
*Max Schons, Content Writer
*Max Schulz, Engineering Team Member and Organisational Consultant
*Ben Wu, Head of Content
*Andreas Melhede, Head of Marketing
*Sharon Wong, Content Translator

===📣 Updates Roundtable===

#Name: Max Schulz
##Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
##Discussed platforms for hosting the Handbook, such as Confluence.
#Name Bogdan
##Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
##Life extension tool is a work in progress.
#Name Jack
##Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
#‍Name Max Schons
##Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
##Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
#Name Ben
##Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
#Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
#Name Andreas
##Provided updates on social media accounts.
##Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
===✅ Action Items===

*Bogdan to create namespace for Handbook, and Handbook landing page
*Jack follow up on Max’s organizational wiki suggestions
*Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
*Bogdan to organize an Engineering team spring meeting
*Jack to create and share a document of organizational processes
*Max Schulz to forward exemplary handbook to Jack
*Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021==

===🧍 Attending===

*Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
*Marc Smeehuijzen, Head of UX
*Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

===📣 Updates Roundtable===

#Name: Bogdan
##Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
##Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
##Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
##There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
##Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
##New marketing expert is interested in joining the project, could work alongside Andreas
##Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
##Looking for someone who can manage the content writers.
#‍Name Marc
##Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
##Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
#Name Andreas
##Made some social media posts on the 5 key articles that we’re working on.
##Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items===

* Ben looks for famous professor as co author for India Times article
*Jack follow up on Maximillian’s organizational wiki suggestions
*Jack looks for someone to manage the content writers
*Jack to assign organizational document writing to other members
*Marc joins the engineering team and moves his Trello cards to Jira
|}

==29/07/2021==

===🧍 Attending===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

===🙌 Celebrate wins ===

*New software developer, Mark Whitlock, will join the IT team to help develop the technical side
*Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

===💬 Discussion Topics ===

*Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

===📣 Updates Roundtable ===

#Name: Jack
##A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
##We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
##Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
#Name Ben
##Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

#We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

#Name Andreas
##Clarifying the target audience as primarily those who are non-specialists
##Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
===✅ Action Items===

*Jack meeting with Max Shulz to discuss further collaboration ideas
*Ben to add list of drugs of interest to lifespan extension tool database
*Ben to add relevant sources to the database for content writers - E.g. ITP
*Assign content writers / other team members with science background to assist with completing data for the life extension tool
*Andreas to create Discord channel for meeting minutes
*Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Template:Draft-article

2021-09-15T07:55:44Z

Schulzm: Add description to template

----
[[File:Under construction icon-blue.png.png|50px|left]]
'''This article is currently a draft.''' 
Material may not yet be complete, information may presently be omitted, and certain parts of the content may be subject to radical, rapid alteration. More information pertaining to this may be available on the [[{{TALKPAGENAME}}|talk page]].
<includeonly>[[Category:Drafts]]</includeonly>
----
<noinclude>
Banner to be included at the start of new articles that haven't been finalized yet.
</noinclude>

Handbook:Meeting Minutes

2021-09-15T07:11:26Z

Schulzm: /* 📓Preparation Notes */ Last changes before meeting

== 15/09/2021 ==

=== 📓Preparation Notes ===
''Max Schulz:''

* Let's go through the Organisational Trello Board?
** We can easily share an organisation instead of a board link: [https://trello.com/invite/longevitywiki/46e20cd2037ee4cf6e326277218f8286 Trello invite link] - change the information and change memberships?
*Content writer meetings set up again: [[Handbook:Content Writer Meetings]]
*New process for draft articles created (see [https://en.longevitywiki.org/wiki/Handbook:Handbook#:~:text=The%20Contribute%20menu-,Create%20a%20page,-%5Bedit%5D Handbook], to be shared at the next content writer meeting as well):
**[[Template:Draft-article|Draft Article banner template]] should be added to beginning of article via <nowiki>{{ Draft-article }}</nowiki> (without spaces), automatically adding a banner and the "Drafts" category (maybe in the future add automatically for new pages/articles?)
**Moved some (non-glossary) articles into Drafts that were very obvious ([https://en.longevitywiki.org/wiki/Articles#:~:text=Risk%20Factor-,Drafts,-%5Bedit%5D Articles Drafts Section])
**Note: The DPL Extensions on the Articles page take a while to update the lists when articles are moved between categories ([[mediawikiwiki:Topic:Qdku9ow0v2z2krrv|MediaWiki Topic]] | [https://phabricator.wikimedia.org/T13685 Related Issue])
*Created doodle for upcoming content writer meetings: [https://doodle.com/poll/pp9uysigaw66ddes Doodle Link]
*On vacation with limited internet access 20/09 - 03/10. Can anyone lead the next content writer meeting?
*Created public google calendar for LW Meetings, inviting everybody who manages meetings: [https://calendar.google.com/calendar/u/0?cid=NDA4YnV2MjhrNmk2aHU2ODhtZ29nZnBnbG9AZ3JvdXAuY2FsZW5kYXIuZ29vZ2xlLmNvbQ Calendar Link]
*Started reaching out to interested people in the past for 1:1 onboarding
** Content writer onboarding checklist (initially created by Jack): [https://docs.google.com/document/d/15pdBEzUpfEakZ4A-lSRAyfitRRQCUkQ5jR1779P4Y8E/edit Google Docs] (moved in the future)
*There seem to be quite many people interested in the ethical aspects of longevity research (e.g. recently Robin Howlett, check the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU/edit#gid=2043094641 Volunteer Survey responses]), however it's not part of the currently defined topics ([[Handbook:Handbook#Mission]]); Shall we add it? Does it fit to "wiki-style" content?
*There are many lists on longevity managed by individuals, such as Karl Pfleger ([https://agingbiotech.info/diagnostics/ Diagnostics Example]) - I think it would make so much more sense to manage them in a community like Longevity Wiki, and also good to offer the primary source for these. For this, the table functionalities of the Wiki need to be improved to enable features such as filtering or sorting (There might be a plugin?)
*It might make sense to look into the plugins Sam Voigt recommends such as the "Structured Discussions" Extension (see associated [https://trello.com/c/YQpe82tv/33-enable-discussion-forums-on-articles Trello Card])
*

==08/09/2021==

===🧍 Attending===
* Jack Harley
*Blake Delaney
* Marc Smeehuijzen
*Bogdan Dziewierz

===📣 Updates===
''Blake Delaney''

*Introduction: hedge fund manager, with programming, and bioscience background. Previously created a longevity wiki but did not gain traction at the time

*Wikipedia doesn't have the highest quality on longevity and cryonics topics as those with higher override capability often prevent a thorough review of the topic
*Media Wiki has the functionality for authors to be notified when their articles are updated - this can be applied to our project
*Created a 'Cryonics' page on the Wiki - should we keep it on the Wiki? Consensus was yes.
*Social funding could be used to raise funding for the Wiki
*Suggest he can fund AWS infrastructure
*Create a Lifespan.io project and pitch our organization to them to attract funding
*Crowdfunding on the Discord server
*Interested in joining the engineering team and will try to make it to this week's meeting
*Can support a member to create an application to register for a US charity
*There is significant work involved in maintaining charity status
*Alternatively, operate as an LLC and avoid most tax liability by spending as much as you earn
*Some US states have very minimal reporting requirements for LLCs.

''Marc''

* How should we provide feedback to each other's article?

*Discussion page makes sense for feedback to specific articles
*Benefit of our Wiki is that it allows for more speculative topics than Wikipedia, such as longevity science and cryonics

''Jack''

*Provided update on content writers meeting
* Block updates to 'Pillar' articles once completed to avoid vandalism
*Can keep the 'cryonics' page on the Wiki, though, pending reaching out to science and medical organizations for content writing

''Sharon Wong''

* Have a header that says, 'version active as of (date)' on multilingual pages to overcome the issue of translated articles requiring frequent updates
*Having issues uploading the image on the rapamycin article - @Bogdan to investigate
*Style and standardising translating terms into Chinese requires a standard glossary
* There is a need to stipulate the translation tool for those who are translating the wiki (e.g. DeepL)
*Need for the 'how to contribute' page on the Wiki Handbook to be updated with translation tasks.
* Higher bar for 'tax deductible status' in Australia. It's a good reason to avoid this for now, to avoid excessive paperwork.

''Bogdan''

*Will have to create 'drafts' namespace
*'Discussion' page associated with pages on the Wiki is currently active
*Discussion page can foster more discussion amongst non-Discord users of the Wiki
*Cryonics discussion brings up an interesting point - what is the included scope of the Wiki? Consensus was that anything 'life-span extending' related should be included. In particular topics that Wikipedia doesn't cover well.
*Updated the onboarding guide for new developers
* Life extension tool in-progress
*Sam Voigt has previously volunteered to pursue the pros and cons of registering as a non-for-profit - @Jack to get in touch
*UK may have a separate charity status to receive money if no goods or services (business-like activities)

==01/09/2021==

=== 🧍 Attending===

*Jack Harley
*Ben Wu
*Sharon Wong
*Marc Smeehuijzen
*Andreas Melhede

===📣 Updates===
''Jack Harley''

*Begun ''Aging and Neurodegeneration'' brainstorm and write-up. References and comments welcome.
*Collaborated with Max to create process for content writers (discussed below)
*Kindly ask all Wiki members to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
*[https://agingpharma.org/ ARDD Conference] has begun - good opportunity for Wiki members to learn more about the field - videos should be uploaded to the website for free viewing in the coming weeks.
*Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021

''Sharon Wong''

* Noted that the translation for the Rapamycin article was updating while
*Found it difficult to quickly copy content and formatting to a new page - Bogdan may able to assist with this
*Noted that it's probably not worth translating references
*Recommended deepl.com as the 'gold standard' for translating of articles. Produces more simplistic sentence structures compared to Google Translate.

''Ben Wu''

*Summary of EARD conference - mentioned Tina Woods' talk on lobbying UK government to increase funding towards aging research, and recognising biology of aging as a critical healthcare mission. Also mentioned that emphasis on healthspan seems more effective in communication than emphasis on lifespan.

''Marc''

*Bi-weekly content writers meetings could be structured around a review process whereby writers provide helpful feedback on other writers' articles. Maybe writers with journalistic/editor experience know of an effective review process similar to how people work at a newspaper/magazine/journal.
*We should prevent information being copied across various parts of the website because this makes maintenance harder. E.g. the 'About us' information is now both on the About us page and in the Handbook. He suggests removing the 'About Us' content from the Handbook, and replace it with a link to the 'About us' page.
* The handbook contains much valuable information for contributors but is not that interesting for most wiki visitors who just visit the wiki for longevity related information. He suggests to show only some high level 'how to contribute' information on the 'How to contribute' page so we don't overwhelm visitors (basically just asking people to contact us if they want to help) and then add a prominent link to the Handbook for if they want to dive into all the details. 

Andreas Melhede:

*Discussed Discord Role Management on Discord with Stuart McWhinney.
**It is very close to finished and ready to be implemented on our server.

''Max Schulz:''

*Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
**Let's focus only on trello boards that are used, and archive others - I propose:
***Archiving ''Engineering'' and ''UX'' -> Moving to Jira
***Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
***Using ''Organisational'' board to manage weekly core meetings
***Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
**''Organisational'' board (people need to be added):
***Should be reviewed and kept up to date weekly
***Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
***I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
***Proposed board usage:
****Future ideas for clearly far in the future (months)
****Backlog for tasks to do soon (weeks)
****Todo for tasks agreed to be done next, or you want to work on next
****Once task is worked on -> Move to In Progress
****If you want someone to review -> Move to In Review
****If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
***Meaningful task definitions
***Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
**Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
*Content writer management:
**Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
**Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
**Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
***Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
*Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
**Should be filled out by all team members so we have an overview.

== 25/08/2021==

===🧍 Attending===

*Jack Harley
*Bogdan Dziewierz
*Marc Smeehuijzen
*Ben Wu
*Andreas Melhede
*Heye Groß
*Max Schons
*Stuart

===📣 Updates===
*Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
*Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
*Database of interests of participants, time zones etc.
*Max Schons working on risk factors, subjective vs objective measures of health, various major disease
*Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
*Heye planning on engaging with EA community at conferences and talking about the Wiki
*Technical meeting bimonthly with Bogdan, Mac, Stuart
*Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items===

*Continue working on core articles
*
|}

==18/08/2021==

===🧍 Attending===
*Jack Harley
*Bogdan Dziewierz
*Max Schulz
*Andreas Melhede
*Sam Voigt
*Marc Smeehujizen
*Heye Groß

===📣 Updates Roundtable===
Jack Harley

*India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

*More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

*Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

*Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

*Custom namespace "Handbook" created on the Wiki
*Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
*Slowly progressing on Life Extension tool

''Heye Groß''

*Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
*Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
*Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

*Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

*Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
**Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
*Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
**5 or 20 pillar articles to start with? Saw conflicting information
**Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
**In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
**Open calendar links for meetings would be good (also are there other meetings to know of...?)
*How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
*There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
*Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

*There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

*Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
===✅ Action Items===

*Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
*Bogdan: How to contribute menu item needs to be replaced with Handbook
*Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
*Jack: Let’s try to organise symposium or conference once we get funding.
*Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

==11/08/2021==

=== Purpose===
Regular weekly meeting

===🧍 Attending===

*Jack Harley, Co-Founder
*Bogdan Dziewierz, Co-founder & Head of Engineering
*Max Schons, Content Writer
*Max Schulz, Engineering Team Member and Organisational Consultant
*Ben Wu, Head of Content
*Andreas Melhede, Head of Marketing
*Sharon Wong, Content Translator

=== 📣 Updates Roundtable===

#Name: Max Schulz
##Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
##Discussed platforms for hosting the Handbook, such as Confluence.
#Name Bogdan
##Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
##Life extension tool is a work in progress.
# Name Jack
##Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
##Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
##Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
##Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
#Name Ben
##Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
#Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
#Name Andreas
##Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
===✅ Action Items===

*Bogdan to create namespace for Handbook, and Handbook landing page
*Jack follow up on Max’s organizational wiki suggestions
*Jack to follow up with Max Schulz regarding content writers management
*Jack to assign organizational document writing to other members
*Bogdan to organize an Engineering team spring meeting
*Jack to create and share a document of organizational processes
*Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
*Ben Wu to continue working on Aging Epigenetics article
|}

==04/08/2021==

===🧍 Attending===

* Jack Harley, Co-Founder
*Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
*Ben Wu, Head of Content
*Andreas Melhede, Head of Marketing

===📣 Updates Roundtable ===

#Name: Bogdan
##Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
##Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
##Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
##Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
#Name Ben
##There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
#Name Jack
##Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
##New marketing expert is interested in joining the project, could work alongside Andreas
##Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
##Looking for someone who can manage the content writers.
#‍Name Marc
##Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
##Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
#Name Andreas
##Made some social media posts on the 5 key articles that we’re working on.
##Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
===✅ Action Items===

* Ben looks for famous professor as co author for India Times article
*Jack follow up on Maximillian’s organizational wiki suggestions
*Jack looks for someone to manage the content writers
*Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

==29/07/2021==

=== 🧍 Attending===

*Jack Harley, Co-Founder
*Andreas Melhede, Head of Marketing
*Ben Wu, Head of Content

===🙌 Celebrate wins===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
*Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

===💬 Discussion Topics===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

===📣 Updates Roundtable===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
##We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
##Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
##Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
#Name Ben
##Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

#We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

#Name Andreas
##Clarifying the target audience as primarily those who are non-specialists
##Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
===✅ Action Items===

*Jack meeting with Max Shulz to discuss further collaboration ideas
*Ben to add list of drugs of interest to lifespan extension tool database
*Ben to add relevant sources to the database for content writers - E.g. ITP
*Assign content writers / other team members with science background to assist with completing data for the life extension tool
*Andreas to create Discord channel for meeting minutes
*Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Meeting Minutes

2021-09-14T19:04:15Z

Schulzm: /* 📓Preparation Notes */

== 15/09/2021 ==

=== 📓Preparation Notes ===
''Max Schulz:''

* Let's go through the Organisational Trello Board?
*Content writer meetings set up again: [[Handbook:Content Writer Meetings]]
*New process for draft articles created (see [https://en.longevitywiki.org/wiki/Handbook:Handbook#:~:text=The%20Contribute%20menu-,Create%20a%20page,-%5Bedit%5D Handbook], to be shared at the next content writer meeting as well):
**[[Template:Draft-article|Draft Article banner template]] should be added to beginning of article via <nowiki>{{ Draft-article }}</nowiki> (without spaces), automatically adding a banner and the "Drafts" category (maybe in the future add automatically for new pages/articles?)
**Moved some (non-glossary) articles into Drafts that were very obvious ([https://en.longevitywiki.org/wiki/Articles#:~:text=Risk%20Factor-,Drafts,-%5Bedit%5D Articles Drafts Section])
**Note: The DPL Extensions on the Articles page take a while to update the lists when articles are moved between categories ([[mediawikiwiki:Topic:Qdku9ow0v2z2krrv|MediaWiki Topic]] | [https://phabricator.wikimedia.org/T13685 Related Issue])
*Created doodle for upcoming meetings: [https://doodle.com/poll/pp9uysigaw66ddes Doodle Link]
*Started reaching out to interested people in the past for 1:1 onboarding
** Content writer onboarding checklist (initially created by Jack): [https://docs.google.com/document/d/15pdBEzUpfEakZ4A-lSRAyfitRRQCUkQ5jR1779P4Y8E/edit Google Docs] (moved in the future)
*There seem to be quite many people interested in the ethical aspects of longevity research (e.g. recently Robin Howlett, check the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU/edit#gid=2043094641 Volunteer Survey responses]), however it's not part of the currently defined topics ([[Handbook:Handbook#Mission]]); Shall we add it? Does it fit to "wiki-style" content?
*There are many lists on longevity managed by individuals, such as Karl Pfleger ([https://agingbiotech.info/diagnostics/ Diagnostics Example]) - I think it would make so much more sense to manage them in a community like Longevity Wiki, and also good to offer the primary source for these. For this, the table functionalities of the Wiki need to be improved to enable features such as filtering or sorting (There might be a plugin?)
*On vacation with limited internet access 20/09 - 03/10. Can anyone lead the next content writer meeting?
*It might make sense to look into the plugins Sam Voigt recommends such as the "Structured Discussions" Extension (see associated [https://trello.com/c/YQpe82tv/33-enable-discussion-forums-on-articles Trello Card])
*

==08/09/2021==

===🧍 Attending===
* Jack Harley
*Blake Delaney
* Marc Smeehuijzen
*Bogdan Dziewierz

===📣 Updates===
''Blake Delaney''

*Introduction: hedge fund manager, with programming, and bioscience background. Previously created a longevity wiki but did not gain traction at the time

*Wikipedia doesn't have the highest quality on longevity and cryonics topics as those with higher override capability often prevent a thorough review of the topic
*Media Wiki has the functionality for authors to be notified when their articles are updated - this can be applied to our project
*Created a 'Cryonics' page on the Wiki - should we keep it on the Wiki? Consensus was yes.
*Social funding could be used to raise funding for the Wiki
*Suggest he can fund AWS infrastructure
*Create a Lifespan.io project and pitch our organization to them to attract funding
*Crowdfunding on the Discord server
*Interested in joining the engineering team and will try to make it to this week's meeting
*Can support a member to create an application to register for a US charity
*There is significant work involved in maintaining charity status
*Alternatively, operate as an LLC and avoid most tax liability by spending as much as you earn
*Some US states have very minimal reporting requirements for LLCs.

''Marc''

* How should we provide feedback to each other's article?

*Discussion page makes sense for feedback to specific articles
*Benefit of our Wiki is that it allows for more speculative topics than Wikipedia, such as longevity science and cryonics

''Jack''

*Provided update on content writers meeting
* Block updates to 'Pillar' articles once completed to avoid vandalism
*Can keep the 'cryonics' page on the Wiki, though, pending reaching out to science and medical organizations for content writing

''Sharon Wong''

* Have a header that says, 'version active as of (date)' on multilingual pages to overcome the issue of translated articles requiring frequent updates
*Having issues uploading the image on the rapamycin article - @Bogdan to investigate
*Style and standardising translating terms into Chinese requires a standard glossary
* There is a need to stipulate the translation tool for those who are translating the wiki (e.g. DeepL)
*Need for the 'how to contribute' page on the Wiki Handbook to be updated with translation tasks.
* Higher bar for 'tax deductible status' in Australia. It's a good reason to avoid this for now, to avoid excessive paperwork.

''Bogdan''

*Will have to create 'drafts' namespace
*'Discussion' page associated with pages on the Wiki is currently active
*Discussion page can foster more discussion amongst non-Discord users of the Wiki
*Cryonics discussion brings up an interesting point - what is the included scope of the Wiki? Consensus was that anything 'life-span extending' related should be included. In particular topics that Wikipedia doesn't cover well.
*Updated the onboarding guide for new developers
* Life extension tool in-progress
*Sam Voigt has previously volunteered to pursue the pros and cons of registering as a non-for-profit - @Jack to get in touch
*UK may have a separate charity status to receive money if no goods or services (business-like activities)

==01/09/2021==

=== 🧍 Attending===

*Jack Harley
*Ben Wu
*Sharon Wong
*Marc Smeehuijzen
*Andreas Melhede

===📣 Updates===
''Jack Harley''

*Begun ''Aging and Neurodegeneration'' brainstorm and write-up. References and comments welcome.
*Collaborated with Max to create process for content writers (discussed below)
*Kindly ask all Wiki members to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
*[https://agingpharma.org/ ARDD Conference] has begun - good opportunity for Wiki members to learn more about the field - videos should be uploaded to the website for free viewing in the coming weeks.
*Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021

''Sharon Wong''

* Noted that the translation for the Rapamycin article was updating while
*Found it difficult to quickly copy content and formatting to a new page - Bogdan may able to assist with this
*Noted that it's probably not worth translating references
*Recommended deepl.com as the 'gold standard' for translating of articles. Produces more simplistic sentence structures compared to Google Translate.

''Ben Wu''

*Summary of EARD conference - mentioned Tina Woods' talk on lobbying UK government to increase funding towards aging research, and recognising biology of aging as a critical healthcare mission. Also mentioned that emphasis on healthspan seems more effective in communication than emphasis on lifespan.

''Marc''

*Bi-weekly content writers meetings could be structured around a review process whereby writers provide helpful feedback on other writers' articles. Maybe writers with journalistic/editor experience know of an effective review process similar to how people work at a newspaper/magazine/journal.
*We should prevent information being copied across various parts of the website because this makes maintenance harder. E.g. the 'About us' information is now both on the About us page and in the Handbook. He suggests removing the 'About Us' content from the Handbook, and replace it with a link to the 'About us' page.
* The handbook contains much valuable information for contributors but is not that interesting for most wiki visitors who just visit the wiki for longevity related information. He suggests to show only some high level 'how to contribute' information on the 'How to contribute' page so we don't overwhelm visitors (basically just asking people to contact us if they want to help) and then add a prominent link to the Handbook for if they want to dive into all the details. 

Andreas Melhede:

*Discussed Discord Role Management on Discord with Stuart McWhinney.
**It is very close to finished and ready to be implemented on our server.

''Max Schulz:''

*Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
**Let's focus only on trello boards that are used, and archive others - I propose:
***Archiving ''Engineering'' and ''UX'' -> Moving to Jira
***Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
***Using ''Organisational'' board to manage weekly core meetings
***Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
**''Organisational'' board (people need to be added):
***Should be reviewed and kept up to date weekly
***Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
***I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
***Proposed board usage:
****Future ideas for clearly far in the future (months)
****Backlog for tasks to do soon (weeks)
****Todo for tasks agreed to be done next, or you want to work on next
****Once task is worked on -> Move to In Progress
****If you want someone to review -> Move to In Review
****If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
***Meaningful task definitions
***Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
**Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
*Content writer management:
**Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
**Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
**Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
***Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
*Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
**Should be filled out by all team members so we have an overview.

== 25/08/2021==

===🧍 Attending===

*Jack Harley
*Bogdan Dziewierz
*Marc Smeehuijzen
*Ben Wu
*Andreas Melhede
*Heye Groß
*Max Schons
*Stuart

===📣 Updates===
*Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
*Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
*Database of interests of participants, time zones etc.
*Max Schons working on risk factors, subjective vs objective measures of health, various major disease
*Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
*Heye planning on engaging with EA community at conferences and talking about the Wiki
*Technical meeting bimonthly with Bogdan, Mac, Stuart
*Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items===

*Continue working on core articles
*
|}

==18/08/2021==

===🧍 Attending===
*Jack Harley
*Bogdan Dziewierz
*Max Schulz
*Andreas Melhede
*Sam Voigt
*Marc Smeehujizen
*Heye Groß

===📣 Updates Roundtable===
Jack Harley

*India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

*More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

*Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

*Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

*Custom namespace "Handbook" created on the Wiki
*Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
*Slowly progressing on Life Extension tool

''Heye Groß''

*Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
*Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
*Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

*Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

*Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
**Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
*Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
**5 or 20 pillar articles to start with? Saw conflicting information
**Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
**In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
**Open calendar links for meetings would be good (also are there other meetings to know of...?)
*How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
*There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
*Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

*There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

*Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
===✅ Action Items===

*Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
*Bogdan: How to contribute menu item needs to be replaced with Handbook
*Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
*Jack: Let’s try to organise symposium or conference once we get funding.
*Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

==11/08/2021==

=== Purpose===
Regular weekly meeting

===🧍 Attending===

*Jack Harley, Co-Founder
*Bogdan Dziewierz, Co-founder & Head of Engineering
*Max Schons, Content Writer
*Max Schulz, Engineering Team Member and Organisational Consultant
*Ben Wu, Head of Content
*Andreas Melhede, Head of Marketing
*Sharon Wong, Content Translator

=== 📣 Updates Roundtable===

#Name: Max Schulz
##Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
##Discussed platforms for hosting the Handbook, such as Confluence.
#Name Bogdan
##Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
##Life extension tool is a work in progress.
# Name Jack
##Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
##Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
##Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
##Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
#Name Ben
##Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
#Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
#Name Andreas
##Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
===✅ Action Items===

*Bogdan to create namespace for Handbook, and Handbook landing page
*Jack follow up on Max’s organizational wiki suggestions
*Jack to follow up with Max Schulz regarding content writers management
*Jack to assign organizational document writing to other members
*Bogdan to organize an Engineering team spring meeting
*Jack to create and share a document of organizational processes
*Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
*Ben Wu to continue working on Aging Epigenetics article
|}

==04/08/2021==

===🧍 Attending===

* Jack Harley, Co-Founder
*Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
*Ben Wu, Head of Content
*Andreas Melhede, Head of Marketing

===📣 Updates Roundtable ===

#Name: Bogdan
##Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
##Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
##Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
##Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
#Name Ben
##There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
#Name Jack
##Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
##New marketing expert is interested in joining the project, could work alongside Andreas
##Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
##Looking for someone who can manage the content writers.
#‍Name Marc
##Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
##Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
#Name Andreas
##Made some social media posts on the 5 key articles that we’re working on.
##Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
===✅ Action Items===

* Ben looks for famous professor as co author for India Times article
*Jack follow up on Maximillian’s organizational wiki suggestions
*Jack looks for someone to manage the content writers
*Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

==29/07/2021==

=== 🧍 Attending===

*Jack Harley, Co-Founder
*Andreas Melhede, Head of Marketing
*Ben Wu, Head of Content

===🙌 Celebrate wins===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
*Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

===💬 Discussion Topics===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

===📣 Updates Roundtable===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
##We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
##Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
##Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
#Name Ben
##Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

#We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

#Name Andreas
##Clarifying the target audience as primarily those who are non-specialists
##Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
===✅ Action Items===

*Jack meeting with Max Shulz to discuss further collaboration ideas
*Ben to add list of drugs of interest to lifespan extension tool database
*Ben to add relevant sources to the database for content writers - E.g. ITP
*Assign content writers / other team members with science background to assist with completing data for the life extension tool
*Andreas to create Discord channel for meeting minutes
*Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Senolytics

2021-09-14T18:57:53Z

Schulzm: Add Draft Article Banner

{{Draft-article}}

Senolytics are a novel class of drugs that clear senescent cells (SCs) from the body, thereby removing this specific type of cell that accumulates with aging. SCs are responsible for generating the senescence-associated secretory phenotype (SASP), which have been shown to drive tissue dysfunction in a large range of organ systems.

== Types of senolytics ==

Senolytics are a novel class of drugs that clear senescent cells (SCs) from the body that are implicated in aging. SCs not only accumulate with aging, but also play a fundamental role in aging and age-related diseases; removal of such cells confers substantial benefit in healthspan and lifespan in animal models of premature aging and normal aging.

SCs are responsible for generating the senescence-associated secretory phenotype (SASP), which have been shown to drive tissue dysfunction in a large range of organ systems.

=== Dasatinib + Quercetin ===
Dasatinib and Quercertin are a specific combination of medicines (D+Q) used for senescent cell clearance, which began from research in the Mayo Clinic.

=== Fisetin ===
[[Fisetin]] is a naturally-occurring flavonoid that is rich in certain fruits and vegetables, such as strawberries, grapes, apples, cucumbers, and onions. It has known antioxidant activity and is a supplement that is regarded as safe, even at high doses.

https://www.thelancet.com/article/S2352-3964(18)30373-6/fulltext
[[Category:Longevity]]

NAD+

2021-09-14T18:56:19Z

Schulzm: Add Draft Article Banner

{{Draft-article}}

== Importance in aging ==
[[Category:Longevity]]

Dasatinib

2021-09-14T18:54:57Z

Schulzm: Add Draft Article Banner

{{Draft-article}}

Dasatinib is a chemotherapeutic drug used for treating certain types of leukaemia<ref name=":0">https://www.drugs.com/monograph/dasatinib.html?references=1</ref>. The compound was originally named dasatinib after one of the research fellows who helped produce it, Jagabandhu Das<ref name=":1">http://cenblog.org/the-haystack/2012/01/jagabandhu-das-dasatinib/</ref>.
[[File:Dasatinib ball-and-stick molecule.png|thumb|The chemical structure of dasatinib.]]
Dasatinib has shown to have [[Senolytics|senolytic]] effect in combination with the drug [[quercetin]] (D+Q) in both mice and humans<ref name=":3">https://linkinghub.elsevier.com/retrieve/pii/S2352396419305912</ref><ref>https://onlinelibrary.wiley.com/doi/10.1111/acel.12344</ref>.

Having performed a risk-benefit analysis<ref>https://brain.forever-healthy.org/display/EN/Dasatinib+and+Quercetin+Senolytic+Therapy</ref>, the Forever Healthy Foundation has decided to "avoid the use of D+Q as a senolytic therapy", until it is more clear what benefits and risks the therapy brings.

Summary of everything below plus additional background information.

Check copyright for the picture (is the attribution enough?)

== Evidence of lifespan extension (WIP) ==

=== Mice ===
Following the discovery that mice's healthspan could be extended by killing senescent cells by activating a sucide gene (find source for this and read and cite), a research team led by Zhu et al. found in 2015 that dasatinib in combination with quercetin could...

Since this pioneering study, many have followed and replicated...

https://brain.forever-healthy.org/display/EN/Dasatinib+and+Quercetin+Senolytic+Therapy+-+Table+3%3A+Preclinical+trials

*Age-related diseases? Other subjects from pre-clinical trials?

=== Humans ===
There has been no evidence to date of dasatinib, or dasatinib in combination with quercetin, contributing to life- or health-span extension in humans.

== Mechanism (WIP) ==

=== Inhibition of tumour growth ===
Dasatinib is a ''tyrosine kinase inhibitor''. This means that it inhibits ''tyrosine kinases'' ''-'' abnormal enzymes that help cancer cells to grow uncontrollably. In particular,

Tyrosine kinases are especially prevalent in patients with chronic myeloid leukaemia (CML), of which most<ref>https://www.cancerresearchuk.org/about-cancer/chronic-myeloid-leukaemia-cml/about</ref> have a so-called ''Philadelphia chromosome1'', which is why dasatinib is used mainly for treating CML (see more below).

Note: A 90% figure can be found in the following source - however, I cannot get access to it:

Nowell, P. C. & Hungerford, D. A. (1960) Science 132, 1947.

''Questions to answer: How do tyrosine kinases help cancer cells grow uncontrollably?''

=== Reducing cellular senescence ===
The first time dasatinib was used as a senolytic was in 2015, when a research team led by Zhu et al. screened for potential drugs to stop the SCAPs...

Dasatinib works as a senolytic in combination with quercetin by targeting senescent human adipocyte progenitors - early versions of fat cells (Q, on the other hand, targets senescent cultured HUVEC's). They disable networks of SCAPs and thus induces apoptosis, cell death.

''Working question: Why, and how, does dasatinib target fat cells exactly? Same for quercetin and HUVECs.''

"...neither D nor Q are senolytic on their own, whilst the combination of D + Q is senolytic"<ref name=":5">https://onlinelibrary.wiley.com/doi/10.1111/joim.13141</ref>
----WORK IN PROGRESS SPACE

"senescent cells upregulate the anti-apoptotic proteins BCL-W and BCL-XL"<ref>https://www.nature.com/articles/ncomms11190</ref>

"D promotes apoptosis caused by dependence receptors, such as the ephrins, in part by inhibiting Src kinase [88, 89]"<ref name=":5" />

ABL1 and SRC family kinases

''How does D promote apoptosis?''

https://pubmed.ncbi.nlm.nih.gov/21528941/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931551/

"Based on their known targets, we predicted that D would target senescent human cultured primary adipocyte progenitor cells, whilst Q would target senescent cultured HUVEC’s. These predictions proved to be correct. The combination of D + Q caused apoptosis of both senescent human primary adipocyte progenitor cells and senescent HUVEC’s, but not nonsenescent adipocyte progenitor cells or HUVEC’s. Furthermore, likely because of redundancy of SCAP pathways, in some cell types, for example, mouse embryonic fibroblasts, neither D nor Q are senolytic on their own, whilst the combination of D + Q is senolytic"<ref name=":5" />

"senescent HUVECs were more susceptible to EFNB1 and BCL-xL siRNAs than nonsenescent cells"<ref name=":6">https://onlinelibrary.wiley.com/doi/10.1111/acel.12344</ref>

LAST LEFT: <ref name=":5" />

"Of these, six triggered senescent cell death, but had little effect on proliferating, nonsenescent cells in two human cell types, preadipocytes (Fig. 1D,F) and endothelial cells (Fig. 1E,G)"<ref name=":6" />

"known to interfere with EFNB-dependent suppression of apoptosis"<ref name=":6" />

"D preferentially reduced viability and caused cell death of senescent human preadipocytes"<ref name=":6" />

''Why are human adipocyte progenitors and endothelial cells (HUVECs) important classes of senescent cells? What are the other types?''

For longevity, not in general.

== Human clinical trials ==

As of May 2020 there have been three human clinical trials using dasatinib in combination with [[quercetin]] (D+Q) as a senolytic<ref>https://brain.forever-healthy.org/display/EN/Dasatinib+and+Quercetin+Senolytic+Therapy</ref>.

The findings of the first ever clinical trial using senolytics in humans was published in December 2018. This pilot study indicated that D+Q may alleviate some of the physical dysfunction experienced by individuals with idiopathic pulmonary fibrosis (IPF), suggesting feasibility of larger, controlled trials evaluating senolytic treatment in IPF and other senescence-associated diseases<ref name=":4">https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(18)30629-7/fulltext</ref>.

A study published in July 2019 showed slight improvement of cardiovascular function in male individuals 21 days after receiving doses of D+Q<ref name=":2">https://www.jbiomeds.com/biomedical-sciences/dasatinib-and-quercetin-shortterm-simultaneous-administration-improves-physical-capacity-in-human.php?aid=24542</ref>.

Finally, a preliminary report published in August 2019 showed that intake of D+Q decreased the number of senescent cells in the body fat of individuals with diabetic kidney disease<ref name=":3" /><ref>https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30810-2/fulltext</ref>, a condition characterised by senescent cell burden<ref>https://pubmed.ncbi.nlm.nih.gov/18768588/</ref>. This is the first and only study to date that has shown a direct effect between senolytic drug treatment and decreased abundance of senescent cells in humans.

Further clinical trials using D+Q as senolytics are on their way, for example investigating their effect on skeletal health, and the progression of Alzheimer's Disease<ref>https://clinicaltrials.gov/ct2/results?cond=&term=dasatinib+AND+quercetin&cntry=&state=&city=&dist=</ref>.

== Regulatory Approval ==
Dasatinib was approved by the US Food and Drug Administration (FDA) in 2006, for the purpose of treating "adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib"<ref>https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021986s000ltr.pdf</ref>, and has been marketed under the brand name Sprycel. Sprycel was similarly approved by the European Medicines Agency (EMA) in the same year<ref>https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel</ref>.

== Safety (WIP) ==
There has been plenty of studies on the side effects of dasatinib<ref>https://brain.forever-healthy.org/display/EN/Dasatinib+and+Quercetin+Senolytic+Therapy+-+Table+2%3A+Clinical+Trials</ref>.

[https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021986lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021986lbl.pdf,] Page 30

Studies indicate that intermittent administration of dasatinib, and senolytics in general, may circumvent potential off-target effects<ref>https://linkinghub.elsevier.com/retrieve/pii/S2352396419305912</ref>.

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405395/ - these state this, too.)

== Current use in medicine ==
Dasatinib is used to treat ''Philadelphia-chromosome-positive'' (Ph+) chronic myeloid leukaemia, sometimes after previous treatment with imatinib has failed. Patients with Ph+ acute lymphoblastic leukaemia (ALL) for which this is also the case, dasatinib can also be used. It is taken orally<ref name=":0" />.

Dasatinib is on the list of the World Health Organization's List of Essential Medicines<ref>https://apps.who.int/iris/handle/10665/330668</ref>.

== Footnotes ==
1 The Philadelphia chromosome is formed when the ''ABL1'' gene on chromosome 9 breaks off and translocates to the ''BCR'' gene on chromosome 22, forming a ''fusion gene'' called ''BCR-ABL1''<ref>https://www.sciencedirect.com/science/article/pii/S0304419X01000221?via%3Dihub#BIB7</ref>. This new ''fusion gene'' instructs cells to produce tyrosine kinases, which in turn permanently "turns on" important cell switches controlling cell division, growth and cell death

LAST UPDATE (20210630):

''Q:'' How does tyrosine kinases help cancer cells? Tyrosine kinase in cancer - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1074718/

''Q:'' How does the ''BCR-ABL1'' gene instruct cells to product tyrosine kinases?

Move this information to mechanism later on?

== References (WIP) ==
Fix this section using APA referencing.<references />
[[Category:Longevity]]
[[Category:Senolytics]]
[[Category:Drugs]]

Cellular senescence

2021-09-14T18:51:51Z

Schulzm: Add Draft Article Banner

{{Draft-article}}

Cellular senescence is one of the [[Hallmarks of Aging|hallmarks of aging]].

== Mechanism ==
''Question to writers: Cellular senescence seems to have a positive function in our bodies - what is that? How does it become dangerous? It seems like it is "a normally adaptive response to injury or infection". Source: <nowiki>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941545/</nowiki>''

Senescent cells secrete a phenotype, appropriately called ''senescence-associated secretory phenotype'' (SASP), which releases various factors that cause inflammation and dysfunction and promotes apoptosis (cell death) in nearby tissues.

''Source references are needed for all of the above, for example:''

https://brain.forever-healthy.org/display/EN/Dasatinib+and+Quercetin+Senolytic+Therapy

=== Diseases associated with cellular senescence ===
Due to the SASP, senescent cells have been associated with a number of age-related diseases:

<nowiki>*</nowiki>Fibrotic Pulmonary Disease: <nowiki>https://pubmed.ncbi.nlm.nih.gov/28230051/</nowiki>

== Senolytics ==
''See the full article on [[senolytics]].''

Senescent cells survive their own SASP, since they are protected by networks of ''senescent cell anti-apoptotic pathways'' (SCAPs). One method of senolytics, therefore, is to interfere with these networks, so that the SASP also induce apoptosis in the senescent cells themselves.

Senescent cells take time to re-build once they are ablated. Hence, an advantage of senolytic treatment is that it can be done in a "hit-and-run" fashion, thus avoiding off-target effects in comparison to other types of treatments.

A way to track if senolytics have any effect is to check out for ''senescent biomarkers''. It seems like p16, p21 and senescence-associated β-galactosidase activity (SA-β-gal) are known markers of senescent cells.

''Writers: Make sure to sync this article with senolytics.''

''Source references are needed for all of the above, see for example the three human clinical trial studies in the article on [[dasatinib]].''

== Negligible senescence ==
''See the full article on [[negligible senescence]].''

The phenomenon of showing no signs of senescence, such as age-related dysfunctions (Wikipedia).
[[Category:Longevity]]

Articles

2021-09-14T18:50:15Z

Schulzm: Fix notcategory argument for Longevity Articles

==Pillar Articles==

<dpl>
category=Pillar Articles
notcategory=Drafts
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>
==General Articles==
<dpl>
category=Longevity
notcategory=Pillar Articles
notcategory=Drafts
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>
==Glossary==
<dpl>
category=Glossary
notcategory=Drafts
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>
==Drafts==
<dpl>
category=Drafts
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>

Aging and depression

2021-09-14T18:43:14Z

Schulzm: Add Draft Article Banner

{{Draft-article}}

== Physical characteristics ==
In the ilSIRENTE study, they found significant differences between older adults with and without depression.<ref>Russo, A., Cesari, M., Onder, G., Zamboni, V., Barillaro, C., Pahor, M., ... & Landi, F. (2007). Depression and physical function: results from the aging and longevity study in the Sirente geographic area (ilSIRENTE Study). ''Journal of geriatric psychiatry and neurology'', ''20''(3), 131-137.</ref> They measured the physical attributes of the participants with Short Physical Performance Battery and a 4-meter walking test, muscle strength with hand-grip capacity a
<references />
[[Category:Longevity]]

Handbook:Handbook

2021-09-14T18:39:02Z

Schulzm: /* How to edit the Wiki */ Add category and draft process

== About the Handbook==
The Longevity Wiki Handbook is the 'source of truth' for the Wiki organisation. It currently contains our mission and strategy, the roles we are looking for, links to our communication platforms and some editing advice. Like the Wiki itself, it's all publicly accessible and transparent and will likely grow and change over time.
== Mission==
Longevity Wiki is an open-access project to create the go-to platform for the science of longevity. The wiki was borne from the need for high quality scientific content on aging and longevity to be freely available and accessible. The Wiki ultimately aims to cover the following topics in detail:

*Longevity drugs and the evidence supporting them
*Personal longevity strategies/advice
*Hallmarks of aging/biology of aging
*Animal models of aging
*Laboratories working in geroscience, and their focus
*Longevity biotech (companies, development pipeline)
*Biology of aging + diseases of aging connection

More information about us can be found on our [[About]] page.

==Strategy==
Instead of producing as much content as possible, we’re going to focus on creating 5 pillar articles written by experts on the topic. These articles will demonstrate the knowledge and quality of our initiative, and then we will build out the wiki from there. These are the pillar articles:

#'''Epigenetic reprogramming'''
#'''Aging and Neurodegeneration'''
#'''Rapamycin'''
#'''Biomarkers of healthspan'''
#'''COVID-19 and Aging'''

In conjunction with these articles, we are going to create a Glossary page of key terms in the longevity space, along with a short (2-3 sentence definition).

== Available Roles and Projects for the Wiki ==
Longevity Wiki is an open access, collaborative project and we invite all volunteers to contribute! The goal of the Wiki is to create a trusted, high quality platform of longevity science content.

This section lists the current projects we are working on, and how you can get involved. If you're interested, please complete our [https://forms.gle/P1huKGcDiPLnRAB17 Volunteer Survey Form] and we will follow up with you by email.

===Pillar article writing===
'''Role: Senior content writer'''

'''Minimum requirements: Masters or PhD training, ideally in a relevant field to content being written'''

We are seeking those with strong scientific backgrounds to help our initial offering of 5 ‘pillar’ articles that will form the initial content on the Wiki.

These articles are designed to be long-form (1.5-2.5k words) articles summarizing the relevant literature as it pertains to aging biology. The style we are aiming for is similar to a literature review, but with a simplified writing style that is accessible to non-specialist readers.

An example is our article on [[Rapamycin]], however, the style and structure of the article may vary by topic.

The following topics have been selected:

*'''Epigenetic reprogramming'''
*'''Aging and Neurodegeneration'''
*'''Rapamycin'''
*'''Biomarkers of healthspan'''
*'''COVID-19 and Aging'''

===Glossary expansion===
'''Role: Junior content writer'''

'''Minimum requirements: High school level biology'''

We are building a glossary of relevant terminology to expand the scope of the Wiki. The glossary will be accessible from an article through the use of so called ‘hovercards’ which makes it possible to display the meaning of a difficult term without leaving the article page.

The list of glossary terms is being populated based on the pillar articles. A full list of glossary terms can be found here (ADD LINK).

To contribute to the glossary, simply choose a term that has not yet been defined, and write a concise, and scientifically accurate definition.

Some guidelines:

*All references should be cited using APA referencing

*All links to internal articles should be linked
*Definitions should be clear and comprehensible to non-specialist audiences
*Definitions can be up to 270 characters in length

An example of a glossary term (ADD LINK).

===Life extension tool database===
'''Role: Researcher'''

'''Minimum requirements: Undergraduate biology, ability to comprehend the longevity data and research'''

We are creating a ‘life extension tool’ that provides an up to date overview of the life extension achieved for different animals with different interventions.

A [https://zpl.io/bePZGJl sample of the tool] can be viewed on our design platform Zeplin.

In order to populate data for the tool, we require assistance in reviewing the literature to identify the lifespan extension associated with different drugs and species, and the original publication in which this was published.

Our current database: [https://docs.google.com/spreadsheets/d/14OLhV4WWSUGomEY-3zko1o8zHHrJwt5YipGbjxhracM/edit?usp=sharing Life Extension Tool Data].

===Software engineering support===
'''Role: Engineer'''

'''Minimum requirements: Interest in software engineering'''

As the wiki grows, we need to ensure that the automation and infrastructure develops. We are especially looking for people with the following abilities:

* AWS reliability engineering/DevOps (people to manage infrastructure and deploy apps)
* PHP
* Front-end development
* Technical product ownership
* A scrum master/iteration manager

===Marketing===
'''Role: Based on experience and performance'''

'''Minimum requirements: Past experience in marketing, splendid communicator and creative individual who is eager to learn'''

Our marketing department is expanding. If you are a creative individual who loves communicating, you could get a lot of significant responsibilities.

=== Graphic design ===
'''Role: Illustrator, data visualization'''

'''Minimum requirements: Experience with graphic design'''

We are looking for individuals with graphic design skills to help us create and re-work pictures, scientific diagrams and graphs to communicate information to non-technical audiences. You will work closely with our content writers to produce high-impact, engaging visuals to accompany the written content.

=== Other roles ===
'''Role: Translator'''

We are looking for individuals with language skills to translate articles into other languages to reach a broader audience - particularly languages spoken commonly around the world. This will be done with the assistance of tools such as Google Translate.

'''Role: UX specialist'''

We are seeking expertise in user experience (UX) to help us design an intuitive and engaging platform. The goal is to create a satisfying experience for our users. You will work with the Head of UX in this role.

== Our communication platforms ==
Besides this Handbook we use a few other platforms for communicating and sharing resources. We're committed to being an open-access platform, and as such, we share all information possible, such as meeting minutes.

=== Discord Server ===
We mostly communicate via the [https://discord.gg/UDKmjcnjye Longevity Wiki Discord Server]. It serves as a day-to-day message board, as well as the host of our meetings. Meetings take place every week at 08:30 GMT.

=== Google Drive ===
Our [https://drive.google.com/drive/folders/19Ol2wcRd2IWUt_gOC5j5Ff7FjSzPVuBf Drive folder] is used for sharing many useful documents, such as draft ideas, spreadsheets, or useful non-wiki resources.

===Organisational weekly meetings===

* Organisanional task management: [https://trello.com/b/0u9pSclR/organisational Trello Board] | [https://trello.com/invite/b/0u9pSclR/0722f6126c69d1341e63765f41d23531/organisational Invitation Link]
* [https://en.longevitywiki.org/wiki/Handbook:Meeting_Minutes Meeting minutes]

The meetings consist of our sprint planning sessions and mid-sprint meetings, which occur on alternating weeks.

=== Bi-weekly content writer meetings ===

* Organisanional task management: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]
* [[Handbook:Content Writer Meetings|Meeting minutes]]

The process of synchronising content writing and ideas is just being set up.

===Engineering Team===

*Source code: [https://github.com/longevitywiki Github]
*Task management: [https://longevitywiki.atlassian.net/jira/software/projects/LW/boards/1 Jira]
*Documentation & roadmap: [https://longevitywiki.atlassian.net/wiki/spaces/LW/overview Confluence]

==How to edit the Wiki==
All articles, no matter what categories they are tagged with, are found on the [[Special:AllPages|All Pages]] site.

===Let us know first===
If you want to edit the wiki, please [[Contact|contact us]] first, so we can help you get started.

===MediaWiki===
Longevity Wiki uses the [[mediawikiwiki:MediaWiki|MediaWiki]] platform - the same as Wikipedia. This is the software that makes it possible to store all content, edit articles, track changes and more.
[[File:Account menu.png|thumb|100x100px|The Account menu]]

===Create an account ===
If you want to edit the wiki, it's a good idea to create an account first. That way it's easier to keep track of your work and you get some extra functionality. To create an account, in the menu click the Account icon on the right (the 'little person') and click '''Create account''' and follow the instructions. Creating an account is not mandatory however for editing.
[[File:Contribute menu.png|thumb|198x198px|The Contribute menu]]

===Create a page===
To create a new article on the wiki, go to the menu and click '''Contribute''' and then '''Create new page'''. You will then be prompted to select a title for your article. After that, the Edit toolbar appears at the top and you can start writing. The Edit toolbar provides you with standard edit functions like making headings, bold text, insert links, insert images and much more.

[[File:Editor Options Menu.png|thumb|198x198px|Editor Options Menu]]

The articles are categorized into four kinds, each with an associated category that should be added by using the '''Categories''' Option in the menu within the editor. (See "Editor Options Menu")

*'''Pillar Articles:''' Described in the [[Handbook:Handbook#Strategy|Strategy]] section, need expert knowledge equivalent to having a post-grad (MSc, Ph.D., MD) in a related area, currently managed by the core group. (Category: Pillar Articles)
*'''Longevity Articles:''' All articles about longevity, traditional wiki development and open for everyone to contribute. Should be created as draft first and reviewed by others in the community. (Category: Longevity)
*'''Glossary:''' Key terms in the longevity space, along with a short 2-3 sentence definition, no draft necessary. (Category: Glossary)
*'''Drafts:''' Articles that haven't been reviewed yet and finalized to a certain stage. (Category: Drafts)
These articles are all shown on the website on the [[Articles]] page.

====Drafts====
When creating a new page, the [[Template:Draft-article|Draft Article banner template]] should be added to beginning of article via <nowiki>{{ Draft-article }}</nowiki> (without spaces), automatically adding a banner and the "Drafts" category.

Drafts will not be actively mantained, but the core team might ask authors sometimes if they are still working on the article. The process for now is simple: Write a draft, have others in the community review it, finalise it and remove the draft banner '''(Work in Progress)'''.

For the review process we encourage to use our Discord server and write comments with the comments feature of the editor; text that is written in the editor but not shown on the published page.

===Edit a page===
To edit an existing article, lookup the article, go to the menu and click '''Contribute''' and then (under 'This page...') click '''Edit'''. Then the Edit toolbar will open at the top, and you can start writing.
[[File:Text editor.png|none|thumb|732x732px|The '''Edit''' toolbar]]

===Images===
Often it's a good idea to include images in your article. Just make sure that if you use an image of someone else, you are not violating any copyright. In general, you are free to use images with a [https://creativecommons.org/ Creative Commons] license, but don't forget to use the right [https://creativecommons.org/use-remix/ attribution]. If you need help creating an image yourself, let us know in the Images channel on our [https://discord.gg/jBR5aRcpfV Discord Server], and we can help you create a unique and copyright-free image.

===Referencing===
For referencing to external sources (e.g. a journal article), Longevity Wiki uses the [[wikipedia:APA_style|APA referencing style]] - the same as Wikipedia. To create a reference, click '''Cite''' on the Edit toolbar. There are a few useful resources for creating citations, such as [https://zbib.org/ Zoterobib].

===Writing style===
The aim of the Wiki is to create '''comprehensive''', '''scientifically accurate''' and '''accessible''' content on longevity. The writing style we are aiming for is essentially the same as Wikipedia, in balancing technical and non-technical content. Here is our '''[[Writing tips for easy reading|writing guide]]''' to help you get started. More information on Wikipedia's writing style can be found in [[wikipedia:Wikipedia:Manual_of_Style|Wikipedia's Manual of Style]].

==Contact information==
See our [[Contact]] page.

File:Editor Options Menu.png

2021-09-14T18:30:09Z

Schulzm:

Options Menu within the Wiki Editor

Articles

2021-09-14T13:13:56Z

Schulzm: Add Drafts to Articles page

==Pillar Articles==
<dpl>
category=Pillar Articles
notcategory=Drafts
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>
==General Articles==
<dpl>
category=Longevity
notcategory=Pillar Articles|Drafts
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>
==Glossary==
<dpl>
category=Glossary
notcategory=Drafts
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>
==Drafts==
<dpl>
category=Drafts
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>

Template:Draft-article

2021-09-14T13:07:29Z

Schulzm: Fix talk page link

Template:Draft-article

2021-09-14T13:03:38Z

Schulzm: Template to label a draft article

----
[[File:Under construction icon-blue.png.png|50px|left]]
'''This article is currently a draft.''' 
Material may not yet be complete, information may presently be omitted, and certain parts of the content may be subject to radical, rapid alteration. More information pertaining to this may be available on the [[<tvar|1>{{TALKPAGENAME}}</>|talk page]].
<includeonly>[[Category:Drafts]]</includeonly>
----

File:Under construction icon-blue.png.png

2021-09-14T12:52:26Z

Schulzm:

Under construction PNG version (original SVG from MediaWiki)

File:Under construction icon-blue.svg

2021-09-14T12:47:51Z

Schulzm:

Originally from MediaWiki: https://www.mediawiki.org/wiki/Template:Draft-section#/media/File:Under_construction_icon-blue.svg

Handbook:Meeting Minutes

2021-09-13T07:23:43Z

Schulzm: /* 📓Preparation Notes */ Add note on vacation

== 15/09/2021 ==

=== 📓Preparation Notes ===
''Max Schulz:''

* Content writer meetings set up again: [[Handbook:Content Writer Meetings]]
* Created doodle for upcoming meetings: [https://doodle.com/poll/pp9uysigaw66ddes Doodle Link]
* Started reaching out to interested people in the past for 1:1 onboarding
* There seem to be quite many people interested in the ethical aspects of longevity research (e.g. recently Robin Howlett, check the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU/edit#gid=2043094641 Volunteer Survey responses]), however it's not part of the currently defined topics ([[Handbook:Handbook#Mission]]); Shall we add it? Does it fit to "wiki-style" content?
* There are many lists on longevity managed by individuals, such as Karl Pfleger ([https://agingbiotech.info/diagnostics/ Diagnostics Example]) - I think it would make so much more sense to manage them in a community like Longevity Wiki, and also good to offer the primary source for these. For this, the table functionalities of the Wiki need to be improved to enable features such as filtering or sorting (There might be a plugin?)
* On vacation with limited internet access 20/09 - 03/10. Anyone can lead the next content writer meeting?

== 08/09/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Blake Delaney
* Marc Smeehuijzen
* Bogdan Dziewierz

=== 📣 Updates ===
''Blake Delaney''

* Introduction: hedge fund manager, with programming, and bioscience background. Previously created a longevity wiki but did not gain traction at the time

* Wikipedia doesn't have the highest quality on longevity and cryonics topics as those with higher override capability often prevent a thorough review of the topic
* Media Wiki has the functionality for authors to be notified when their articles are updated - this can be applied to our project
* Created a 'Cryonics' page on the Wiki - should we keep it on the Wiki? Consensus was yes.
* Social funding could be used to raise funding for the Wiki
* Suggest he can fund AWS infrastructure
* Create a Lifespan.io project and pitch our organization to them to attract funding
* Crowdfunding on the Discord server
* Interested in joining the engineering team and will try to make it to this week's meeting
* Can support a member to create an application to register for a US charity
* There is significant work involved in maintaining charity status
* Alternatively, operate as an LLC and avoid most tax liability by spending as much as you earn
* Some US states have very minimal reporting requirements for LLCs.

''Marc''

* How should we provide feedback to each other's article?

* Discussion page makes sense for feedback to specific articles
* Benefit of our Wiki is that it allows for more speculative topics than Wikipedia, such as longevity science and cryonics

''Jack''

* Provided update on content writers meeting
* Block updates to 'Pillar' articles once completed to avoid vandalism
* Can keep the 'cryonics' page on the Wiki, though, pending reaching out to science and medical organizations for content writing

''Sharon Wong''

* Have a header that says, 'version active as of (date)' on multilingual pages to overcome the issue of translated articles requiring frequent updates
* Having issues uploading the image on the rapamycin article - @Bogdan to investigate
* Style and standardising translating terms into Chinese requires a standard glossary
* There is a need to stipulate the translation tool for those who are translating the wiki (e.g. DeepL)
* Need for the 'how to contribute' page on the Wiki Handbook to be updated with translation tasks.
* Higher bar for 'tax deductible status' in Australia. It's a good reason to avoid this for now, to avoid excessive paperwork.

''Bogdan''

* Will have to create 'drafts' namespace
* 'Discussion' page associated with pages on the Wiki is currently active
* Discussion page can foster more discussion amongst non-Discord users of the Wiki
* Cryonics discussion brings up an interesting point - what is the included scope of the Wiki? Consensus was that anything 'life-span extending' related should be included. In particular topics that Wikipedia doesn't cover well.
* Updated the onboarding guide for new developers
* Life extension tool in-progress
* Sam Voigt has previously volunteered to pursue the pros and cons of registering as a non-for-profit - @Jack to get in touch
* UK may have a separate charity status to receive money if no goods or services (business-like activities)

== 01/09/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Ben Wu
* Sharon Wong
* Marc Smeehuijzen
* Andreas Melhede

=== 📣 Updates ===
''Jack Harley''

* Begun ''Aging and Neurodegeneration'' brainstorm and write-up. References and comments welcome.
* Collaborated with Max to create process for content writers (discussed below)
* Kindly ask all Wiki members to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
* [https://agingpharma.org/ ARDD Conference] has begun - good opportunity for Wiki members to learn more about the field - videos should be uploaded to the website for free viewing in the coming weeks.
* Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021

''Sharon Wong''

* Noted that the translation for the Rapamycin article was updating while
* Found it difficult to quickly copy content and formatting to a new page - Bogdan may able to assist with this
* Noted that it's probably not worth translating references
* Recommended deepl.com as the 'gold standard' for translating of articles. Produces more simplistic sentence structures compared to Google Translate.

''Ben Wu''

* Summary of EARD conference - mentioned Tina Woods' talk on lobbying UK government to increase funding towards aging research, and recognising biology of aging as a critical healthcare mission. Also mentioned that emphasis on healthspan seems more effective in communication than emphasis on lifespan.

''Marc''

* Bi-weekly content writers meetings could be structured around a review process whereby writers provide helpful feedback on other writers' articles. Maybe writers with journalistic/editor experience know of an effective review process similar to how people work at a newspaper/magazine/journal.
* We should prevent information being copied across various parts of the website because this makes maintenance harder. E.g. the 'About us' information is now both on the About us page and in the Handbook. He suggests removing the 'About Us' content from the Handbook, and replace it with a link to the 'About us' page.
* The handbook contains much valuable information for contributors but is not that interesting for most wiki visitors who just visit the wiki for longevity related information. He suggests to show only some high level 'how to contribute' information on the 'How to contribute' page so we don't overwhelm visitors (basically just asking people to contact us if they want to help) and then add a prominent link to the Handbook for if they want to dive into all the details. 

Andreas Melhede:

* Discussed Discord Role Management on Discord with Stuart McWhinney.
** It is very close to finished and ready to be implemented on our server.

''Max Schulz:''

* Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
*** Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
*** Using ''Organisational'' board to manage weekly core meetings
*** Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
** ''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
*** Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
*** I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
*** Proposed board usage:
**** Future ideas for clearly far in the future (months)
**** Backlog for tasks to do soon (weeks)
**** Todo for tasks agreed to be done next, or you want to work on next
**** Once task is worked on -> Move to In Progress
**** If you want someone to review -> Move to In Review
**** If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
*** Meaningful task definitions
*** Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
* Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
** Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
** Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
* Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
** Should be filled out by all team members so we have an overview.

== 25/08/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Bogdan Dziewierz
* Marc Smeehuijzen
* Ben Wu
* Andreas Melhede
* Heye Groß
* Max Schons
* Stuart

=== 📣 Updates ===
* Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
* Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
* Max Schons working on risk factors, subjective vs objective measures of health, various major disease
* Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
* Heye planning on engaging with EA community at conferences and talking about the Wiki
* Technical meeting bimonthly with Bogdan, Mac, Stuart
* Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items ===

* Continue working on core articles
*
|}

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Meeting Minutes

2021-09-10T08:53:17Z

Schulzm: /* 15/09/2021 */ Add first preparation notes for 15/09/21 meeting

== 15/09/2021 ==

=== 📓Preparation Notes ===
''Max Schulz:''

* Content writer meetings set up again: [[Handbook:Content Writer Meetings]]
* Created doodle for upcoming meetings: [https://doodle.com/poll/pp9uysigaw66ddes Doodle Link]
* Started reaching out to interested people in the past for 1:1 onboarding
* There seem to be quite many people interested in the ethical aspects of longevity research (e.g. recently Robin Howlett, check the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU/edit#gid=2043094641 Volunteer Survey responses]), however it's not part of the currently defined topics ([[Handbook:Handbook#Mission]]); Shall we add it? Does it fit to "wiki-style" content?
* There are many lists on longevity managed by individuals, such as Karl Pfleger ([https://agingbiotech.info/diagnostics/ Diagnostics Example]) - I think it would make so much more sense to manage them in a community like Longevity Wiki, and also good to offer the primary source for these. For this, the table functionalities of the Wiki need to be improved to enable features such as filtering or sorting (There might be a plugin?)

== 08/09/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Blake Delaney
* Marc Smeehuijzen
* Bogdan Dziewierz

=== 📣 Updates ===
''Blake Delaney''

* Introduction: hedge fund manager, with programming, and bioscience background. Previously created a longevity wiki but did not gain traction at the time

* Wikipedia doesn't have the highest quality on longevity and cryonics topics as those with higher override capability often prevent a thorough review of the topic
* Media Wiki has the functionality for authors to be notified when their articles are updated - this can be applied to our project
* Created a 'Cryonics' page on the Wiki - should we keep it on the Wiki? Consensus was yes.
* Social funding could be used to raise funding for the Wiki
* Suggest he can fund AWS infrastructure
* Create a Lifespan.io project and pitch our organization to them to attract funding
* Crowdfunding on the Discord server
* Interested in joining the engineering team and will try to make it to this week's meeting
* Can support a member to create an application to register for a US charity
* There is significant work involved in maintaining charity status
* Alternatively, operate as an LLC and avoid most tax liability by spending as much as you earn
* Some US states have very minimal reporting requirements for LLCs.

''Marc''

* How should we provide feedback to each other's article?

* Discussion page makes sense for feedback to specific articles
* Benefit of our Wiki is that it allows for more speculative topics than Wikipedia, such as longevity science and cryonics

''Jack''

* Provided update on content writers meeting
* Block updates to 'Pillar' articles once completed to avoid vandalism
* Can keep the 'cryonics' page on the Wiki, though, pending reaching out to science and medical organizations for content writing

''Sharon Wong''

* Have a header that says, 'version active as of (date)' on multilingual pages to overcome the issue of translated articles requiring frequent updates
* Having issues uploading the image on the rapamycin article - @Bogdan to investigate
* Style and standardising translating terms into Chinese requires a standard glossary
* There is a need to stipulate the translation tool for those who are translating the wiki (e.g. DeepL)
* Need for the 'how to contribute' page on the Wiki Handbook to be updated with translation tasks.
* Higher bar for 'tax deductible status' in Australia. It's a good reason to avoid this for now, to avoid excessive paperwork.

''Bogdan''

* Will have to create 'drafts' namespace
* 'Discussion' page associated with pages on the Wiki is currently active
* Discussion page can foster more discussion amongst non-Discord users of the Wiki
* Cryonics discussion brings up an interesting point - what is the included scope of the Wiki? Consensus was that anything 'life-span extending' related should be included. In particular topics that Wikipedia doesn't cover well.
* Updated the onboarding guide for new developers
* Life extension tool in-progress
* Sam Voigt has previously volunteered to pursue the pros and cons of registering as a non-for-profit - @Jack to get in touch
* UK may have a separate charity status to receive money if no goods or services (business-like activities)

== 01/09/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Ben Wu
* Sharon Wong
* Marc Smeehuijzen
* Andreas Melhede

=== 📣 Updates ===
''Jack Harley''

* Begun ''Aging and Neurodegeneration'' brainstorm and write-up. References and comments welcome.
* Collaborated with Max to create process for content writers (discussed below)
* Kindly ask all Wiki members to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
* [https://agingpharma.org/ ARDD Conference] has begun - good opportunity for Wiki members to learn more about the field - videos should be uploaded to the website for free viewing in the coming weeks.
* Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021

''Sharon Wong''

* Noted that the translation for the Rapamycin article was updating while
* Found it difficult to quickly copy content and formatting to a new page - Bogdan may able to assist with this
* Noted that it's probably not worth translating references
* Recommended deepl.com as the 'gold standard' for translating of articles. Produces more simplistic sentence structures compared to Google Translate.

''Ben Wu''

* Summary of EARD conference - mentioned Tina Woods' talk on lobbying UK government to increase funding towards aging research, and recognising biology of aging as a critical healthcare mission. Also mentioned that emphasis on healthspan seems more effective in communication than emphasis on lifespan.

''Marc''

* Bi-weekly content writers meetings could be structured around a review process whereby writers provide helpful feedback on other writers' articles. Maybe writers with journalistic/editor experience know of an effective review process similar to how people work at a newspaper/magazine/journal.
* We should prevent information being copied across various parts of the website because this makes maintenance harder. E.g. the 'About us' information is now both on the About us page and in the Handbook. He suggests removing the 'About Us' content from the Handbook, and replace it with a link to the 'About us' page.
* The handbook contains much valuable information for contributors but is not that interesting for most wiki visitors who just visit the wiki for longevity related information. He suggests to show only some high level 'how to contribute' information on the 'How to contribute' page so we don't overwhelm visitors (basically just asking people to contact us if they want to help) and then add a prominent link to the Handbook for if they want to dive into all the details. 

Andreas Melhede:

* Discussed Discord Role Management on Discord with Stuart McWhinney.
** It is very close to finished and ready to be implemented on our server.

''Max Schulz:''

* Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
*** Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
*** Using ''Organisational'' board to manage weekly core meetings
*** Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
** ''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
*** Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
*** I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
*** Proposed board usage:
**** Future ideas for clearly far in the future (months)
**** Backlog for tasks to do soon (weeks)
**** Todo for tasks agreed to be done next, or you want to work on next
**** Once task is worked on -> Move to In Progress
**** If you want someone to review -> Move to In Review
**** If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
*** Meaningful task definitions
*** Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
* Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
** Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
** Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
* Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
** Should be filled out by all team members so we have an overview.

== 25/08/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Bogdan Dziewierz
* Marc Smeehuijzen
* Ben Wu
* Andreas Melhede
* Heye Groß
* Max Schons
* Stuart

=== 📣 Updates ===
* Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
* Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
* Max Schons working on risk factors, subjective vs objective measures of health, various major disease
* Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
* Heye planning on engaging with EA community at conferences and talking about the Wiki
* Technical meeting bimonthly with Bogdan, Mac, Stuart
* Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items ===

* Continue working on core articles
*
|}

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Handbook

2021-09-10T07:44:21Z

Schulzm: /* Bi-weekly content writer meetings */ Add meeting minutes link

== About the Handbook==
The Longevity Wiki Handbook is the 'source of truth' for the Wiki organisation. It currently contains our mission and strategy, the roles we are looking for, links to our communication platforms and some editing advice. Like the Wiki itself, it's all publicly accessible and transparent and will likely grow and change over time.
== Mission==
Longevity Wiki is an open-access project to create the go-to platform for the science of longevity. The wiki was borne from the need for high quality scientific content on aging and longevity to be freely available and accessible. The Wiki ultimately aims to cover the following topics in detail:

*Longevity drugs and the evidence supporting them
*Personal longevity strategies/advice
*Hallmarks of aging/biology of aging
*Animal models of aging
*Laboratories working in geroscience, and their focus
*Longevity biotech (companies, development pipeline)
*Biology of aging + diseases of aging connection

More information about us can be found on our [[About]] page.

==Strategy==
Instead of producing as much content as possible, we’re going to focus on creating 5 pillar articles written by experts on the topic. These articles will demonstrate the knowledge and quality of our initiative, and then we will build out the wiki from there. These are the pillar articles:

#'''Epigenetic reprogramming'''
#'''Aging and Neurodegeneration'''
#'''Rapamycin'''
#'''Biomarkers of healthspan'''
#'''COVID-19 and Aging'''

In conjunction with these articles, we are going to create a Glossary page of key terms in the longevity space, along with a short (2-3 sentence definition).

== Available Roles and Projects for the Wiki ==
Longevity Wiki is an open access, collaborative project and we invite all volunteers to contribute! The goal of the Wiki is to create a trusted, high quality platform of longevity science content.

This section lists the current projects we are working on, and how you can get involved. If you're interested, please complete our [https://forms.gle/P1huKGcDiPLnRAB17 Volunteer Survey Form] and we will follow up with you by email.

===Pillar article writing===
'''Role: Senior content writer'''

'''Minimum requirements: Masters or PhD training, ideally in a relevant field to content being written'''

We are seeking those with strong scientific backgrounds to help our initial offering of 5 ‘pillar’ articles that will form the initial content on the Wiki.

These articles are designed to be long-form (1.5-2.5k words) articles summarizing the relevant literature as it pertains to aging biology. The style we are aiming for is similar to a literature review, but with a simplified writing style that is accessible to non-specialist readers.

An example is our article on [[Rapamycin]], however, the style and structure of the article may vary by topic.

The following topics have been selected:

*'''Epigenetic reprogramming'''
*'''Aging and Neurodegeneration'''
*'''Rapamycin'''
*'''Biomarkers of healthspan'''
*'''COVID-19 and Aging'''

===Glossary expansion===
'''Role: Junior content writer'''

'''Minimum requirements: High school level biology'''

We are building a glossary of relevant terminology to expand the scope of the Wiki. The glossary will be accessible from an article through the use of so called ‘hovercards’ which makes it possible to display the meaning of a difficult term without leaving the article page.

The list of glossary terms is being populated based on the pillar articles. A full list of glossary terms can be found here (ADD LINK).

To contribute to the glossary, simply choose a term that has not yet been defined, and write a concise, and scientifically accurate definition.

Some guidelines:

*All references should be cited using APA referencing

*All links to internal articles should be linked
*Definitions should be clear and comprehensible to non-specialist audiences
*Definitions can be up to 270 characters in length

An example of a glossary term (ADD LINK).

===Life extension tool database===
'''Role: Researcher'''

'''Minimum requirements: Undergraduate biology, ability to comprehend the longevity data and research'''

We are creating a ‘life extension tool’ that provides an up to date overview of the life extension achieved for different animals with different interventions.

A [https://zpl.io/bePZGJl sample of the tool] can be viewed on our design platform Zeplin.

In order to populate data for the tool, we require assistance in reviewing the literature to identify the lifespan extension associated with different drugs and species, and the original publication in which this was published.

Our current database: [https://docs.google.com/spreadsheets/d/14OLhV4WWSUGomEY-3zko1o8zHHrJwt5YipGbjxhracM/edit?usp=sharing Life Extension Tool Data].

===Software engineering support===
'''Role: Engineer'''

'''Minimum requirements: Interest in software engineering'''

As the wiki grows, we need to ensure that the automation and infrastructure develops. We are especially looking for people with the following abilities:

* AWS reliability engineering/DevOps (people to manage infrastructure and deploy apps)
* PHP
* Front-end development
* Technical product ownership
* A scrum master/iteration manager

===Marketing===
'''Role: Based on experience and performance'''

'''Minimum requirements: Past experience in marketing, splendid communicator and creative individual who is eager to learn'''

Our marketing department is expanding. If you are a creative individual who loves communicating, you could get a lot of significant responsibilities.

=== Graphic design ===
'''Role: Illustrator, data visualization'''

'''Minimum requirements: Experience with graphic design'''

We are looking for individuals with graphic design skills to help us create and re-work pictures, scientific diagrams and graphs to communicate information to non-technical audiences. You will work closely with our content writers to produce high-impact, engaging visuals to accompany the written content.

=== Other roles ===
'''Role: Translator'''

We are looking for individuals with language skills to translate articles into other languages to reach a broader audience - particularly languages spoken commonly around the world. This will be done with the assistance of tools such as Google Translate.

'''Role: UX specialist'''

We are seeking expertise in user experience (UX) to help us design an intuitive and engaging platform. The goal is to create a satisfying experience for our users. You will work with the Head of UX in this role.

== Our communication platforms ==
Besides this Handbook we use a few other platforms for communicating and sharing resources. We're committed to being an open-access platform, and as such, we share all information possible, such as meeting minutes.

=== Discord Server ===
We mostly communicate via the [https://discord.gg/UDKmjcnjye Longevity Wiki Discord Server]. It serves as a day-to-day message board, as well as the host of our meetings. Meetings take place every week at 08:30 GMT.

=== Google Drive ===
Our [https://drive.google.com/drive/folders/19Ol2wcRd2IWUt_gOC5j5Ff7FjSzPVuBf Drive folder] is used for sharing many useful documents, such as draft ideas, spreadsheets, or useful non-wiki resources.

===Organisational weekly meetings===

* Organisanional task management: [https://trello.com/b/0u9pSclR/organisational Trello Board] | [https://trello.com/invite/b/0u9pSclR/0722f6126c69d1341e63765f41d23531/organisational Invitation Link]
* [https://en.longevitywiki.org/wiki/Handbook:Meeting_Minutes Meeting minutes]

The meetings consist of our sprint planning sessions and mid-sprint meetings, which occur on alternating weeks.

=== Bi-weekly content writer meetings ===

* Organisanional task management: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]
* [[Handbook:Content Writer Meetings|Meeting minutes]]

The process of synchronising content writing and ideas is just being set up.

===Engineering Team===

*Source code: [https://github.com/longevitywiki Github]
*Task management: [https://longevitywiki.atlassian.net/jira/software/projects/LW/boards/1 Jira]
*Documentation & roadmap: [https://longevitywiki.atlassian.net/wiki/spaces/LW/overview Confluence]

==How to edit the Wiki==
=== Let us know first ===
If you want to edit the wiki, please [[Contact|contact us]] first, so we can help you get started.

=== MediaWiki ===
Longevity Wiki uses the [[mediawikiwiki:MediaWiki|MediaWiki]] platform - the same as Wikipedia. This is the software that makes it possible to store all content, edit articles, track changes and more.
[[File:Account menu.png|thumb|100x100px|The Account menu]]

=== Create an account ===
If you want to edit the wiki, it's a good idea to create an account first. That way it's easier to keep track of your work and you get some extra functionality. To create an account, in the menu click the Account icon on the right (the 'little person') and click '''Create account''' and follow the instructions. Creating an account is not mandatory however for editing.
[[File:Contribute menu.png|thumb|198x198px|The Contribute menu]]

=== Create a page ===
To create a new article on the wiki, go to the menu and click '''Contribute''' and then '''Create new page'''. You will then be prompted to select a title for your article. After that, the Edit toolbar appears at the top and you can start writing. The Edit toolbar provides you with standard edit functions like making headings, bold text, insert links, insert images and much more.

When adding a new page related to longevity to the wiki, please make sure to categorize it as 'Longevity' so that it automatically appears in the [[Articles]] listing. (Save Changes -> Categories)

=== Edit a page ===
To edit an existing article, lookup the article, go to the menu and click '''Contribute''' and then (under 'This page...') click '''Edit'''. Then the Edit toolbar will open at the top, and you can start writing.
[[File:Text editor.png|none|thumb|732x732px|The '''Edit''' toolbar]]

=== Images ===
Often it's a good idea to include images in your article. Just make sure that if you use an image of someone else, you are not violating any copyright. In general, you are free to use images with a [https://creativecommons.org/ Creative Commons] license, but don't forget to use the right [https://creativecommons.org/use-remix/ attribution]. If you need help creating an image yourself, let us know in the Images channel on our [https://discord.gg/jBR5aRcpfV Discord Server], and we can help you create a unique and copyright-free image.

=== Referencing ===
For referencing to external sources (e.g. a journal article), Longevity Wiki uses the [[wikipedia:APA_style|APA referencing style]] - the same as Wikipedia. To create a reference, click '''Cite''' on the Edit toolbar. There are a few useful resources for creating citations, such as [https://zbib.org/ Zoterobib].

=== Writing style ===
The aim of the Wiki is to create '''comprehensive''', '''scientifically accurate''' and '''accessible''' content on longevity. The writing style we are aiming for is essentially the same as Wikipedia, in balancing technical and non-technical content. Here is our '''[[Writing tips for easy reading|writing guide]]''' to help you get started. More information on Wikipedia's writing style can be found in [[wikipedia:Wikipedia:Manual_of_Style|Wikipedia's Manual of Style]].

==Contact information==
See our [[Contact]] page.

Handbook:Meeting Minutes

2021-09-09T06:54:20Z

Schulzm: /* 08/09/2021 */ Formatting of attending header and meeting section for next week

== 15/09/2021 ==

== 08/09/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Blake Delaney
* Marc Smeehuijzen
* Bogdan Dziewierz

=== 📣 Updates ===
''Blake Delaney''

* Introduction: hedge fund manager, with programming, and bioscience background. Previously created a longevity wiki but did not gain traction at the time

* Wikipedia doesn't have the highest quality on longevity and cryonics topics as those with higher override capability often prevent a thorough review of the topic
* Media Wiki has the functionality for authors to be notified when their articles are updated - this can be applied to our project
* Created a 'Cryonics' page on the Wiki - should we keep it on the Wiki? Consensus was yes.
* Social funding could be used to raise funding for the Wiki
* Suggest he can fund AWS infrastructure
* Create a Lifespan.io project and pitch our organization to them to attract funding
* Crowdfunding on the Discord server
* Interested in joining the engineering team and will try to make it to this week's meeting
* Can support a member to create an application to register for a US charity
* There is significant work involved in maintaining charity status
* Alternatively, operate as an LLC and avoid most tax liability by spending as much as you earn
* Some US states have very minimal reporting requirements for LLCs.

''Marc''

* How should we provide feedback to each other's article?

* Discussion page makes sense for feedback to specific articles
* Benefit of our Wiki is that it allows for more speculative topics than Wikipedia, such as longevity science and cryonics

''Jack''

* Provided update on content writers meeting
* Block updates to 'Pillar' articles once completed to avoid vandalism
* Can keep the 'cryonics' page on the Wiki, though, pending reaching out to science and medical organizations for content writing

''Sharon Wong''

* Have a header that says, 'version active as of (date)' on multilingual pages to overcome the issue of translated articles requiring frequent updates
* Having issues uploading the image on the rapamycin article - @Bogdan to investigate
* Style and standardising translating terms into Chinese requires a standard glossary
* There is a need to stipulate the translation tool for those who are translating the wiki (e.g. DeepL)
* Need for the 'how to contribute' page on the Wiki Handbook to be updated with translation tasks.
* Higher bar for 'tax deductible status' in Australia. It's a good reason to avoid this for now, to avoid excessive paperwork.

''Bogdan''

* Will have to create 'drafts' namespace
* 'Discussion' page associated with pages on the Wiki is currently active
* Discussion page can foster more discussion amongst non-Discord users of the Wiki
* Cryonics discussion brings up an interesting point - what is the included scope of the Wiki? Consensus was that anything 'life-span extending' related should be included. In particular topics that Wikipedia doesn't cover well.
* Updated the onboarding guide for new developers
* Life extension tool in-progress
* Sam Voigt has previously volunteered to pursue the pros and cons of registering as a non-for-profit - @Jack to get in touch
* UK may have a separate charity status to receive money if no goods or services (business-like activities)

== 01/09/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Ben Wu
* Sharon Wong
* Marc Smeehuijzen
* Andreas Melhede

=== 📣 Updates ===
''Jack Harley''

* Begun ''Aging and Neurodegeneration'' brainstorm and write-up. References and comments welcome.
* Collaborated with Max to create process for content writers (discussed below)
* Kindly ask all Wiki members to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
* [https://agingpharma.org/ ARDD Conference] has begun - good opportunity for Wiki members to learn more about the field - videos should be uploaded to the website for free viewing in the coming weeks.
* Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021

''Sharon Wong''

* Noted that the translation for the Rapamycin article was updating while
* Found it difficult to quickly copy content and formatting to a new page - Bogdan may able to assist with this
* Noted that it's probably not worth translating references
* Recommended deepl.com as the 'gold standard' for translating of articles. Produces more simplistic sentence structures compared to Google Translate.

''Ben Wu''

* Summary of EARD conference - mentioned Tina Woods' talk on lobbying UK government to increase funding towards aging research, and recognising biology of aging as a critical healthcare mission. Also mentioned that emphasis on healthspan seems more effective in communication than emphasis on lifespan.

''Marc''

* Bi-weekly content writers meetings could be structured around a review process whereby writers provide helpful feedback on other writers' articles. Maybe writers with journalistic/editor experience know of an effective review process similar to how people work at a newspaper/magazine/journal.
* We should prevent information being copied across various parts of the website because this makes maintenance harder. E.g. the 'About us' information is now both on the About us page and in the Handbook. He suggests removing the 'About Us' content from the Handbook, and replace it with a link to the 'About us' page.
* The handbook contains much valuable information for contributors but is not that interesting for most wiki visitors who just visit the wiki for longevity related information. He suggests to show only some high level 'how to contribute' information on the 'How to contribute' page so we don't overwhelm visitors (basically just asking people to contact us if they want to help) and then add a prominent link to the Handbook for if they want to dive into all the details. 

Andreas Melhede:

* Discussed Discord Role Management on Discord with Stuart McWhinney.
** It is very close to finished and ready to be implemented on our server.

''Max Schulz:''

* Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
*** Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
*** Using ''Organisational'' board to manage weekly core meetings
*** Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
** ''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
*** Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
*** I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
*** Proposed board usage:
**** Future ideas for clearly far in the future (months)
**** Backlog for tasks to do soon (weeks)
**** Todo for tasks agreed to be done next, or you want to work on next
**** Once task is worked on -> Move to In Progress
**** If you want someone to review -> Move to In Review
**** If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
*** Meaningful task definitions
*** Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
* Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
** Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
** Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
* Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
** Should be filled out by all team members so we have an overview.

== 25/08/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Bogdan Dziewierz
* Marc Smeehuijzen
* Ben Wu
* Andreas Melhede
* Heye Groß
* Max Schons
* Stuart

=== 📣 Updates ===
* Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
* Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
* Max Schons working on risk factors, subjective vs objective measures of health, various major disease
* Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
* Heye planning on engaging with EA community at conferences and talking about the Wiki
* Technical meeting bimonthly with Bogdan, Mac, Stuart
* Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items ===

* Continue working on core articles
*
|}

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Content Writer Meetings

2021-09-07T13:24:49Z

Schulzm: Add meeting notes for 07/09/2021 meeting

== 07/09/2021 ==

===📓Preparation Notes===
''Max Schulz:''

*'''Proposed Content writer meeting process'''
** Introductions by new members (short, 1 min / person):
***Name & where you are based
***Background & interest in longevity
***What topics you want to contribute to
**Meeting notes writer?
**Content writer manager (Max) sharing process & technology updates
**Going through pillar articles updates (content, reviews, contributions)
**Round table: Unblocking writers - suggestions what to write on, asking for reviews etc.
* '''Proposed Trello board process'''
** Article writing is organized on the Trello board: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]
** Three kind of articles: "Pillar Articles" (Expert Knowledge), "General Articles" (Open to anyone) and "Glossary" (2-3 sentences description from a longevity perspective) | [[Articles]] page is now organised accordingly
***On Trello: Pillar articles are labeled (as well as the introductory article)
*** Categories to use when saving articles: "Pillar Articles", "Longevity", "Glossary" '''(handbook has to be updated accordingly)'''
**Trello board organisation:
***Unsassigned for article ideas
***Assigned when someone wants to write an article
***Once working on a draft: In progress
*** When finished with a first draft: In Review (merged past columns)
***When reviewed by at least one other writer in the group: Completed
** Articles are never '''really''' done, as science progresses, so if you want to add something meaningful - please do so and share your idea both on Trello and this meeting!
**Feel free to add ideas about the processes & tools either in these meetings or on the Trello column "Feedback for tooling & organisation"!
**Non-structured contributions: Just get started writing on topics that interest you - the Trello board is to synchronise your efforts with the team and share your work!
*'''Process for creating drafts directly on Wiki:'''
**I think it would be great if we also wrote the drafts directly into the wiki; Instead of creating local google docs
**References from Wikipedia: [[wikipedia:Wikipedia:Drafts|Draft Namespace]] | [[mediawikiwiki:Draft_namespace|MediaWiki Draft Discussions]]
**Possibilities: change title, e.g. "[DRAFT] Biomarkers of healthspan", use Draft Namespace or Category, or simply add a template banner at the start of an article and/or section (used like this <nowiki>{{ Draft-article }}</nowiki>)
**Max simple proposal (for now): Add template banner and discuss directly on the draft, adding comments with the comment feature of the editor (see source)
*'''Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021'''
*Kindly ask all writers to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
*Meeting slot not set in stone, will send out a doodle again with more choice after this meeting (with ~10 days response deadline)

===🧍 Attending===

*Maximilian Schulz
*Jack Harley
*Ben Wu
*Joly Ghanawi
*Habakuk Hain
*Lindsay Ciocco
*Sharon Wong
*Robin Howlett

===📣 Updates===

*Introductions of all participants, newcomers:
**Habakuk Hain: Graduate with an MD and something like a Master’s in Molecular Biology from the University of Göttingen in 2022 - interested in contributing to Neurodegeneration article
**Robin Howlett: Non-technical background, interested in writing about the ethical implications of longevity
*Process updates shared, see Preparation Notes - in addition discussed:
**'''Drafting process: Draft Banner (using templates), Category "Draft" and using Editor comments to discuss'''
**It was brought up that we should make discussion pages visible to have discussions on existing articles as well
*Updates on pillar articles:
**Overview Article: Max Schulz and Ben to collaborate on this
**Rapamycin (Ben): Completed to a high standard, ready to share
**Epigenetic reprogramming (Ben & Lindsay): Requires a few additions, that are currently being worked on
**Aging and Neurodegeneration (Jack): Draft for aging and neurodegeneration article can be completed by the end of September. Habakuk could collaborate?
**COVID-19 and Aging (Ben): Max Schons can begin work on this after completing the biomarkers of healthspan piece (additional perspective of infectious disease research)
*Other longevity articles:
**References need to be added for calorie restriction article - will be done by Joly
*New writers can contribute to ‘unassigned’ topics, in particular drugs purported to extend lifespan. The rapamycin article can be used as a ‘template’ – specifically the subheadings (Note: process should be added to handbook)
*Sharon Wong: Will put together a table to summarise main challenges and points to note for the translation efforts
*In addition to the Wiki itself, discussions for specific articles can also be had in the ‘content writers chat’ channel on Discord - but the wiki is preferred whenever possible.

{| class="wikitable"
|
===✅ Action Items===

*Enable drafting process & document in the handbook (Max Schulz)
*Enable discussion pages on Wiki (Max Schulz)
*
|}

Handbook:Meeting Minutes

2021-09-07T10:40:08Z

Schulzm: /* 08/09/2021 */ No preparation notes from Max Schulz for this meeting

== 08/09/2021 ==

== 01/09/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Ben Wu
* Sharon Wong
* Marc Smeehuijzen
* Andreas Melhede

=== 📣 Updates ===
''Jack Harley''

* Begun ''Aging and Neurodegeneration'' brainstorm and write-up. References and comments welcome.
* Collaborated with Max to create process for content writers (discussed below)
* Kindly ask all Wiki members to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
* [https://agingpharma.org/ ARDD Conference] has begun - good opportunity for Wiki members to learn more about the field - videos should be uploaded to the website for free viewing in the coming weeks.
* Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021

''Sharon Wong''

* Noted that the translation for the Rapamycin article was updating while
* Found it difficult to quickly copy content and formatting to a new page - Bogdan may able to assist with this
* Noted that it's probably not worth translating references
* Recommended deepl.com as the 'gold standard' for translating of articles. Produces more simplistic sentence structures compared to Google Translate.

''Ben Wu''

* Summary of EARD conference - mentioned Tina Woods' talk on lobbying UK government to increase funding towards aging research, and recognising biology of aging as a critical healthcare mission. Also mentioned that emphasis on healthspan seems more effective in communication than emphasis on lifespan.

''Marc''

* Bi-weekly content writers meetings could be structured around a review process whereby writers provide helpful feedback on other writers' articles. Maybe writers with journalistic/editor experience know of an effective review process similar to how people work at a newspaper/magazine/journal.
* We should prevent information being copied across various parts of the website because this makes maintenance harder. E.g. the 'About us' information is now both on the About us page and in the Handbook. He suggests removing the 'About Us' content from the Handbook, and replace it with a link to the 'About us' page.
* The handbook contains much valuable information for contributors but is not that interesting for most wiki visitors who just visit the wiki for longevity related information. He suggests to show only some high level 'how to contribute' information on the 'How to contribute' page so we don't overwhelm visitors (basically just asking people to contact us if they want to help) and then add a prominent link to the Handbook for if they want to dive into all the details. 

Andreas Melhede:

* Discussed Discord Role Management on Discord with Stuart McWhinney.
** It is very close to finished and ready to be implemented on our server.

''Max Schulz:''

* Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
*** Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
*** Using ''Organisational'' board to manage weekly core meetings
*** Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
** ''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
*** Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
*** I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
*** Proposed board usage:
**** Future ideas for clearly far in the future (months)
**** Backlog for tasks to do soon (weeks)
**** Todo for tasks agreed to be done next, or you want to work on next
**** Once task is worked on -> Move to In Progress
**** If you want someone to review -> Move to In Review
**** If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
*** Meaningful task definitions
*** Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
* Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
** Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
** Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
* Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
** Should be filled out by all team members so we have an overview.

== 25/08/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Bogdan Dziewierz
* Marc Smeehuijzen
* Ben Wu
* Andreas Melhede
* Heye Groß
* Max Schons
* Stuart

=== 📣 Updates ===
* Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
* Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
* Max Schons working on risk factors, subjective vs objective measures of health, various major disease
* Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
* Heye planning on engaging with EA community at conferences and talking about the Wiki
* Technical meeting bimonthly with Bogdan, Mac, Stuart
* Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items ===

* Continue working on core articles
*
|}

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Content Writer Meetings

2021-09-07T08:50:35Z

Schulzm: Meeting minutes ready for 07/09/2021

Articles

2021-09-07T08:24:18Z

Schulzm: Divide into 3 categories: pillar, general, glossary

==Pillar Articles==
<dpl>
category=Pillar Articles
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>
==General Articles==
<dpl>
category=Longevity
notcategory=Pillar Articles
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>
==Glossary==
<dpl>
category=Glossary
includesubpages=false
mode=category
ordermethod=titlewithoutnamespace
</dpl>

COVID-19

2021-09-07T07:45:25Z

Schulzm: Add Pillar Articles category

[[File:Covid risk 1.png|alt=Age as a risk factor for COVID-19 mortality|thumb|462x462px|* Fold risk of COVID-19 mortality versus reference group aged 5-17 [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html (US CDC statistics)]]]
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The novel coronavirus emerged in late 2019 and rapidly spread throughout the world, evolving into a human pandemic. The substantial suffering and mortality that followed ranks it as one of the greatest pandemics in human history.

While the precise molecular reasons for why COVID-19 disproportionately affects the elderly remain unanswered, what is apparent is that age is the largest - and by several orders of magnitude - risk factor for mortality.<ref name=":0">Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020). Why does COVID-19 disproportionately affect older people?. ''Aging (Albany NY)'', ''12''(10), 9959.</ref>

== SARS-CoV-2 as a disease of aging: epidemiology and risk factors ==
The salient feature of the COVID-19 pandemic was the extreme predisposition of the elderly to morbidity and mortality; therefore, understanding why and how this occurs should be a primary focus of therapeutic strategy.

For decades, scientists and doctors have known of the disproportionate susceptibility of older adults to respiratory infections.<ref name=":0" /> Similarly to COVID-19, respiratory infections such as pneumonia, influenza and other coronaviruses show similar mortality risk profiles in the elderly.

Influenza is a notable example of the age-related susceptibility to various pathogen-induced infections, which is historically linked to the annual deaths of 389,000 worldwide, 67% of which occur in people aged 65 or older.<ref>Paget, J., Spreeuwenberg, P., Charu, V., Taylor, R. J., Iuliano, A. D., Bresee, J., ... & Viboud, C. (2019). Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. ''Journal of global health'', ''9''(2).</ref> Possible reasons for mortality being age-related, from the perspective of broad biological mechanisms, include immunosenescence (immune aging) and inflammaging (age-related systemic inflammation).<ref name=":0" /><ref>Akbar, A. N., & Gilroy, D. W. (2020). Aging immunity may exacerbate COVID-19. ''Science'', ''369''(6501), 256-257.</ref><ref name=":2">[[Barzilai, N., Appleby, J. C., Austad, S. N., Cuervo, A. M., Kaeberlein, M., Gonzalez-Billault, C., ... & Sierra, F. (2020). Geroscience in the Age of COVID-19. Aging and disease, 11(4), 725.|Barzilai, N., Appleby, J. C., Austad, S. N., Cuervo, A. M., Kaeberlein, M., Gonzalez-Billault, C., ... & Sierra, F. (2020). Geroscience in the Age of COVID-19. ''Aging and disease'', ''11''(4), 725.]]</ref>

=== Aging, comorbidities, and COVID-19 ===
Current epidemiological data provides limited support for the idea that ''single'' comorbidities (often age-related diseases such as type 2 diabetes or hypertension) are important in isolation as predictors (risk factors) for SARS-CoV-2 mortality.<ref name=":4" /> While COVID-19 can be comorbid with one other disease, the resulting increase in mortality risk is small; any single comorbidity as a risk factor for mortality remains on the order of single-digit magnitude.<ref>Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., ... & Goldacre, B. (2020). Factors associated with COVID-19-related death using OpenSAFELY. ''Nature'', ''584''(7821), 430-436.</ref>

Multimorbidity, or having more than two comorbidities, appears to be more important in predicting COVID-19 mortality. In developed countries, the risk of having multimorbidity increases exponentially with age, with a prevalence of 20% before age 40, increasing to 75% at age 70.<ref name=":4" /><ref>Violan, C., Foguet-Boreu, Q., Flores-Mateo, G., Salisbury, C., Blom, J., Freitag, M., ... & Valderas, J. M. (2014). Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. ''PloS one'', ''9''(7), e102149.</ref>

Analyses of the available epidemiological data for COVID-19 reveals that age uniquely confers the greatest risk for mortality, with no other putative risk factor approaching comparable magnitude.<ref name=":0" />'''<ref name=":1" />''' When [[wikipedia:Comorbidity|comorbidities]] are controlled for in correlational analyses, by separating apparently healthy older adults from those of similar age with chronic diseases, age still remains as the dominant risk factor for mortality.'''<ref name=":1" />'''

Similarly, when controlling for age, the predictive value of comorbidities on mortality to SARS-CoV-2 infections fades, indicating substantial confounding by age. Conversely, the residual predictive value of various comorbidities, such as hypertension and cardiovascular diseases, is consistent with the idea that comorbidities may act as partial indicators of biological age, reflecting differences in aging that cannot simply be captured by chronological age.<ref name=":4">Polidori, M. C., Sies, H., Ferrucci, L., & Benzing, T. (2021). COVID-19 mortality as a fingerprint of biological age. ''Ageing Research Reviews'', 101308.
</ref> Furthermore, most pre-existing conditions that are risk factors for COVID-19 mortality are age-related diseases, which adds to the idea that biological aging is fundamental to the ability of SARS-CoV-2 (age-dependent mortality) to induce mortality the elderly.

=== COVID-19 as a disease of aging ===
'''As detailed in the paper, "[https://onlinelibrary.wiley.com/doi/full/10.1111/acel.13230 COVID‐19 is an emergent disease of aging"],<ref name=":1">[[Santesmasses, D., Castro, J. P., Zenin, A. A., Shindyapina, A. V., Gerashchenko, M. V., Zhang, B., ... & Gladyshev, V. N. (2020). COVID‐19 is an emergent disease of aging. Aging cell, 19(10), e13230.|Santesmasses, D., Castro, J. P., Zenin, A. A., Shindyapina, A. V., Gerashchenko, M. V., Zhang, B., ... & Gladyshev, V. N. (2020). COVID‐19 is an emergent disease of aging. ''Aging cell'', ''19''(10), e13230.]]</ref> COVID-19 can be defined as an age-related disease due to the following epidemiological traits:<ref name=":2" /><ref>[[Promislow, D. E. (2020). A geroscience perspective on COVID-19 mortality. The Journals of Gerontology: Series A, 75(9), e30-e33.|Promislow, D. E. (2020). A geroscience perspective on COVID-19 mortality. ''The Journals of Gerontology: Series A'', ''75''(9), e30-e33.]]</ref><ref>Alberts, S. C., Archie, E. A., Gesquiere, L. R., Altmann, J., Vaupel, J. W., & Christensen, K. (2014). The male-female health-survival paradox: a comparative perspective on sex differences in aging and mortality. In ''Sociality, hierarchy, health: comparative biodemography: a collection of papers''. National Academies Press (US).</ref><ref>[[Sierra, F. (2020). Geroscience and the Coronavirus Pandemic: The Whack‐a‐Mole Approach is not Enough. Journal of the American Geriatrics Society, 68(5), 951.|Sierra, F. (2020). Geroscience and the Coronavirus Pandemic: The Whack‐a‐Mole Approach is not Enough. ''Journal of the American Geriatrics Society'', ''68''(5), 951.]]</ref>'''

'''1) The doubling time for COVID-19 mortality approaches that of the doubling time of 8 years for all-cause mortality/morbidity (as observed for all age-related diseases), per the Gompertz law.'''

'''2) There is a greater mortality rate in men, consistent with known sex differences in rates of aging.'''

'''3) There is a greater mortality rate for those with age-related comorbidities, consistent with accelerated biological aging.'''

'''4) Age dwarfs all other putative [[wikipedia:Risk_factor|risk factors]] for mortality by several orders of magnitude.'''

''Risk factors are used medicine to assess individual and population risks for certain diseases, in order to guide diagnosis and clinical management. An example of a risk factor is smoking status, which increases the risk of lung cancer by approximately 7 fold.<ref>[[O’Keeffe, L. M., Taylor, G., Huxley, R. R., Mitchell, P., Woodward, M., & Peters, S. A. (2018). Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ open, 8(10), e021611.|O’Keeffe, L. M., Taylor, G., Huxley, R. R., Mitchell, P., Woodward, M., & Peters, S. A. (2018). Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. ''BMJ open'', ''8''(10), e021611.]]</ref>''[[File:CDC stat table.jpg|center|thumb|883x883px|link=https://longevitywiki.org/wiki/File:CDC_stat_table.jpg]]When compared to a reference group of youths aged 5-14, the risk of death for COVID-19 patients over the age of 85 is 8700 times greater, according to data from the United States Centers for Disease Control and Prevention. Other common risk factors identified in COVID-19 scientific discourse are comparatively inconsequential; for example, a history of chronic lung disease confers only a 2 times greater risk of mortality.<ref>[[Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., ... & Goldacre, B. (2020). Factors associated with COVID-19-related death using OpenSAFELY. Nature, 584(7821), 430-436.|Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., ... & Goldacre, B. (2020). Factors associated with COVID-19-related death using OpenSAFELY. ''Nature'', ''584''(7821), 430-436.]]</ref> COVID-19 results in systemic involvement with neurologic, kidney, liver, heart, endocrine, and gut complications;<ref>Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., ... & Landry, D. W. (2020). Extrapulmonary manifestations of COVID-19. ''Nature medicine'', ''26''(7), 1017-1032.</ref> therefore, geroprotectors that treat aging may be valuable for increasing the resilience of multiple aged and vulnerable organ systems.<ref>[[Sierra, F. (2020). Geroscience and the Coronavirus Pandemic: The Whack‐a‐Mole Approach is not Enough. Journal of the American Geriatrics Society, 68(5), 951.|Sierra, F. (2020). Geroscience and the Coronavirus Pandemic: The Whack‐a‐Mole Approach is not Enough. ''Journal of the American Geriatrics Society'', ''68''(5), 951.]]</ref><ref>[[Barzilai, N., Appleby, J. C., Austad, S. N., Cuervo, A. M., Kaeberlein, M., Gonzalez-Billault, C., ... & Sierra, F. (2020). Geroscience in the Age of COVID-19. Aging and disease, 11(4), 725.|Barzilai, N., Appleby, J. C., Austad, S. N., Cuervo, A. M., Kaeberlein, M., Gonzalez-Billault, C., ... & Sierra, F. (2020). Geroscience in the Age of COVID-19. ''Aging and disease'', ''11''(4), 725.]]</ref>

The disproportionate susceptibility to mortality from all causes with age is fundamentally related to age-related decreases in resilience.<ref>Pyrkov, T. V., Avchaciov, K., Tarkhov, A. E., Menshikov, L. I., Gudkov, A. V., & Fedichev, P. O. (2021). Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit. ''Nature Communications'', ''12''(1), 1-10.

Chicago</ref> The multiple systemic consequences of SARS-CoV-2 and the magnitude of risk conferred by age shows that the complex, multisystem phenomenon of biological aging must have a role in disease susceptibility.'''<ref name=":1" />''' It has been suggested that an emphasis on the specific organ system of respiration (or the virus itself), rather than the aging host, may be a short-sighted therapeutic strategy.<ref>[https://agsjournals.onlinelibrary.wiley.com/doi/full/10.1111/jgs.16489 Sierra, F. (2020). Geroscience and the Coronavirus Pandemic: The Whack‐a‐Mole Approach is not Enough. ''Journal of the American Geriatrics Society'', ''68''(5), 951.]</ref> Targeting aging biology mechanisms to improve the resilience of an aging population may also be a strategy to help prevent catastrophic outcomes of future pandemics.<ref name=":2" />

==== Clinician advocacy for clinical trials targeting the biology of aging for COVID-19 ====
As published in various journals, including ''The Lancet Healthy Longevity'', various professors, scientists, and physicians have advocated the need for clinical trials targeting the biology of aging for COVID-19.<ref name=":2" />'''<ref name=":1" />'''<ref>Mannick, J. B., Teo, G., Bernardo, P., Quinn, D., Russell, K., Klickstein, L., ... & Shergill, S. (2021). Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. ''The Lancet Healthy Longevity'', ''2''(5), e250-e262.</ref> Investigating drugs that target aging biology could be an important strategy to improving immune function in the elderly,<ref>Cox, L. S., Bellantuono, I., Lord, J. M., Sapey, E., Mannick, J. B., Partridge, L., ... & Witham, M. D. (2020). Tackling Immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. ''The Lancet Healthy Longevity'', ''1''(2), e55-e57.</ref> because severe outcomes and mortality are linked primarily to aging (i.e. immunosenescence and inflammaging). Because of the far reaching consequences of biological aging, this has implications for not just seasonal infectious diseases such as influenza, but also for pandemics such as [[COVID-19]], as well as other diseases that disproportionately affect the elderly.<ref>Akbar, A. N., & Gilroy, D. W. (2020). Aging immunity may exacerbate COVID-19. ''Science'', ''369''(6501), 256-257.</ref>

=== Aging and COVID-19 Infection Fatality Rate (IFR) ===
In the research field of [[wikipedia:Epidemiology|epidemiology]], the infection fatality rate (IFR) – the ratio of fatalities to total infections – is an important metric for determining the virulence of an infectious disease.<ref>Levin, A. T., Hanage, W. P., Owusu-Boaitey, N., Cochran, K. B., Walsh, S. P., & Meyerowitz-Katz, G. (2020). Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. ''European journal of epidemiology'', 1-16.</ref> In the early stages of the pandemic, determining the IFR of COVID-19 was subject to significant uncertainty due to lack of data.

One estimate found that the IFR of a given country's population was significantly dependent on the age structure, indicating that IFR is age-specific.<ref name=":7">O’Driscoll, M., Dos Santos, G. R., Wang, L., Cummings, D. A., Azman, A. S., Paireau, J., ... & Salje, H. (2021). Age-specific mortality and immunity patterns of SARS-CoV-2. ''Nature'', ''590''(7844), 140-145.</ref> For example, Japan had the highest estimated IFR of 1.09% (95% credible interval, 0.94–1.26%), whereas Kenya had the lowest estimated IFR of 0.09% (95% credible interval, 0.08–0.10%).<ref name=":7" /> This predominantly reflects demographic differences, as Japan has a significantly larger proportion of elderly citizens.

From the perspective of COVID-19 mortality, countries with minimal public health resources have generally fared well during the SARS-CoV-2 pandemic. Instead, the acute impacts of COVID-19 felt by such countries are anticipated to be secondary or indirect effects.<ref name=":8">Weiss, D. J., Bertozzi-Villa, A., Rumisha, S. F., Amratia, P., Arambepola, R., Battle, K. E., ... & Gething, P. W. (2021). Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis. ''The Lancet Infectious Diseases'', ''21''(1), 59-69.</ref> In developing countries that have a younger demographic structure, age-specific IFRs must be considered by public health stakeholders. Neglecting to consider tradeoffs that apply to populations with differing susceptibility to diseases may cause unnecessary harm. For example, infectious disease experts estimate that disruptions to malaria vaccinations in Africa due to the pandemic could double Malaria mortality in 2020.<ref name=":8" /><ref>Sherrard-Smith, E., Hogan, A. B., Hamlet, A., Watson, O. J., Whittaker, C., Winskill, P., ... & Churcher, T. S. (2020). The potential public health consequences of COVID-19 on malaria in Africa. ''Nature medicine'', ''26''(9), 1411-1416.</ref>

=== Immune aging and vulnerability to infectious diseases ===
Both immunosenescence and inflammaging are well-known biological mechanisms that underlie age-related susceptibility to various infectious diseases, such as the common cold, influenza, and pneumonia.

Immunosenescence is characterised by the age-related decline in the host's ability to mount an appropriate immune response to an infectious agent.<ref name=":6">Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C., ... & Slavich, G. M. (2019). Chronic inflammation in the etiology of disease across the life span. ''Nature medicine'', ''25''(12), 1822-1832.</ref> A major reason for this decline is related to atrophy of the thymus (thymic involution), an important organ that is important for generating naive T cells. It is therefore central to the adaptive immune system, which is integral to providing long-term protection against old and new infectious pathogens.

Inflammaging describes the age-related systemic inflammation, which affects various systems across the body that leads to organ and tissue dysfunction.<ref name=":6" /> It is known that with aging, dysregulation of the innate immune system results in chronic hyperactivation, and becomes a key driver of multiple age-related diseases via chronic inflammation.<ref>Shaw, A. C., Goldstein, D. R., & Montgomery, R. R. (2013). Age-dependent dysregulation of innate immunity. ''Nature Reviews Immunology'', ''13''(12), 875-887.</ref>

== COVID-19 clinical trials targeting aging ==
The following drugs are currently being investigated in clinical trials for the treatment of COVID-19; they are not currently regarded as safe or effective for this indication.

=== RTB101 ===
<blockquote>RTB101 (dactolisib) is an FDA-approved drug used in oncology, with primary mechanism of action of ATP-competitive PI3K/mTOR dual kinase inhibition.

Inhibition of mTOR has been shown in human clinical studies to improve immune function in older adults.<ref>Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., ... & Klickstein, L. B. (2014). mTOR inhibition improves immune function in the elderly. ''Science translational medicine'', ''6''(268), 268ra179-268ra179.</ref><ref>Mannick, J. B., Morris, M., Hockey, H. U. P., Roma, G., Beibel, M., Kulmatycki, K., ... & Klickstein, L. B. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. ''Science translational medicine'', ''10''(449).</ref> Phase 2 studies have shown that mTOR inhibitors can reduce viral infection severity and improve the effectiveness of vaccination, such as for influenza. This is in contrast to the known ability for rapamycin (and its analogues) to induce immunosuppression, which is related to its primary indication as an FDA-approved liver and lung transplant drug.

Following the success of two [https://clinicaltrials.gov/ct2/show/NCT03373903?term=restorbio&draw=2&rank=4 phase 2 clinical trials] investigating mTOR inhibition for targeting the aging immune system, RTB101 (dactolisib) is currently being pursued for the treatment of COVID-19 in a phase 2a placebo-controlled trial, exploring the potential for preventing severe disease in asymptomatic elderly adults who have been exposed to COVID-19.<ref>Restorbio Inc. ''A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Adults Age ≥65 Years''. Clinical trial registration, NCT04584710, clinicaltrials.gov, 5 Feb. 2021. ''clinicaltrials.gov'', https://clinicaltrials.gov/ct2/show/NCT04584710.</ref><ref>Restorbio Inc. ''Randomized Double Blind Placebo-Controlled Study to Determine If Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults ≥65 Years in a Nursing Home in Which ≥1 Person(s) Have Lab Confirmed COVID19''. Clinical trial registration, NCT04409327, clinicaltrials.gov, 5 Feb. 2021. ''clinicaltrials.gov'', https://clinicaltrials.gov/ct2/show/NCT04409327.</ref>

This trial is being run by the biopharmaceutical company resTORbio and has obtained funding from the [https://www.nia.nih.gov/ National Institute on Aging].

The primary rationale for why RTB101 has potential to show benefit for the 2019 strain of coronavirus stems from phase 2b and phase 3 clinical trial data of RTB101, showing [https://www.globenewswire.com/NewsRoom/AttachmentNg/2efab205-5689-453e-b2c6-5bdb006d89d4 fewer laboratory-confirmed (non-COVID-19) coronavirus cases], and [https://www.globenewswire.com/NewsRoom/AttachmentNg/4e5cdc45-cc2b-4d9a-815f-4907690bb06f reduced severity of coronavirus infection] in elderly adults aged ≥ 65. The phase 3 randomised, double-blind, placebo-controlled clinical trial for RTB101 was withdrawn in November 2019, following failure to meet its primary endpoint of reducing symptoms of respiratory tract infections (RTIs) in adults aged ≥ 65, with or without laboratory-confirmed viral illness.

Considering the promising clinical data from the phase 2 trials, which involved investigations of both rapamycin and RTB101, some regard this failure as unsurprising due to the decision to move ahead with only RTB101 in the phase 3 trial.<ref name=":5">Kaeberlein, M. (2020). RTB101 and immune function in the elderly: Interpreting an unsuccessful clinical trial. ''Translational Medicine of Aging'', ''4'', 32-34.
</ref> This is because only rapamycin, an allosteric inhibitor of mTOR, has demonstrated the extension of healthspan and lifespan in various animal models, with a rejuvenation of immune function; while RTB101, an ATP-competitive PI3K/mTOR dual kinase inhibitor of differing mechanism of action to rapamycin, has not yet demonstrated these effects in animal models.<ref name=":5" /> The decision to omit the use of rapamycin and continue with RTB101 in the phase 3 trial is speculated to be related to the off-patent status; it would be prohibitive for a publicly-traded company with fiduciary responsibility to shareholders to advance a drug with no commercial potential into late-stage clinical trials.<ref name=":5" />

Joan Mannick, the Chief Medical Officer of resTORbio, has since justified the trial's failure at several [https://www.youtube.com/watch?v=BVQci0V8uPk medical conferences] with the belief that it was related to a change in the primary endpoint, as requested by the [[wikipedia:Food_and_Drug_Administration|US FDA]], when the trial advanced from phase 2 to 3. In the prior successful phase 2 trial, the primary endpoint had been RTI symptoms ''with'' laboratory confirmation of a causative virus, but this endpoint was changed to RTI symptoms ''with or without'' laboratory-confirmed viral illness in the [https://clinicaltrials.gov/ct2/show/NCT04139915?cond=rtb101&draw=2&rank=1 failed phase 3 trial]. This is a problem for interpreting the clinical trial because it was not the original endpoint for which the drug had showed benefits, and is also introduced as older adults inherently experience respiratory tract symptoms at greater rates, even ''without'' laboratory-confirmation of viral presence. </blockquote>

=== Fisetin ===
Fisetin is a [[Senolytics|senolytic]] that is being investigated in two phase 2 clinical trials at the Mayo Clinic<ref>Kirkland, James L. ''COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults''. Clinical trial registration, NCT04476953, clinicaltrials.gov, 16 Feb. 2021. ''clinicaltrials.gov'', <nowiki>https://clinicaltrials.gov/ct2/show/NCT04476953</nowiki>.</ref>, with the second trial being funded by the National Institute on Aging of the [[wikipedia:National_Institutes_of_Health|US NIH]]<ref>PhD, James L. Kirkland, MD. ''COVID-FIS: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing Homes''. Clinical trial registration, NCT04537299, clinicaltrials.gov, 1 June 2021. ''clinicaltrials.gov'', <nowiki>https://clinicaltrials.gov/ct2/show/NCT04537299</nowiki>.</ref>.

For SARS-CoV-2, fibrosis of the lung tissue is a well-known serious complication following acute respiratory distress syndrome (ARDS). Senolytic drugs are capable of slowing and/or reversing age-related lung fibrosis in mice, as well as promoting health in multiple tissues/organs, and so may provide benefit for both acute and chronic manifestations of COVID-19.<ref name=":3" /> The pro-inflammatory secretions of senescent cells have been identified as key drivers of tissue and organ dysfunction with aging, which have been linked to the cytokine storm associated with COVID-19 ARDS.<ref name=":3" /> It is hypothesised that senolytics may alleviate the age-associated decline in lung function, in addition to improving immune function such as via the clearance of senescent T cells.<ref name=":3">Nehme, J., Borghesan, M., Mackedenski, S., Bird, T. G., & Demaria, M. (2020). Cellular senescence as a potential mediator of COVID‐19 severity in the elderly. ''Aging Cell'', ''19''(10), e13237</ref><ref>Akbar, A. N., & Gilroy, D. W. (2020). Aging immunity may exacerbate COVID-19. ''Science'', ''369''(6501), 256-257.</ref>

=== BGE-175 ===
BGE-175 is an investigational new drug for COVID-19 that was previously studied in phase 1 to 3 trials for allergic rhinitis involving 2400 study participants. It is an oral inhibitor of prostaglandin D2 (PGD2) DP1 signaling.<ref>https://www.businesswire.com/news/home/20210322005146/en/BioAge-Initiates-Phase-2-Trial-of-BGE-175-to-Treat-COVID-19-by-Reversing-Immune-Aging-a-Key-Cause-of-Morbidity-and-Mortality-in-Older-Patients</ref> It is being advanced in clinical trials by BioAge, a privately-held biotechnology company that aims to treat aging and aging-related diseases.

While BGE-175 has not been shown to extend healthspan and/or lifespan in published animal models, the company claims that the rationale for its consideration as an aging drug is based on targeting the apelin pathway that is associated with healthspan and lifespan in humans.<ref>https://www.fiercebiotech.com/biotech/bioage-picks-up-muscle-aging-program-from-amgen-bringing-pipeline-count-to-3</ref><ref>Zhou, Q., Chen, L., Tang, M., Guo, Y., & Li, L. (2018). Apelin/APJ system: A novel promising target for anti-aging intervention. ''Clinica Chimica Acta'', ''487'', 233-240.</ref>

<references />
[[Category:Longevity]]
[[Category:Pillar Articles]]

Epigenetic reprogramming

2021-09-07T07:43:39Z

Schulzm: Add Pillar Articles category

Epigenetic reprogramming is based on work that earnt [https://embryology.med.unsw.edu.au/embryology/index.php/Embryology_History_-_Shinya_Yamanaka Shinya Yamanaka] the 2012 Nobel Prize in Medicine. Yamanaka showed that it was possible to reprogram adult body cells back into biologically immortal pluripotent stem cells that are capable of turning into any cell of the body.<ref name=":17">Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. ''cell'', ''126''(4), 663-676.</ref><ref name=":18">Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. ''cell'', ''131''(5), 861-872.</ref> This was achieved by activating only four transcription factors - the [[Yamanaka factors|''Yamanaka factors'']] - OCT4, SOX2, KLF4, and MYC (or OSKM).<ref name=":17" /><ref name=":18" /> These transcription factors cause epigenetic changes that alter gene expression, instead of making changes to DNA itself.<ref name=":17" /><ref name=":18" />

Scientists in the aging biology field have since expanded upon this work to show that a partial version of this epigenetic reprogramming technique may reverse multiple aspects of aging.<ref name=":15">[[Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., ... & Belmonte, J. C. I. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell, 167(7), 1719-1733.|Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., ... & Belmonte, J. C. I. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. ''Cell'', ''167''(7), 1719-1733.]]</ref> Work from Juan Carlos Izpisua Belmonte's lab showed that it is possible to modify the reprogramming technique and achieve 'youthful' rejuvenation, without resetting a cell with a defined identity into a stem cell. This is known as partial reprogramming, and commonly referred to as epigenetic reprogramming. Epigenetic aging clocks, which measure the methylation status of various tissues and predict biological age, have been observed to be reset with partial cellular reprogramming.<ref>Olova, N., Simpson, D. J., Marioni, R. E., & Chandra, T. (2019). Partial reprogramming induces a steady decline in epigenetic age before loss of somatic identity. ''Aging cell'', ''18''(1), e12877.</ref>

[[File:ONH regeneration epigenetic reprogramming.png|center|frame|In vivo epigenetic reprogramming can lead to regeneration of the optic nerve in injury and glaucoma mouse models, and lead to visual recovery in natural aging]]

In 2016, the Belmonte lab first showed that temporarily expressing the Yamanaka factors in a controlled manner could rejuvenate multiple aged organs and extend healthy lifespan in mice with accelerated aging.<ref name=":15" /><ref>Rando, T. A., & Chang, H. Y. (2012). Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock. ''Cell'', ''148''(1-2), 46-57.</ref> The authors also showed that uncontrolled, persistent expression of the Yamanaka factors led to teratomas, or tissue tumors.<ref name=":15" /> Another strategy, advanced by the Sinclair lab, was to use only 3 of the 4 transcription factors by excluding MYC.<ref name=":16">Lu Y, Brommer B, Tian X, Krishnan A, Meer M, Wang C, Vera DL, Zeng Q, Yu D, Bonkowski MS, Yang JH. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020 Dec;588(7836):124-9. https://www.nature.com/articles/s41586-020-2975-4</ref> This is because it has a known role in promoting cancer as an oncogene, but appears not to be necessary for rejuvenation; this reprogramming strategy has also shown to be safe in mice.<ref name=":16" />

Using epigenetic reprogramming in ''naturally aged'' mice has more recently been shown to improve memory/cognition, promote muscle regeneration, and restore vision.<ref>Wang, C., Ros, R. R., Martinez-Redondo, P., Ma, Z., Shi, L., Xue, Y., ... & Belmonte, J. C. I. (2021). In vivo partial reprogramming of myofibers promotes muscle regeneration by remodeling the stem cell niche. ''Nature Communications'', ''12''(1), 1-15.</ref><ref>Rodríguez-Matellán, A., Alcazar, N., Hernández, F., Serrano, M., & Ávila, J. (2020). In Vivo Reprogramming Ameliorates Aging Features in Dentate Gyrus Cells and Improves Memory in Mice. ''Stem cell reports'', ''15''(5), 1056-1066.</ref><ref name=":16" /> Analyses using epigenetic aging clocks, which measure some aspects of biological age, show that cellular reprogramming resets epigenetic age.<ref>Ocampo, A., Reddy, P., & Belmonte, J. C. I. (2016). Anti-aging strategies based on cellular reprogramming. ''Trends in molecular medicine'', ''22''(8), 725-738.</ref>

It has been envisioned by some scientists as a therapy that could be used periodically, perhaps every few decades, to continually reverse aging in humans.

====Citations====
*
<references />
[[Category:Longevity]]
[[Category:Pillar Articles]]

Rapamycin

2021-09-07T07:41:55Z

Schulzm: Add Pillar Articles category

[[File:Rapamycin2.jpg|thumb|211x211px|The chemical structure of rapamycin.]]
Rapamycin, also known by its brand name Rapamune®, is a compound used to prevent the rejection of organ transplants by the immune system. Rapamycin is a natural antifungal produced by soil bacteria of Eastern Island, named after its native island, Rapa Nui.<ref>''Sirolimus - Wikipedia''. En.wikipedia.org. (2021). Retrieved 27 May 2021, from <nowiki>https://en.wikipedia.org/wiki/Sirolimus</nowiki>.</ref>

Rapamycin was approved by the US Food and Drug Administration in September 1999 and is marketed under the trade name Rapamune® by Pfizer.<ref>Accessdata.fda.gov. 2021. ''Drug Approval Package: Rapamune (Sirolimus) NDA# 021083''. [online] Available at: <<nowiki>https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21083A.cfm</nowiki>> [Accessed 27 May 2021].</ref> Rapamycin has an immunosuppressant function that is especially useful in preventing rejection of kidney transplants by the immune system. It is also used to coat coronary stents, and to treat rare lung diseases.<ref>Doggrell, S. (2006). Sirolimus- or paclitaxel-eluting stents for coronary artery revascularisation. ''Expert Opinion On Pharmacotherapy'', ''7''(2), 225-228. <nowiki>https://doi.org/10.1517/14656566.7.2.225</nowiki></ref> The patent on rapamycin has expired, and pharmacological companies have developed similar drugs such as everolimus.<ref>Cancer, C. (2021). ''Everolimus - Drug Information - Chemocare''. Chemocare.com. Retrieved 27 May 2021, from <nowiki>http://chemocare.com/chemotherapy/drug-info/everolimus.aspx</nowiki>.</ref>

Rapamycin has been shown to extend healthy lifespan in worms, yeast, flies, and mice.<ref>[https://science.sciencemag.org/content/328/5976/321.abstract?casa_token=ptqabKjuDxMAAAAA:qBvrJQ01NpHQ8WyJSQf6HeQIhaaexgZXZMvi9i_AP4fE2iHhvMzLV-z3_eF5T3rEauJkg0eQNQFfbA Fontana, L., Partridge, L., & Longo, V. D. (2010). Extending healthy life span—from yeast to humans. ''science'', ''328''(5976), 321-326.]</ref> Some physicians and scientists have thus suggested that rapamycin may slow down aging.<ref name=":2" /><ref>Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013). mTOR is a key modulator of ageing and age-related disease. ''Nature'', ''493''(7432), 338-345.</ref>

Scientists who study the biology of aging believe that, due to evidence of rapamycin slowing aging in animals, it could be used to prevent the onset of all age-related diseases in humans – to become one of the first identified “anti-aging drugs”.<ref name=":2">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814615/ Blagosklonny, M. (2019). Rapamycin for longevity: opinion article. ''Aging'', ''11''(19), 8048-8067. https://doi.org/10.18632/aging.102355]</ref><ref>Blagosklonny, M. (2006). Aging and Immortality: Quasi-Programmed Senescence and Its Pharmacologic Inhibition. ''Cell Cycle'', ''5''(18), 2087-2102. <nowiki>https://doi.org/10.4161/cc.5.18.3288</nowiki></ref> It is being repurposed for humans as an anti-aging drug in the PEARL clinical study, which is expected to conclude in 2023.<ref>[https://clinicaltrials.gov/ct2/show/NCT04488601 ''Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study - Full Text View - ClinicalTrials.gov''. Clinicaltrials.gov. (2021). Retrieved 27 May 2021, from https://clinicaltrials.gov/ct2/show/NCT04488601.]</ref>

== Evidence of lifespan extension ==

=== Dogs ===
There is preliminary evidence that rapamycin may prevent age-related decline in dogs. One study showed statistically significant improvements in heart function in dogs receiving rapamycin, relative to those that received placebo, similar to what has been observed in older laboratory mice.<ref name=":9">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411365/ Urfer, S. R., Kaeberlein, T. L., Mailheau, S., Bergman, P. J., Creevy, K. E., Promislow, D. E., & Kaeberlein, M. (2017). A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. ''Geroscience'', ''39''(2), 117-127.]</ref>
=== Mice ===
In multiple studies in different breeds of mice, rapamycin demonstrates a robust effect on increasing healthy lifespan. Rapamycin significantly extends lifespan in approximately 90% of the mice models it has been tested in.<ref>Selvarani, R., Mohammed, S., & Richardson, A. (2020). Effect of rapamycin on aging and age-related diseases—past and future. ''GeroScience'', 1-24.</ref>

In 2009, rapamycin was shown to increase the lifespan of both male and female mice when given in late life (600 days).<ref name=":5">[https://doi.org/10.1038%2Fnature08221 Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., ... & Miller, R. A. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. ''nature'', ''460''(7253), 392-395.]</ref> Mean survival was extended by 28% for males and 38% for females, while maximal lifespan increased by 9% for males and 14% for females.<ref name=":5" /> This was the first evidence that the lifespan of a mammal could be significantly increased by a pharmacological drug. This mouse study is special because the results were obtained following the US National Institute on Aging's Interventions Testing Program (ITP) protocol. The ITP is regarded as the gold standard for testing drugs that target aging.<ref>Nadon, N. L., Strong, R., Miller, R. A., Nelson, J., Javors, M., Sharp, Z. D., ... & Harrison, D. E. (2008). Design of aging intervention studies: the NIA interventions testing program. ''Age'', ''30''(4), 187-199.</ref>

The landmark 2009 study also showed that rapamycin could increase healthy lifespan when given in old age. This has important implications for human testing, as it suggests that the drug might still exhibit healthspan and lifespan benefits even when given to the elderly. Rapamycin contrasts with calorie restriction in this regard; some evidence suggests that calorie restriction needs to be practised from early adulthood, and may even fail to provide benefit for animals that are already old.<ref>Szafranski, K., & Mekhail, K. (2014). The fine line between lifespan extension and shortening in response to caloric restriction. ''Nucleus'', ''5''(1), 56-65.</ref>
==== Rapidly aging mice models ====
Using a mouse model that mimics the accelerated aging disease Hutchinson-Gilford progeria, rapamycin was shown to increase lifespan by over 50%. It also improved cardiac and skeletal muscle function in these mice.<ref>[https://doi.org/10.1126%2Fscitranslmed.3003802 Ramos, F. J., Chen, S. C., Garelick, M. G., Dai, D. F., Liao, C. Y., Schreiber, K. H., ... & Kennedy, B. K. (2012). Rapamycin reverses elevated mTORC1 signaling in lamin A/C–deficient mice, rescues cardiac and skeletal muscle function, and extends survival. ''Science translational medicine'', ''4''(144), 144ra103-144ra103.]
</ref> In one short-lived mutant strain of mice that mimics Leigh syndrome, rapamycin was shown to extend maximum life span nearly three-fold.<ref>[https://www.ncbi.nlm.nih.gov/pubmed/24231806/ Johnson, S. C., Yanos, M. E., Kayser, E. B., Quintana, A., Sangesland, M., Castanza, A., ... & Kaeberlein, M. (2013). mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. ''Science'', ''342''(6165), 1524-1528.]</ref>

==== Middle-aged mice ====
Several recent studies have shown that rapamycin can extend the lifespan of middle-aged mice. One study showed that treating 20-month-old mice (the equivalent of 56–69 years in humans) with a high dose of rapamycin for only 3 months resulted in a dramatic increase in median lifespan of up to 60%.<ref>Bitto, A., Ito, T.K., Pineda, V.V., LeTexier, N.J., Huang, H.Z., Sutlief, E., Tung, H., Vizzini, N., Chen, B., Smith, K. and Meza, D., 2016. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. ''elife'', ''5'', p.e16351.</ref> A study from 2020 showed that administering rapamycin in late life enhanced the lifespan of male but not female mice, providing evidence for sex differences in rapamycin response.<ref>[https://onlinelibrary.wiley.com/doi/full/10.1111/acel.13269 Strong, R., Miller, R. A., Bogue, M., Fernandez, E., Javors, M. A., Libert, S., ... & Harrison, D. E. (2020). Rapamycin‐mediated mouse lifespan extension: Late‐life dosage regimes with sex‐specific effects. ''Aging cell'', ''19''(11), e13269.]</ref> These studies were important because it suggests that rapamycin could be used in older adults, so that dosing would not need to start at youth for health benefits.

=== Yeast ===
Inhibition of TOR signalling by rapamycin significantly increases the lifespan of yeast known as ''Saccharomyces cerevisiae.''<ref>Powers, R. W., Kaeberlein, M., Caldwell, S. D., Kennedy, B. K., & Fields, S. (2006). Extension of chronological life span in yeast by decreased TOR pathway signaling. ''Genes & development'', ''20''(2), 174-184.</ref>

=== Flies ===
Rapamycin extends the lifespan of the fruitfly, ''Drosophila melanogaster.'' The extent of lifespan extension observed is beyond what is achievable by flies undergoing other pro-longevity interventions like dietary restriction, or in mutant flies with mild decrements in insulin/insulin-like growth factor signaling (IIS).<ref>Bjedov, I., Toivonen, J. M., Kerr, F., Slack, C., Jacobson, J., Foley, A., & Partridge, L. (2010). Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. ''Cell metabolism'', ''11''(1), 35-46.</ref> Combining rapamycin with two other drugs that target metabolic pathways, lithium and trametinib, results in additive lifespan extension effects, substantially increasing ''Drosophila'' lifepsan by 48%.<ref>Castillo-Quan, J. I., Tain, L. S., Kinghorn, K. J., Li, L., Grönke, S., Hinze, Y., ... & Partridge, L. (2019). A triple drug combination targeting components of the nutrient-sensing network maximizes longevity. ''Proceedings of the National Academy of Sciences'', ''116''(42), 20817-20819.</ref>

=== Roundworms ===
TOR inhibition by rapamycin extends lifespan of ''Caenorhabditis Elegans,'' a roundworm species with an extensive research history in the aging biology field. The beneficial effects of rapamycin in ''C. elegans'' is mediated via the SKN-1/Nrf and DAF-16/FoxO pathways.<ref>Robida-Stubbs, S., Glover-Cutter, K., Lamming, D. W., Mizunuma, M., Narasimhan, S. D., Neumann-Haefelin, E., ... & Blackwell, T. K. (2012). TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. ''Cell metabolism'', ''15''(5), 713-724.</ref>

=== Age-related diseases ===
Rapamycin has been investigated in specific diseases, showing major impacts on reducing mouse cancer risk, cardiac diseases, neurodegenerative-like processes, and many other pathologies.<ref>Selvarani, R., Mohammed, S., & Richardson, A. (2020). Effect of rapamycin on aging and age-related diseases—past and future. ''GeroScience'', 1-24.
</ref>

===== Cancer =====
In the transgenic HER-2/neu mouse model, mice die prematurely due to susceptibility to cancer.<ref name=":6" /> Rapamycin was hypothesized to improve survival in this model due to its ability to slow aging, which would also address an age-related disease like cancer.<ref name=":6" /> The drug was shown to extend maximal lifespan, by delaying aging in multiple different organs and also suppressing cancer development.<ref name=":6">Anisimov, V. N., Zabezhinski, M. A., Popovich, I. G., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., ... & Blagosklonny, M. V. (2010). Rapamycin extends maximal lifespan in cancer-prone mice. ''The American journal of pathology'', ''176''(5), 2092-2097.</ref>

Other studies suggest that rapamycin can extend lifespan in mouse models where cancer naturally develops, such as in mice prone to cancer due to the Apc tumor suppressor gene mutation, or in mice heterozygous for the Rb1 tumor supressor gene, among others.<ref>Hasty, P., Livi, C. B., Dodds, S. G., Jones, D., Strong, R., Javors, M., ... & Sharp, Z. D. (2014). eRapa restores a normal life span in a FAP mouse model. ''Cancer Prevention Research'', ''7''(1), 169-178.</ref><ref>Livi, C. B., Hardman, R. L., Christy, B. A., Dodds, S. G., Jones, D., Williams, C., ... & Sharp, Z. D. (2013). Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors. ''Aging (Albany NY)'', ''5''(2), 100.</ref><ref>Hambright, H. G., Hurez, V., & Curiel, T. J. (2020). Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?. ''Geriatric Oncology'', 111-128.</ref>

===== Heart Disease =====
In one study that investigated the effects of rapamycin administration in naturally aged mice, improvements in cardiac muscle stiffness, diastolic function were observed.<ref name=":7">Quarles, E., Basisty, N., Chiao, Y. A., Merrihew, G., Gu, H., Sweetwyne, M. T., ... & Rabinovitch, P. S. (2020). Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment. ''Aging Cell'', ''19''(2), e13086.</ref> Improvements in heart function were shown with only a brief treatment course of 8 weeks.<ref name=":7" /> Benefits persisted even after rapamycin was stopped, which appears consistent with the hypothesis that rapamycin slows aging.<ref name=":7" />

===== Alzheimer's =====
Alzheimer's Disease (AD) is a progressive neurodegenerative disease for which age is the greatest risk factor. In an Alzheimer's model of transgenic PDAPP mice, rapamycin was shown to reduce Amyloid-β, one of the hallmark indicators of AD.<ref name=":8" /> This led to alleviation of AD-like symptoms, such as restored cognition and memory.<ref name=":8">Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., ... & Galvan, V. (2010). Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer's disease. ''PloS one'', ''5''(4), e9979.</ref>

=== Dose response ===
Rapamycin has shown a dose-response in which higher doses produce larger lifespan extension effects. UMHET3 mice of diverse genetic background were treated with varying doses of dietary rapamycin at 4.7, 14, or 42 ppm, revealing that those fed with the highest rapamycin dose had the greatest lifespan extension.<ref>Miller, R. A., Harrison, D. E., Astle, C. M., Fernandez, E., Flurkey, K., Han, M., ... & Strong, R. (2014). Rapamycin‐mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. ''Aging cell'', ''13''(3), 468-477.</ref><ref name=":0">[[Kaeberlein, M. (2014). Rapamycin and aging: when, for how long, and how much?. Journal of genetics and genomics= Yi chuan xue bao, 41(9), 459.|Kaeberlein, M. (2014). Rapamycin and aging: when, for how long, and how much?. ''Journal of genetics and genomics= Yi chuan xue bao'', ''41''(9), 459.]]</ref> Sex differences in response to rapamycin have been hypothesized to also be related to the effective dose, due to male/female differences in drug metabolism. The optimal dose for longevity in mice remains to be seen, but determining this dose will require consideration of the side effect profile of rapamycin.<ref name=":0" />

== Mechanism ==

=== Manipulating key metabolic pathways ===
Rapamycin has often been described as a 'calorie restriction (CR) mimetic'.<ref name=":4" /> This is in part because, similar to CR, it inhibits the nutrient-sensing mammalian target of rapamycin (mTOR) pathway.<ref name=":3">Cornu, M., Albert, V., & Hall, M. N. (2013). mTOR in aging, metabolism, and cancer. ''Current opinion in genetics & development'', ''23''(1), 53-62.</ref> mTOR plays key roles in cellular growth in response to amino acids, including effects that inhibit cancer and aging mechanisms.<ref name=":3" /><ref>Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013). mTOR is a key modulator of ageing and age-related disease. ''Nature'', ''493''(7432), 338-345.</ref> However, later studies have disentangled the effects of rapamycin from that of caloric restriction, showing that they differ significantly.<ref name=":4">Unnikrishnan, A., Kurup, K., Salmon, A. B., & Richardson, A. (2020). Is rapamycin a dietary restriction mimetic?. ''The Journals of Gerontology: Series A'', ''75''(1), 4-13.</ref> This has important implications for understanding biological aging, including the possibility of using CR and rapalogues in combination therapy to slow aging.<ref name=":4" />

Fasting and calorie restriction inhibit muscle-specific mTOR signaling with reduced effect in old vs young mice, indicating a poorer autophagy and proteosomal degradation response with age.<ref>White, Z., White, R. B., McMahon, C., Grounds, M. D., & Shavlakadze, T. (2016). High mTORC1 signaling is maintained, while protein degradation pathways are perturbed in old murine skeletal muscles in the fasted state. ''The international journal of biochemistry & cell biology'', ''78'', 10-21.</ref><ref>[https://www.ncbi.nlm.nih.gov/pubmed/21179166/ Sengupta, S., Peterson, T. R., Laplante, M., Oh, S., & Sabatini, D. M. (2010). mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. ''Nature'', ''468''(7327), 1100-1104.]</ref> However, the ability for rapamycin to inhibit mTOR appears to remain robust throughout life, and significant extension of median and maximal lifespan can be achieved even when treatment is initiated in mid-to-late life.<ref>Blagosklonny, M. V. (2019). Rapamycin for longevity: opinion article. ''Aging (Albany NY)'', ''11''(19), 8048.
</ref><ref>[[Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., ... & Miller, R. A. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. nature, 460(7253), 392-395.|Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., ... & Miller, R. A. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. ''nature'', ''460''(7253), 392-395.]]</ref> It contrasts significantly with CR, as the former appears effective in late life, while the latter is potentially detrimental when used in late life in mice models. Rapamycin also targets multiple aspects of aging, but in a segmented, tissue-specific manner.

=== mTORC1 and mTORC2 ===
In non-mammals the mTOR equivalent is known as the target of rapamycin (TOR), first discovered by Michael Hall in the yeast ''Saccharomyces cerevisiae''.<ref>Thomas, G., & Hall, M. N. (1997). TOR signalling and control of cell growth. ''Current opinion in cell biology'', ''9''(6), 782-787.</ref> mTOR signalling appears to be evolutionarily conserved, and this extends further to include various mammals, such as mice, rats, and dogs.

Rapamycin acts on mTOR, with multiple signaling functions subdivided across two major protein complexes known as mTORC1 and mTORC2.<ref name=":3" /> There is some evidence suggesting that the health and lifespan benefit of rapamycin is more related to mTORC1 than mTORC2.<ref>Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., ... & Baur, J. A. (2012). Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. ''science'', ''335''(6076), 1638-1643.</ref><ref name=":11">Lamming, D. W., Mihaylova, M. M., Katajisto, P., Baar, E. L., Yilmaz, O. H., Hutchins, A., ... & Sabatini, D. M. (2014). Depletion of Rictor, an essential protein component of m TORC 2, decreases male lifespan. ''Aging cell'', ''13''(5), 911-917.</ref> In mice, males exhibit weaker lifespan extension effects from rapamycin than in females. One study suggests that inhibiting mTORC2 explains why there exists such a sex difference in the response to mTOR inhibition by rapamycin.<ref name=":11" />

=== Reducing the effects of cellular senescence ===
The accumulation of senescent cells is thought to be an important mechanism underlying aging. Rapamycin is regarded as a senomorphic that may inhibit the pro-inflammatory secretory phenotype produced by senescent cells in humans, mice, and rats.<ref>[[Wang, R., Yu, Z., Sunchu, B., Shoaf, J., Dang, I., Zhao, S., ... & Perez, V. I. (2017). Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2‐independent mechanism. Aging cell, 16(3), 564-574.|Wang, R., Yu, Z., Sunchu, B., Shoaf, J., Dang, I., Zhao, S., ... & Perez, V. I. (2017). Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2‐independent mechanism. ''Aging cell'', ''16''(3), 564-574.]]</ref><ref>Selvarani, R., Mohammed, S., & Richardson, A. (2020). Effect of rapamycin on aging and age-related diseases—past and future. ''GeroScience'', 1-24.
</ref> A preliminary study in humans aged 40 years or older showed that topical rapamycin reduced markers of cellular senescence in the skin and improved its physical appearance.<ref>[https://doi.org/10.1007%2Fs11357-019-00113-y Chung, C. L., Lawrence, I., Hoffman, M., Elgindi, D., Nadhan, K., Potnis, M., ... & Sell, C. (2019). Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. ''Geroscience'', ''41''(6), 861-869.]
</ref>

== Human clinical trials ==
[[File:Rapamycin.jpg|thumb|235x235px|Part of the rationale of the PEARL study is that an optimal dose of rapamycin may extend healthy lifespan.]]

=== PEARL study ===
Rapamycin is currently being tested for safety and efficacy in a clinical trial called the Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity (PEARL) study. The clinical trial aims to systematically investigate the use of rapamycin to promote healthy longevity, and is expected to conclude in 2023.<ref>[https://clinicaltrials.gov/ct2/show/NCT04488601 ''Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study - Full Text View - ClinicalTrials.gov''. Clinicaltrials.gov. (2021). Retrieved 27 May 2021, from https://clinicaltrials.gov/ct2/show/NCT04488601.]</ref>

The study will begin with 200 adults aged 50 years or older who will receive rapamycin for up to one year. The study is being conducted by AgelessRX, a new company dedicated to developing scientifically supported interventions to prevent and treat age-related diseases, in collaboration with the University of California.<ref>[https://www.longevity.technology/agelessrx-and-funding-an-irb-approved-rapamycin-trial/ ''AgelessRx and funding an IRB-approved rapamycin trial - Longevity.Technology''. Longevity.Technology. (2021). Retrieved 27 May 2021, from https://www.longevity.technology/agelessrx-and-funding-an-irb-approved-rapamycin-trial/.]</ref>

The trial aims to obtain clinical data at 6 and 12 months of treatment, such as via testing of blood, body composition DXA, fecal microbiome, immune function, inflammation, skeletal muscle, and epigenetic aging clocks.

== Dog clinical trials ==
The Dog Aging Project is a US Government NIH-funded intiative investigating dog aging.<ref>https://dogagingproject.org/</ref> The project is led by Professor Matt Kaeberlein at the University of Washington.<ref name=":10">Kaeberlein, M., Creevy, K. E., & Promislow, D. E. (2016). The dog aging project: translational geroscience in companion animals. ''Mammalian genome'', ''27''(7), 279-288.</ref>

The Test of Rapamycin In Aging Dogs (TRIAD) study is investigating rapamycin as a treatment to slow aging in dogs. The investigators hope to increase healthy canine lifespan with rapamycin by delaying the onset of age-related diseases like cancer and heart disease.<ref name=":9" /><ref name=":10" />

Aging biology scientists believe that studying dog aging might not only help improve canine healthspan, but also have implications for humans.<ref name=":10" /> It is believed that dogs would serve a good animal model because they share the same environment that humans live in, and suffer from similar chronic diseases with aging.<ref>Hoffman, J. M., Creevy, K. E., Franks, A., O'Neill, D. G., & Promislow, D. E. (2018). The companion dog as a model for human aging and mortality. ''Aging Cell'', ''17''(3), e12737.</ref>

== Regulatory approval ==
Rapamycin was approved by the US Food and Drug Administration (FDA) in 1999 to prevent organ rejection in liver transplant patients, and has been marketed under the brand name Rapamune.<ref>[https://link.springer.com/article/10.1007/s11357-020-00274-1 Selvarani, R., Mohammed, S., & Richardson, A. (2020). Effect of rapamycin on aging and age-related diseases—past and future. ''GeroScience'', 1-24.]</ref> The patent on rapamycin has expired, and chemically similar compounds called 'rapalogs' are being researched by biotechnology companies.<ref>[https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.9b00215 Abdel-Magid, A. F. (2019). Rapalogs potential as practical alternatives to rapamycin.]
</ref> It is not currently approved for use as an anti-aging medication, due to lack of sufficient human clinical data for this purpose.

== Safety ==
Rapamycin has been used to treat millions of patients over several decades since obtaining FDA approval in 1999. It is generally considered safe in humans, but only when used under clinical supervision for specific indications. Various side effects have been reported with the high dose of rapamycin used to prevent rejection in organ transplant patients, who are often concurrently treated with multiple other medications.<ref>Webster, A. C., Lee, V. W., Chapman, J. R., & Craig, J. C. (2006). Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. ''Transplantation'', ''81''(9), 1234-1248.</ref> These include pain, headache, fever, high blood pressure, glucose intolerance, nausea, abdominal pain, constipation, diarrhea, thrombocytopenia, leukopenia, among others. However, side effects are mostly reversible and represent worst-case scenarios, particularly because the patients sampled in clinical studies are already severely ill and taking high doses of the drug along with other medications.<ref>Bischof, E., Siow, R.C., Zhavoronkov, A. and Kaeberlein, M., 2021. The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. ''The Lancet Healthy longevity'', ''2''(2), pp.e105-e111.
</ref>

Case studies of the safety profile of rapamycin in the context of overdosing have suggested that it may have a large margin of safety or a high median lethal dose, but only in the acute setting.<ref>Ceschi, A., Heistermann, E., Gros, S., Reichert, C., Kupferschmidt, H., Banner, N. R., ... & Taegtmeyer, A. B. (2015). Acute sirolimus overdose: a multicenter case series. ''PLoS One'', ''10''(5), e0128033.</ref> The distinction with chronic high dose mTOR inhibition must be made because resultant immunosuppression can lead to susceptibility to infection with fatal consequences. Some preclinical data suggests that the longevity benefits of rapamycin may be retained via intermittent dosing.<ref name=":2" /> In considering the known clinical data about rapamycin's controversial safety at continuous, high doses, some researchers have proposed that rapamycin should dosed intermittently to minimize side effects while sufficiently inhibiting mTOR for an effect on aging.<ref name=":2" />

From a longevity perspective, there is a lack of published clinical data demonstrating the safety of rapamycin in healthy adults. One randomized pilot study of rapamycin in 25 older adults aged 70-95 showed no clinically significant effects, including a lack of effect on immune function.<ref name=":13">Kraig, E., Linehan, L. A., Liang, H., Romo, T. Q., Liu, Q., Wu, Y., ... & Kellogg Jr, D. L. (2018). A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. ''Experimental gerontology'', ''105'', 53-69.</ref> This was a small study with a low dose of rapamycin, dosed over a short duration of 8 weeks. Considering the fact that, based on preclinical animal data, any potential benefit of rapamycin for aging will require long-term dosing, further testing in clinical trials is necessary to better characterize safety.<ref name=":13" />

Clinical trials such as the PEARL study are needed to provide evidence for the safety profile of rapamycin in otherwise healthy older adults.

== Rapalogs ==
Rapalogs are molecules that have a similar mechanism to rapamycin (primarily inhibiting the mTORC1 protein). These drugs are generally predicted to function similarly to rapamycin in enhancing lifespan and reducing age-related decline in physiological function. However, only one rapalog, everolimus, has been studied in this context.<ref>[https://www.thelancet.com/servlet/linkout?suffix=e_1_5_1_2_55_2&dbid=8&doi=10.1016/S2666-7568(20)30068-4&key=24379984&cf= Kaeberlein, M. (2013). mTOR inhibition: from aging to autism and beyond. ''Scientifica'', ''2013''.]</ref>

=== mTOR inhibition improves immune function in the elderly ===

In a phase 2 randomized clinical trial published in ''Science Translational Medicine'' in 2014, low-dose TORC1 inhibition with the rapalog everolimus showed improvement in immune function in the elderly. The clinical trial enrolled 218 adults aged ≥65 years, observing decreased incidence of all infections, as well as improved influenza vaccination responses and upregulation of antiviral immunity.<ref>Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., ... & Klickstein, L. B. (2014). mTOR inhibition improves immune function in the elderly. ''Science translational medicine'', ''6''(268), 268ra179-268ra179.</ref>

=== TORC1 inhibition enhances immune function and reduces infections in the elderly ===

A similar phase 2a trial clinical trial randomized 264 older adults to treatment with everolimus and placebo, and was published in ''Science Translational Medicine'' in 2018. The trial showed potential for reducing the effects of immune aging, with improvement in influenza vaccination response in the elderly.<ref name=":1">Mannick, J. B., Morris, M., Hockey, H. U. P., Roma, G., Beibel, M., Kulmatycki, K., ... & Klickstein, L. B. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. ''Science translational medicine'', ''10''(449).</ref>

Everolimus enhanced the influenza vaccine response by approximately 20% at relatively well tolerated doses. One mechanism was related to a reduction in the percentage of CD4 and CD8 T cells expressing the programmed death-1 receptor, which has increased expression with age and a major role in inhibiting T cell signaling.<ref name=":1" /> These findings suggest that, at an appopriate dose, mTOR inhibition may improve the age-related decline in immune function in the elderly.
[[File:Rtb101 Ph2 Ph3.jpg|thumb|461x461px|A) Number of patients with laboratory-confirmed RTIs of ''any severity'' caused by specific viruses, comparing RTB101 group (blue) versus placebo (grey) in the phase 2b, phase 3, and combined phase 2b/3 RCTs B) Number of patients with laboratory-confirmed RTIs with ''severe symptoms'' caused by specific viruses in the RTB101 group (blue) versus placebo (grey) in the phase 2b, phase 3, and combined phase 2b/3 trials. RTI = respiratory tract infection]]

=== Improving immune function in older adults for respiratory tract infections, including coronaviruses ===
Low-dose mTOR inhibition with dactolisib in a Phase 2b and phase 3 trial in the elderly showed reduced coronavirus (non [[COVID-19]]) incidence, as well as reductions in severe symptoms.<ref name=":12">Mannick, J. B., Teo, G., Bernardo, P., Quinn, D., Russell, K., Klickstein, L., ... & Shergill, S. (2021). Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. ''The Lancet Healthy Longevity'', ''2''(5), e250-e262.</ref> However, the data remains inconclusive as the study was powered statistically for a reduction in clinically symptomatic respiratory tract infections (RTIs), and not laboratory-confirmed RTIs.<ref name=":12" />

Following the success of two phase 2 clinical trials investigating mTOR inhibition for targeting the aging immune system, dactolisib is currently being pursued for the treatment of COVID-19 in a phase 2a placebo-controlled trial (ClinicalTrials.gov Identifier: NCT04584710, NCT04409327), exploring the potential for preventing severe disease in elderly adults with no symptoms, who have been exposed to [[COVID-19]].<ref name=":12" />

This trial is being run by the biopharmaceutical company resTORbio and has obtained funding from the National Institute on Aging (NIA/NIH). The studies with dactolisib for COVID-19 is one of several clinical trials in the aging biology field aiming to target aging to improve the aging immune system.<ref name=":12" />

== References ==
<references />
[[Category:Longevity]]
[[Category:Pillar Articles]]

Aging and longevity

2021-09-07T07:36:39Z

Schulzm: Added "Pillar Article" Category

[[File:Updated deaths and aging.png|alt=|thumb|618x618px|Incidence of all age-related diseases increases exponentially with increasing age]]
People have yearned for the fountain of youth all throughout history. However, until recently, there has yet to exist a concerted research effort for actualizing this at a societal level. In the modern era, humanity is supportive of research towards the cure of age-related diseases (e.g. Alzheimer’s, heart disease, and [[Aging and Cancer|most cancers]]) – a desire present at every level of human organisation that spans across individuals, communities, and society. This reflects a core human desire to be healthy. Yet, recognizing that humanity should strive towards a cure for aging is a sentiment that does not attract such widespread popularity.

Lack of societal support stems from two fundamental misconceptions – that ‘aging’ merely represents the natural chronological passage of time, and that aging is an entirely separate category from ''age-related disease.''<ref>Sierra, F. (2016). The emergence of geroscience as an interdisciplinary approach to the enhancement of health span and life span. ''Cold Spring Harbor perspectives in medicine'', ''6''(4), a025163.</ref> In contrast, the biology of aging (biogerontology) research field understands the mechanisms of aging as the root cause of society’s most prevalent, costly, and debilitating diseases.<ref name=":2">[https://www.nature.com/articles/s41586-019-1365-2 Campisi, J., Kapahi, P., Lithgow, G. J., Melov, S., Newman, J. C., & Verdin, E. (2019). From discoveries in ageing research to therapeutics for healthy ageing. ''Nature'', ''571''(7764), 183-192.]</ref><ref name=":14">[[Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020). The quest to slow ageing through drug discovery. Nature Reviews Drug Discovery, 19(8), 513-532.|Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020). The quest to slow ageing through drug discovery. ''Nature Reviews Drug Discovery'', ''19''(8), 513-532.]]</ref><ref name=":3">[[Longo, V. D., Antebi, A., Bartke, A., Barzilai, N., Brown‐Borg, H. M., Caruso, C., ... & Fontana, L. (2015). Interventions to slow aging in humans: are we ready?. Aging cell, 14(4), 497-510.|Longo, V. D., Antebi, A., Bartke, A., Barzilai, N., Brown‐Borg, H. M., Caruso, C., ... & Fontana, L. (2015). Interventions to slow aging in humans: are we ready?. ''Aging cell'', ''14''(4), 497-510.]]</ref>

In 2018, for the first time in human history, the number of people aged over 64 became greater than those aged under 5. This disparity is projected to only widen further with a rapidly aging population.<ref>Ritchie, H., & Roser, M. (2019). Age structure. ''Our World in Data''.</ref> The clear implications for a substantial increase in age-related disease burden has led to urgent calls from scientists for global society to support aging biology research to increase healthy life expectancy.<ref name=":3" /><ref>[[Rae, M. J., Butler, R. N., Campisi, J., De Grey, A. D., Finch, C. E., Gough, M., ... & Logan, B. J. (2010). The demographic and biomedical case for late-life interventions in aging. Science translational medicine, 2(40), 40cm21-40cm21.|Rae, M. J., Butler, R. N., Campisi, J., De Grey, A. D., Finch, C. E., Gough, M., ... & Logan, B. J. (2010). The demographic and biomedical case for late-life interventions in aging. ''Science translational medicine'', ''2''(40), 40cm21-40cm21.]]</ref>

== What is Aging? ==
Aging is an imprecise term with multiple definitions that depend on context. It may describe a time-dependent process in a physical, biological or sociological sense, and apply to the level of molecules, organisms, or inanimate objects.<ref>Hayflick, L. (2002). Anarchy in Gerontological Terminology. Handbook of the Biology of Aging, edited by Edward J. Masoro and Steven N. Austad. ''Gerontologist'', ''42''(3), 416-420.</ref><ref>Hayflick, L. (2021). The greatest risk factor for the leading cause of death is ignored. ''Biogerontology'', ''22''(1), 133-141.</ref> Even when narrowly considered in a biological context, an exact consensus definition is difficult among researchers for such a complex phenomenon.<ref name=":20">Cohen, A. A., Kennedy, B. K., Anglas, U., Bronikowski, A. M., Deelen, J., Dufour, F., ... & Fülöp, T. (2020). Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary framework. ''Mechanisms of ageing and development'', ''191'', 111316.</ref>

There is now a rapidly growing base of biogerontology researchers that study the biology of aging. This discipline of biomedical science is specifically interested in how the molecular mechanisms of aging are fundamental to the development of age-related diseases, and how these mechanisms unite seemingly unrelated diseases of aging.<ref>Franceschi, C., Garagnani, P., Morsiani, C., Conte, M., Santoro, A., Grignolio, A., ... & Salvioli, S. (2018). The continuum of aging and age-related diseases: common mechanisms but different rates. ''Frontiers in medicine'', ''5'', 61.</ref>

Medically speaking, aging may be thought of as the progressive physiological decline in the body’s resilience and ability to overcome stressors.<ref name=":9">[https://www.nature.com/articles/s43587-020-00009-z Thuault, S. (2021). Reflections on aging research from within the National Institute on Aging. ''Nature Aging'', ''1''(1), 14-18.]</ref><ref>[https://www.sciencedirect.com/science/article/pii/S1525861015002273?casa_token=0mXyA5DkGbEAAAAA:IQPQkZclcbJtVBP9n_FSw8f73B6h4ptjncaxATMkzTDU4Q_-I0-gUSoBgGhV2XodczzaItKCcA Fabbri E, Zoli M, Gonzalez-Freire M, Salive ME, Studenski SA, Ferrucci L. Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research. Journal of the American Medical Directors Association. 2015 Aug 1;16(8):640-7.]</ref> Aging-related decline in physical and mental capacity leads to permanent loss of function, independence, and dignity.<ref>de Grey, A.D. (2013). The desperate need for a biomedically useful definition of “aging”. ''Rejuvenation Research'',16:89–90.</ref><ref name=":12">[https://linkinghub.elsevier.com/retrieve/pii/S0092-8674(14)01366-X Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., ... & Sierra, F. (2014). Geroscience: linking aging to chronic disease. ''Cell'', ''159''(4), 709-713.]</ref> This occurs due to the accumulation of multiple age-related diseases (ARDs), leading to an extended period of suffering from mid to late life.<ref>[https://linkinghub.elsevier.com/retrieve/pii/S1525-8610(15)00227-3 Fabbri, E., Zoli, M., Gonzalez-Freire, M., Salive, M. E., Studenski, S. A., & Ferrucci, L. (2015). Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research. ''Journal of the American Medical Directors Association'', ''16''(8), 640-647.]</ref> Eventually, people die of a specific ARD, but many will suffer from multiple such diseases before death. Indeed, it is a common misconception that the elderly die of 'old age', although this term is useful when a specific cause of death is elusive.

Over the last few decades, biomedical scientists have identified several ''[[Hallmarks of Aging]]''<ref name=":13">[https://doi.org/10.1016/j.cell.2013.05.039 López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013 Jun 6;153(6):1194-217.]</ref> that represent fundamental biological mechanisms of aging. These hallmarks form a basis for how aging might be targeted to slow, stop, or even reverse multiple age-related diseases. There are various theories for what is or what causes biological aging<ref>[[Jin, K. (2010). Modern biological theories of aging. Aging and disease, 1(2), 72.|Jin, K. (2010). Modern biological theories of aging. ''Aging and disease'', ''1''(2), 72.]]</ref><ref name=":1" /> - though there remains no consensus - and some argue that aging is not a unitary phenomenon.<ref name=":1">[https://www.sciencedirect.com/science/article/pii/S0047637420301408#bib0210 Cohen, A. A., Legault, V., & Fülöp, T. (2020). What if there’s no such thing as “aging”?. ''Mechanisms of Ageing and Development'', ''192'', 111344.]</ref><ref>[https://www.bmj.com/content/315/7115/1030 Peto, R., & Doll, R. (1997). There is no such thing as aging: Old age is associated with disease, but does not cause it.]</ref> However, it is now widely accepted among biogerontology researchers that various aging processes, such as the ''[[Hallmarks of Aging]]'', may be considered for medical intervention. This change in thinking is reflected by the dramatic increase in biotech companies and human clinical trials targeting aging.<ref>[https://www.sciencedirect.com/science/article/pii/S0167779917301713 De Magalhães, J. P., Stevens, M., & Thornton, D. (2017). The business of anti-aging science. ''Trends in biotechnology'', ''35''(11), 1062-1073.]</ref>

The current approach to medicine is generally focused on increasing lifespan by attempting to cure single diseases. In contrast, therapies that target biological aging are hypothesized to uniquely have the ability to significantly increase ''healthy'' lifespan. This is because the latter approach addresses what appears to be the fundamental biological mechanisms that unite ostensibly unrelated age-related diseases.<ref name=":0" /> This distinction is supported by decades of experimental evidence in animals, where the biology of aging is manipulated. It may also be inferred theoretically: If the incidence of all age-related diseases increases in an exponential relationship from progressive systemic decline with age, then eliminating any single age-related disease would achieve little, as it would merely allow one to develop another age-related disease soon after.

==Animal Studies Reveal that Aging is Malleable==
Numerous experimental breakthroughs over the last few decades have shown clearly that, contrary to common knowledge, biological aging is medically treatable in animals. Slowing or even hastening of aging in animals can be achieved via manipulation of diet, environment, genetics, epigenetics, or with drugs, with experiments ranging from roundworms to mice and even non-human primates.<ref>de Cabo, R., & Mattson, M. P. (2019). Effects of intermittent fasting on health, aging, and disease. ''New England Journal of Medicine'', ''381''(26), 2541-2551.</ref><ref>Keil, G., Cummings, E., & de Magalhaes, J. P. (2015). Being cool: how body temperature influences ageing and longevity. ''Biogerontology'', ''16''(4), 383-397.</ref><ref>Moskalev, A., Aliper, A., Smit-McBride, Z., Buzdin, A., & Zhavoronkov, A. (2014). Genetics and epigenetics of aging and longevity. ''Cell Cycle'', ''13''(7), 1063-1077.</ref><ref>Brunet, A., & Berger, S. L. (2014). Epigenetics of aging and aging-related disease. ''Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences'', ''69''(Suppl_1), S17-S20.</ref><ref>[[Campisi, J., Kapahi, P., Lithgow, G. J., Melov, S., Newman, J. C., & Verdin, E. (2019). From discoveries in ageing research to therapeutics for healthy ageing. Nature, 571(7764), 183-192.|Campisi, J., Kapahi, P., Lithgow, G. J., Melov, S., Newman, J. C., & Verdin, E. (2019). From discoveries in ageing research to therapeutics for healthy ageing. ''Nature'', ''571''(7764), 183-192.]]</ref> Among the hundreds of aging laboratories across the world, aging is routinely manipulated by biogerontology researchers. This is a global endeavour attempting to understand what aging is, and to determine how this knowledge may be used to develop widely-accessible medicines for humanity.

=== Senolytics ===
An example of the striking differences in health that are possible with therapies that target aging biology can be seen in animal experiments of [[senolytics]], first conducted by researchers at the Mayo Clinic.[[File:Unity mice.png|alt=|center|thumb|664x664px|Senolytic drugs clear the senescent cells that accumulate with aging to treat multiple age-related diseases, leading to extension of healthspan and lifespan in normally aging mice ]]Senescent cells are known to accumulate with aging throughout the body, and drive multiple age-related diseases. Experiments done in mice show that removing these cells with drugs that clear these cells - senolytics - restores health. This is because senolytics can slow and even partially reverse aging, which leads to increased healthspan from addressing multiple age-related diseases. As a side effect of the old mice being rejuvenated, studies have observed increases in median lifespan of up to 35%.

=== Epigenetic Reprogramming ===
Recent experimental breakthroughs have provided early evidence that aspects of aging can be reversed,<ref name=":15">[[Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., ... & Belmonte, J. C. I. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell, 167(7), 1719-1733.|Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., ... & Belmonte, J. C. I. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. ''Cell'', ''167''(7), 1719-1733.]]</ref><ref name=":16">Lu Y, Brommer B, Tian X, Krishnan A, Meer M, Wang C, Vera DL, Zeng Q, Yu D, Bonkowski MS, Yang JH. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020 Dec;588(7836):124-9.

https://www.nature.com/articles/s41586-020-2975-4</ref> further challenging old assumptions about aging simply being a result of chronological time.[[File:ONH regeneration epigenetic reprogramming.png|center|frame|In vivo epigenetic reprogramming can lead to regeneration of the optic nerve in injury and glaucoma mouse models, and lead to visual recovery in natural aging]]

[[Epigenetic reprogramming]] is based on work that earnt [https://embryology.med.unsw.edu.au/embryology/index.php/Embryology_History_-_Shinya_Yamanaka Shinya Yamanaka] the 2012 Nobel Prize in Medicine. Yamanaka showed that it was possible to reprogram adult body cells back into biologically immortal pluripotent stem cells that are capable of turning into any cell of the body.<ref name=":17">Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. ''cell'', ''126''(4), 663-676.</ref><ref name=":18">Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. ''cell'', ''131''(5), 861-872.</ref> This was achieved by activating only four transcription factors - the [[Yamanaka factors|''Yamanaka factors'']] - OCT4, SOX2, KLF4, and MYC (or OSKM).<ref name=":17" /><ref name=":18" />

Scientists in the aging biology field have since expanded upon this work to show that a partial version of this epigenetic reprogramming technique may reverse multiple aspects of aging.<ref name=":15" /> Work from Juan Carlos Izpisua Belmonte's lab showed that it is possible to modify the reprogramming technique and achieve 'youthful' rejuvenation, without resetting a cell with a defined identity into a stem cell. This research was published in 2016, when the Belmonte lab first showed that temporarily expressing the Yamanaka factors in a controlled manner could rejuvenate multiple aged organs and extend healthy lifespan in mice with accelerated aging.<ref name=":152">[[Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., ... & Belmonte, J. C. I. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell, 167(7), 1719-1733.|Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., ... & Belmonte, J. C. I. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. ''Cell'', ''167''(7), 1719-1733.]]</ref><ref>Rando, T. A., & Chang, H. Y. (2012). Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock. ''Cell'', ''148''(1-2), 46-57.</ref>

Using epigenetic reprogramming in ''naturally aged'' mice has more recently been shown to improve memory/cognition, promote muscle regeneration, and restore vision.<ref>Wang, C., Ros, R. R., Martinez-Redondo, P., Ma, Z., Shi, L., Xue, Y., ... & Belmonte, J. C. I. (2021). In vivo partial reprogramming of myofibers promotes muscle regeneration by remodeling the stem cell niche. ''Nature Communications'', ''12''(1), 1-15.</ref><ref>Rodríguez-Matellán, A., Alcazar, N., Hernández, F., Serrano, M., & Ávila, J. (2020). In Vivo Reprogramming Ameliorates Aging Features in Dentate Gyrus Cells and Improves Memory in Mice. ''Stem cell reports'', ''15''(5), 1056-1066.</ref><ref name=":16" /> It has been envisioned by some scientists as a therapy that could be used periodically, perhaps every few decades, to continually reverse aging in humans. However, evidence for a truly comprehensive reversal of aging via partial reprogramming in mice, let alone in humans, is lacking.
=== Dietary Restriction Mimetics and mTOR Inhibitors ===
'''...Work in Progress...'''

Dietary restriction (DR) has consistently been shown to extend healthy lifespan in animals ranging from worms, to mice, and to primates.<ref>Fontana, L., Partridge, L., & Longo, V. D. (2010). Extending healthy life span—from yeast to humans. ''science'', ''328''(5976), 321-326.</ref> In animals, DR leads to substantial benefits to healthy lifespan; however, the proportional lifespan benefit generally declines with increasing species size/complexity.

Dysregulation of nutrient-sensing is regarded as a hallmark of aging, playing a key role in the aging process. Relevant metabolic pathways such as IGF-1, mTOR and AMPK, are influenced by DR in extending healthy lifespan in animals.

Given the difficulty of implementing DR as an intervention in humans, due to difficulty with adherence, drugs that mimic the effects of dietary restriction are being developed. Similarly, there is a significant and ongoing research effort that aims to determine whether intermittent fasting or time restricted eating may capture some of the potential health benefits of DR, while being easier for patients to adhere to. There is generally a lack of evidence in human clinical trials in justifying the use of these lifestyle interventions for slowing aging.

==== Metformin ====
'''...Work in Progress...'''

Metformin extends healthy lifespan in worms, mice and rats.<ref>Song, J., Jiang, G., Zhang, J., Guo, J., Li, Z., Hao, K., ... & Dai, F. (2019). Metformin prolongs lifespan through remodeling the energy distribution strategy in silkworm, Bombyx mori. ''Aging (Albany NY)'', ''11''(1), 240.</ref><ref>Novelle, M. G., Ali, A., Diéguez, C., Bernier, M., & de Cabo, R. (2016). Metformin: a hopeful promise in aging research. ''Cold Spring Harbor perspectives in medicine'', ''6''(3), a025932.</ref>

The Targeting Aging with Metformin (TAME) trial is investigating a drug with over 6 decades of human use, currently the first-line therapy for the age-related disease type 2 diabetes (T2DM). Metformin is one of the cheapest and most commonly prescribed medications in the world, and has been linked to lower incidence of cancer, heart disease, dementia, and mortality in patients with T2DM.<ref name=":19">Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016). Metformin as a tool to target aging. ''Cell metabolism'', ''23''(6), 1060-1065.</ref> One study suggested that despite the life-shortening effects of diabetes, T2DM patients on metformin, but not other medications, outlive those who are not diabetic.<ref>Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy, K. (2017). Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. ''Ageing Research Reviews'', ''40'', 31-44.</ref> As metformin has also shown healthspan and lifespan extension effects in naturally aging worms and mice, some researchers believe that it may slow aging.<ref name=":19" />

The Targeting Aging with Metformin (TAME) trial is a US, nation-wide, six-year clinical trial of over 3000 individuals aged 65 to 79.<ref name=":19" /> The goal is to investigate whether metformin will slow aging in humans, as it has been shown to extend healthspan in some animals. This will be measured by whether metformin can prevent the onset of multiple age-related diseases such as heart disease, cancer, and dementia.

A key defining aspect in qualifying whether a drug targets aging (a gerotherapeutic or geroprotective drug), is the ability to delay or reverse the onset of multiple age-related diseases in tandem, to increase healthy lifespan.<ref>[https://www.nature.com/articles/s41573-020-0067-7 Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020). The quest to slow ageing through drug discovery. ''Nature Reviews Drug Discovery'', ''19''(8), 513-532.]</ref> The aging field continues to debate whether a geroprotector necessarily needs to increase healthspan, or both healthspan and lifespan.<ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869575/ Blagosklonny, M. V. (2021). The goal of geroscience is life extension. ''Oncotarget'', ''12''(3), 131.]</ref> Yet, what is clear now is that aging has a biology of critical relevance to the diseases associated with aging. This, along with multiple other lines of evidence across [[wikipedia:Biology|biology]] and [[wikipedia:Epidemiology|epidemiology]], suggest that the accumulation of multiple age-related diseases with time are not simply disparate processes or chance events that bear no relationship with one another. These diseases of older age, may in fact, be driven by an underlying aging process.<ref name=":2" /><ref name=":14" /><ref name=":3" />

=== The Link Between Lifespan and Aging ===
*Lifespan can range from mere days in mayflies, to several years in dogs, and up to centuries in bowhead whales<ref>[[Ogden, L. E. (2019). Travels through Time. BioScience, 69(11), 860-866.|Ogden, L. E. (2019). Travels through Time. ''BioScience'', ''69''(11), 860-866.]]</ref>

*Studying aging in animals has led to an understanding that aging is biological and not a mere consequence of time<ref name=":2" />

*Research in a range of different animals show that there exists extreme variance in rates of aging, within and across species<ref name=":2" />
*
*Humans have been observed to exhibit substantial variance in rates of aging, both in terms of accelerated and decelerated aging<ref>[[Margolick, J. B., & Ferrucci, L. (2015). Accelerating aging research: how can we measure the rate of biologic aging?. Experimental gerontology, 64, 78-80.|Margolick, J. B., & Ferrucci, L. (2015). Accelerating aging research: how can we measure the rate of biologic aging?. ''Experimental gerontology'', ''64'', 78-80.]]</ref>
*Centenarians (those living to age 100 or more) live longer due to a delayed onset of all age-related diseases, influenced primarily by genetics<ref>Govindaraju, D., Atzmon, G., & Barzilai, N. (2015). Genetics, lifestyle and longevity: lessons from centenarians. ''Applied & translational genomics'', ''4'', 23-32.</ref>
*Not only do centenarians live longer, but the period of suffering in late life from age-related diseases is also far shorter than non-centenarians - known as the compression of morbidity<ref>Andersen, S. L., Sebastiani, P., Dworkis, D. A., Feldman, L., & Perls, T. T. (2012). Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span. ''Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences'', ''67''(4), 395-405.</ref>

== Aging and Age-related Disease==
[[File:Aging as a risk factor.png|alt=Aging as a risk factor for common diseases|thumb|406x406px|Aging as a risk factor for common diseases]]
The totality of age-related diseases is prohibitively long to list in text, but includes Alzheimer’s, cardiovascular disease, most cancers, stroke, osteoarthritis, macular degeneration, and [[COVID-19]].[[File:Age is the -1 risk factor for COVID-19 mortality.jpg|alt=Age is the #1 risk factor for COVID-19 mortality - based on US CDC statistics|left|thumb|572x572px|* Fold risk of COVID-19 mortality versus reference group aged 5-17 [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html (US CDC statistics)]]]

Age-related diseases can be identified by a characteristic exponential increase in incidence with age, following the [[wikipedia:Gompertz–Makeham_law_of_mortality|Gompertz-Makeham law of mortality]]. This law essentially describes how all-cause mortality rate doubles every 8 years, which is a relationship common to age-related diseases alone.

==== COVID-19 defined as a disease of aging ====
As detailed in the paper "[https://onlinelibrary.wiley.com/doi/full/10.1111/acel.13230 COVID‐19 is an emergent disease of aging",]<ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576244/ Santesmasses, D., Castro, J. P., Zenin, A. A., Shindyapina, A. V., Gerashchenko, M. V., Zhang, B., ... & Gladyshev, V. N. (2020). COVID‐19 is an emergent disease of aging. ''Aging cell'', ''19''(10), e13230.]</ref> COVID-19 meets several criteria for definition as an age-related disease:<ref>[[Promislow, D. E. (2020). A geroscience perspective on COVID-19 mortality. The Journals of Gerontology: Series A, 75(9), e30-e33.|Promislow, D. E. (2020). A geroscience perspective on COVID-19 mortality. ''The Journals of Gerontology: Series A'', ''75''(9), e30-e33.]]</ref><ref>Alberts, S. C., Archie, E. A., Gesquiere, L. R., Altmann, J., Vaupel, J. W., & Christensen, K. (2014). The male-female health-survival paradox: a comparative perspective on sex differences in aging and mortality. In ''Sociality, hierarchy, health: comparative biodemography: a collection of papers''. National Academies Press (US).</ref><ref name=":10">[[Sierra, F. (2020). Geroscience and the Coronavirus Pandemic: The Whack‐a‐Mole Approach is not Enough. Journal of the American Geriatrics Society, 68(5), 951.|Sierra, F. (2020). Geroscience and the Coronavirus Pandemic: The Whack‐a‐Mole Approach is not Enough. ''Journal of the American Geriatrics Society'', ''68''(5), 951.]]</ref><ref name=":11">[[Barzilai, N., Appleby, J. C., Austad, S. N., Cuervo, A. M., Kaeberlein, M., Gonzalez-Billault, C., ... & Sierra, F. (2020). Geroscience in the Age of COVID-19. Aging and disease, 11(4), 725.|Barzilai, N., Appleby, J. C., Austad, S. N., Cuervo, A. M., Kaeberlein, M., Gonzalez-Billault, C., ... & Sierra, F. (2020). Geroscience in the Age of COVID-19. ''Aging and disease'', ''11''(4), 725.]]</ref><ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288963/</ref>

'''1) The doubling time for COVID-19 mortality approaches that of the doubling time of 8 years for all-cause mortality (characteristic exponential increase shared among major age-related chronic diseases);'''

'''2) Greater mortality rate in men, consistent with known sex differences in rates of aging;'''

'''3) Greater mortality rate for those with comorbidities (age-related diseases), consistent with accelerated biological aging; and,'''

'''4) Age dwarfs all other putative [[wikipedia:Risk_factor|risk factors]] for mortality by several orders of magnitude, exhibiting several thousand fold increase in risk across the lifespan'''

Risk factors are used medicine to assess individual and population risks for certain diseases, in order to guide diagnosis and clinical management. An example of a risk factor is smoking status, which increases the risk of lung cancer by approximately 7 fold.<ref>[[O’Keeffe, L. M., Taylor, G., Huxley, R. R., Mitchell, P., Woodward, M., & Peters, S. A. (2018). Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ open, 8(10), e021611.|O’Keeffe, L. M., Taylor, G., Huxley, R. R., Mitchell, P., Woodward, M., & Peters, S. A. (2018). Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. ''BMJ open'', ''8''(10), e021611.]]</ref>
[[File:CDC stat table.jpg|center|thumb|883x883px]]
As compared to a reference group ''aged'' ''5-14'', the risk of death for COVID-19 is 8700 fold greater in those aged ''over'' ''85'', as per the [[US Center for Disease Control (CDC)]]. Common ''independent'' risk factors identified in scientific discourse are comparatively inconsequential; for example, a history of chronic lung disease confers only a 2x greater risk of COVID-19 mortality<ref>[[Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., ... & Goldacre, B. (2020). Factors associated with COVID-19-related death using OpenSAFELY. Nature, 584(7821), 430-436.|Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., ... & Goldacre, B. (2020). Factors associated with COVID-19-related death using OpenSAFELY. ''Nature'', ''584''(7821), 430-436.]]</ref>, despite reputation as a 'respiratory disease'. The epidemiological data also makes clear that 'healthy' older adults with one or no comorbidities are still at substantially greater risk of severe disease than in the young. More importantly, those with accelerated biological aging with multiple comorbidities of age are at even greater risk.<ref>Polidori, M. C., Sies, H., Ferrucci, L., & Benzing, T. (2021). COVID-19 mortality as a fingerprint of biological age. ''Ageing Research Reviews'', 101308.</ref> This not only highlights how age is the ultimate risk factor for mortality, but also emphasizes the importance of biological age.

COVID-19 results in systemic involvement with neurologic, kidney, liver, heart, endocrine, and gut complications.<ref>Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., ... & Landry, D. W. (2020). Extrapulmonary manifestations of COVID-19. ''Nature medicine'', ''26''(7), 1017-1032.</ref> Therefore, geroprotectors that provide improvement to multiple aged and vulnerable organ systems would be desirable.<ref name=":10" /><ref name=":11" /> What is important about SARS-CoV-2 is that not only does the virus have many consequences across the entire body, but it also uniquely affects those with higher biological age disproportionately. Therefore, an emphasis on the specific organ system of respiration (or the virus itself), instead of on the aging host, may be regarded by biogerontology researchers as a short-sighted therapeutic strategy in the long-term.<ref name=":10" /> This is especially important for preventing future pandemics, as well as to address multiple other age-related diseases of an aging population that is burdening global healthcare systems.

==== Traditional Risk Factors and Heart Disease ====
[[File:CVD 1st Risk Factor .png|alt=Aging dwarfs all other risk factors for heart disease|center|thumb|933x933px|Aging dwarfs all other risk factors for heart disease - suggesting a central role - yet remains an unexplored target for drug development]]
Hypertension, smoking, and cholesterol are examples of well-known heart disease risk factors that have been used by scientists/physicians to guide the research and development of effective therapies. This strategy originated from the Framingham Heart Study – an initiative spanning decades that observed thousands of people to understand what genetic and environmental factors influence heart disease.<ref>Mahmooda, S. S., Levy, D., Vasan, R. S., & Wang, T. J. (2014). The Framingham Heart Study and the epidemiology of cardiovascular diseases: A historical perspective. ''Lancet'', ''383''(9921), 999-1008.</ref>The resulting risk factor paradigm has since been adopted across all domains of disease in biomedical research, and is core to the practice of clinical medicine
Coordinated research efforts have helped identify genetic and environmental factors important to heart disease risk. As scientific research has identified whether these risk factors are modifiable, been critical to developing effective therapeutics. For example, identified risk factors, such as high blood pressure and cholesterol, have led to anti-hypertensive and cholesterol medications now being among the most commonly prescribed drugs across the world for the prevention of cardiovascular diseases.<ref>Hajar, R. (2016). Framingham contribution to cardiovascular disease. ''Heart views: the official journal of the Gulf Heart Association'', ''17''(2), 78.</ref> Aging is widely accepted among physicians and biomedical scientists as the greatest risk factor for almost all the major diseases in developed countries.<ref>Kaeberlein, M., Rabinovitch, P. S., & Martin, G. M. (2015). Healthy aging: the ultimate preventative medicine. ''Science'', ''350''(6265), 1191-1193.</ref> However, aging is also traditionally viewed as a risk factor that cannot be modified. Unmodifiable risk factors are regarded as unimportant for the development of interventions. The prevailing assumption that aging is an unmodifiable risk factor is now being challenged by biogerontology researchers.

The overall exponential relationship between increasing age and mortality is consistent for various age-related diseases, regardless of whether a disease is acute or chronic. This reflects the continually increasing vulnerability and decreasing resilience of the human body with age.

== Why is Population Aging a Problem? ==
Often described as the ‘climate change of healthcare’, an aging population comes with challenges due to declines in productivity, loss of independence, and increasingly unsustainable healthcare costs.
In 2018, human civilisation reached an unprecedented point in history. People aged over 65 now outnumber those aged under 5, and this disparity is projected only to widen across the world as the global population ages and fertility rates continue to decline.<ref>https://ourworldindata.org/age-structure?source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Amain_content%7Cbutton%3Abody_link</ref><ref>[https://doi.org/10.1038/nature06516 Lutz, W., Sanderson, W., & Scherbov, S. (2008). The coming acceleration of global population ageing. ''Nature'', ''451''(7179), 716-719.]</ref>

The aging population is a major contributor to increasing [https://ourworldindata.org/financing-healthcare global healthcare costs, which have risen steadily since the 1900s] and are projected only to grow further.<ref name=":8">[[Jin, K., Simpkins, J. W., Ji, X., Leis, M., & Stambler, I. (2015). The critical need to promote research of aging and aging-related diseases to improve health and longevity of the elderly population. Aging and disease, 6(1), 1.|Jin, K., Simpkins, J. W., Ji, X., Leis, M., & Stambler, I. (2015). The critical need to promote research of aging and aging-related diseases to improve health and longevity of the elderly population. ''Aging and disease'', ''6''(1), 1.]]</ref> These costs are increasingly unsustainable, and demographic change is also expected to place a greater burden on society due to increased dependency and reduced productivity.

The COVID-19 pandemic is an example of what a single age-related disease (albeit one that is more acute than chronic) can do to society. [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html US CDC statistics] show that 97.11% of mortality occurs in those aged over 45, and the exponential increase in mortality risk with age is essentially identical to all other leading causes of death and suffering, such as for cardiovascular diseases and cancer. The pandemic has highlighted the vulnerability of our aging population, and foreshadows how global societies are unprepared for the impending healthcare crisis of an aging world - the climate change of healthcare.

Aging is not just a problem for the ‘elderly’, as various aspects of aging begin well before middle-age. Many people suffer from accelerated aging and develop multiple age-related diseases prematurely, such as with depression, stress, poverty, smoking, HIV/AIDs, diabetes, Down Syndrome, accelerated aging syndromes (e.g. progerias) and in childhood cancer survivors.<ref>[https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2776612 Wertz, J., Caspi, A., Ambler, A., Broadbent, J., Hancox, R. J., Harrington, H., ... & Moffitt, T. E. (2021). Association of History of Psychopathology With Accelerated Aging at Midlife. JAMA psychiatry.]</ref><ref>[[Bersani, F. S., Mellon, S. H., Reus, V. I., & Wolkowitz, O. M. (2019). Accelerated aging in serious mental disorders. Current opinion in psychiatry, 32(5), 381.]] </ref><ref>[[Yegorov, Y. E., Poznyak, A. V., Nikiforov, N. G., Sobenin, I. A., & Orekhov, A. N. (2020). The link between chronic stress and accelerated aging. Biomedicines, 8(7), 198.]]</ref><ref>[[Crimmins, E. M., Kim, J. K., & Seeman, T. E. (2009). Poverty and biological risk: the earlier “aging” of the poor. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 64(2), 286-292.|Crimmins, E. M., Kim, J. K., & Seeman, T. E. (2009). Poverty and biological risk: the earlier “aging” of the poor. ''Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences'', ''64''(2), 286-292.]]</ref><ref>[./Https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-019-0777-z Wu, X., Huang, Q., Javed, R., Zhong, J., Gao, H., & Liang, H. (2019). Effect of tobacco smoking on the epigenetic age of human respiratory organs. Clinical epigenetics, 11(1), 1-9.]</ref><ref>Aung, H. L., Aghvinian, M., Gouse, H., Robbins, R. N., Brew, B. J., Mao, L., & Cysique, L. A. (2020). Is There Any Evidence of Premature, Accentuated and Accelerated Aging Effects on Neurocognition in People Living with HIV? A Systematic Review. AIDS and Behavior, 1-44.</ref><ref>[https://www.sciencedirect.com/science/article/pii/S1550413119302463 Aguayo-Mazzucato, C., Andle, J., Lee Jr, T. B., Midha, A., Talemal, L., Chipashvili, V., ... & Bonner-Weir, S. (2019). Acceleration of β cell aging determines diabetes and senolysis improves disease outcomes. Cell metabolism, 30(1), 129-142.] </ref><ref>[[Gensous, N., Bacalini, M. G., Franceschi, C., & Garagnani, P. (2020, July). Down syndrome, accelerated aging and immunosenescence. In Seminars in Immunopathology (pp. 1-11). Springer Berlin Heidelberg.]] </ref><ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559172/ Yamaga, M., Takemoto, M., Shoji, M., Sakamoto, K., Yamamoto, M., Ishikawa, T., ... & Yokote, K. (2017). Werner syndrome: a model for sarcopenia due to accelerated aging. Aging (Albany NY), 9(7), 1738.]</ref><ref name=":4">[https://academic.oup.com/jnci/article/113/2/112/5827003?login=true Guida, J. L., Agurs-Collins, T., Ahles, T. A., Campisi, J., Dale, W., Demark-Wahnefried, W., ... & Ness, K. K. (2020). Strategies to Prevent or Remediate Cancer and Treatment-Related Aging. ''JNCI: Journal of the National Cancer Institute'']</ref><ref>Kohanski, R. A., Deeks, S. G., Gravekamp, C., Halter, J. B., High, K., Hurria, A., ... & Sierra, F. (2016). Reverse geroscience: how does exposure to early diseases accelerate the age‐related decline in health?.</ref>

As a result of the potential for rejuvenation of multiple tissues and organs which has been seen in aging biology research, the applications of such research to human health are not merely limited to age-related diseases. In addition to the above-mentioned examples of accelerated aging, there are also significant implications for orphan or rare diseases.

== Economic Implications of Targeting Aging ==
'''...Work in Progress...'''

In 2019, the Bank of America projected the longevity industry to reach $600 billion by 2025. This is almost a six-fold increase over 6 years, reflecting how rapidly aging biology research is gaining traction.

[https://www.calicolabs.com/ Calico Labs], a subsidiary of Google, is a biotech company that aims to target aging to address age-related diseases.

The company launched a partnership with the pharmaceutical giant AbbVie, starting from 2014. This collaboration has since developed into a $2.5 billion venture in the pursuit of improving “health, wellbeing and longevity.” Calico, which stands for “California Life Company”,

A recent paper published by Professors at Harvard Medical School, Oxford University, and London Business School, estimated that a drug that slows aging by merely one year could add $US 38 trillion to the economy. This is justified by estimating how slowed aging can result in both improved health and longevity. The resultant increases in independence and productivity is subject to a virtuous cycle of further gains. This analysis highlights the profound difference between targeting single diseases, versus targeting aging.

==== '''Healthspan versus lifespan''' ====
'''The concept of healthspan describes the period of life spent free from disease'''

In the 21st Century, population healthspan contrasts significantly with lifespan. Although the latter has steadily increased over the last two centuries, the evidence strongly suggests that healthspan has not kept up with lifespan.<ref name=":0">[https://academic.oup.com/gerontologist/article/55/6/901/2605490?login=true Crimmins, E. M. (2015). Lifespan and healthspan: past, present, and promise. ''The Gerontologist'', ''55''(6), 901-911.]</ref>

Advances in various public health measures, substantial reductions in childhood mortality, and effective treatments for several leading causes of death such as cardiovascular diseases have led to increased human life expectancy.<ref name=":8" /><ref name=":0" /> However, many human populations now spend a greater proportion of life in ill health.<ref name=":8" /><ref name=":0" /><ref>[[Crimmins, E. M. (2011). Beltrán-‐Sánchez, H.(2010). Mortality and morbidity trends: Is there compression of morbidity. Journal of Gerontology: Social Sciences, 66B, 1.|Crimmins, E. M. (2011). Beltrán-‐Sánchez, H.(2010). Mortality and morbidity trends: Is there compression of morbidity. ''Journal of Gerontology: Social Sciences, 66B'', ''1''.]]</ref> Reduced mortality from specific diseases may allow humans to survive into older age, but the quantity of life gained is minimal due to diminishing returns from competing risks of mortality.<ref name=":5">Keyfitz, N. (1977). What difference would it make if cancer were eradicated? An examination of the Taeuber paradox. ''Demography'', ''14''(4), 411-418.</ref><ref name=":6">Mitra, S. (1978). A short note on the Taeuber paradox. ''Demography'', ''15''(4), 621-623.</ref> More importantly, this is permissive for increased periods of suffering from typically non-fatal conditions such as osteoarthritis or cognitive decline.<ref name=":0" />

'''Single Disease Medicine and the Taeuber Paradox'''

A major problem in the current healthcare strategy for an aging population lies in the traditional medical paradigm of single-disease medicine.<ref name=":7">[https://www.sciencedirect.com/science/article/pii/S2468501117300081 Kaeberlein, M. (2017). Translational geroscience: A new paradigm for 21st century medicine. ''Translational medicine of aging'', ''1'', 1-4.]</ref>

The infectious disease model of medicine, which originates from [[wikipedia:Germ_theory_of_disease|germ theory]], accounts for historic human public health achievements of the 20th Century. These include substanial reductions in mortality from communicable diseases, such as smallpox, measles, and HIV/AIDS.<ref>Armstrong, G. L., Conn, L. A., & Pinner, R. W. (1999). Trends in infectious disease mortality in the United States during the 20th century. ''Jama'', ''281''(1), 61-66.</ref><ref>Fauci, A. S. (2001). Infectious diseases: considerations for the 21st century. ''Clinical Infectious Diseases'', ''32''(5), 675-685.</ref> This model may also be referred to as single-disease medicine, where diagnoses are made based on disease classifications. These classifications are characterised by sets of symptoms and signs, which are then treated with intervention(s) targeting the given disease.

The current approach to medicine is often described by proponents of preventive medicine as 'sick care' rather than healthcare. The overall approach being taken is to wait until people get sick with various chronic diseases, and then attempt to treat them. In healthcare, there is little emphasis on keeping aging people 'healthy', at least as compared to what is commonly regarded as youthful health. From the perspective of geroscience, the physiological changes with aging that precede disease should be considered within the domain of medicine.

While originally used for acute diseases such as the Flu, this paradigm has since permeated into chronic diseases that persist in the long-term...

We know that the prognosis of age-related disease means that no one escapes from the long journey of decrepitude, even if we contract different age-related diseases at different chronological ages.

Additionally, it can be inferred from the current approach to medicine of the prevailing belief that medical outcomes are attained with an approach that subcategorises into organ or physiologic systems. This is reflected in increasing subspecialisation. For example, for type 2 diabetes, patients typically begin with a general practitioner; further disease progression may then involve physicians specialising in endocrinology, or even further with diabetology. At the level of single diseases, specialisation makes sense...But at the level of population health, in the context of aging, this fails to recognise the complexities of multimorbidity, the age-related development of multiple chronic diseases. Geriatricians... ?

This paradigm may theoretically be flawed. Even if a cure for a specific age-related disease is possible, the exponential increase in risk of death from other ARDs continues unabated.'''<ref name=":7" />'''This flaw can be further understood via the Taeuber Paradox:

Completely curing heart disease or cancer, which are among the leading causes of deaths globally, would each add only ~2.5 years to life expectancy.''<ref name=":5" />''<ref name=":6" /> Eliminating Alzheimer's disease as a cause of death would add only 2 months to life expectancy.<ref>Arias, E., Heron, M. P., & Tejada-Vera, B. (2013). United States life tables eliminating certain causes of death, 1999-2001.</ref><ref>Hayflick, L. (2021). The greatest risk factor for the leading cause of death is ignored. ''Biogerontology'', ''22''(1), 133-141.</ref>

Additionally, such cures would have minimal or even detrimental effects on healthspan - for example, it is well known that the stress induced by cancer therapies accelerates aging;<ref>[https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djab064/6207975?login=true Prasanna, P. G., Citrin, D. E., Hildesheim, J., Ahmed, M. M., Venkatachalam, S., Riscuta, G., ... & Coleman, C. N. (2021). Therapy-Induced Senescence: Opportunities to Improve Anti-Cancer Therapy. ''JNCI: Journal of the National Cancer Institute''.]</ref> childhood cancer survivors develop heart disease, Alzheimer’s, frailty and other age-related diseases. years or even decades earlier.<ref name=":4" />

Aiming to cure diseases one at a time, instead of addressing aging itself, results in diminishing returns due to competing risks of morbidity and mortality. Delaying heart disease with cholesterol medications does not address incipient frailty, treating kidney disease to live longer may result in eventual Alzheimer’s...

== The Geroscience Hypothesis ==
'''...Work in Progress...'''

‘Geroscience’ represents the maturation of the research field of aging biology, transitioning from a research field mainly concerned with animal aging, to one that is now concerned with human aging. The inextricable link between aging and age-related disease has been formally identified by the aging research field as the ''geroscience hypothesis''.<ref name=":12" /> This hypothesis posits that there are foundational biological mechanisms or 'pillars' of aging shared between apparently unrelated age-related diseases, which may be targeted for intervention to address multiple diseases in tandem.<ref name=":12" /><ref name=":13" />

In other words, if aging is the primary cause of the various diseases that accumulate with age, then targeting this biology will lead to the amelioration of multiple diseases. This affords far greater potential to extend healthy lifespan than single-disease approaches. The implications of the geroscience hypothesis is therefore - within the context of an aging population - of revolutionary potential for human society.
'''"There has been a shift in how we have considered aging, from something that we needed to account for and eliminate by statistical adjustment to a causal factor in disease...understanding aging provides the strongest chance to prevent chronic diseases and expand healthspan"<ref name=":9" />'''
''Luigi Ferrucci, MD/PhD, Scientific Director of the National Institute on Aging (NIA, of the US National Institutes of Health)''

One of the key aspects that distinguishes a geroprotective therapy from medicine developed in the past is that the former would address what appears to be the primary cause of age-related diseases. The term 'cause' is not typically used rigorously in the biomedical sciences. After all, it implies that a given cause is the (major) reason for producing a disease. Given that the acceleration and deceleration of biological aging influences the development of various diseases that share age as the major risk factor but are otherwise unrelated, there is a case to be made that aging is a primary cause of age-related disease.

It is possible that in humans, aging drives multiple age-related diseases simultaneously, even if such diseases do not arise at the same period of an individual's life, and do not follow a specific order for a given individual.

As the salient risk factor, aging can be understood as the principal driver of age-related disease - for which there are further interactions with individual genetic and environmental factors that predispose to a specific age-related pathology. Therefore, aging ARDs can be understood to be 'symptoms' of aging

E.g. A female with 2 copies of the APOE4 gene might have a 12x greater risk of Alzheimer’s and begin developing early AD symptoms at age 65.<ref name=":23">Ungar, L., Altmann, A., & Greicius, M. D. (2014). Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction. ''Brain imaging and behavior'', ''8''(2), 262-273.</ref> If she had instead been homozygous for APOE4 with only 1 copy of the disease-predisposing gene, this risk would only be 4x;<ref name=":23" /> she may instead die of a heart attack at age 73.

== Is Aging a Disease? ==
'''...Work in Progress...'''

Aging is often regarded as a natural and universal fact of life. In medicine, physicians are tasked with the need to classify whether the patient in front of them has a disease or not. This is a necessary part of the current approach of disease-centric medicine, because a binary decision must be made to determine whether treatment is necessary.

However, some level of collective confusion in meaning is prevalent among the public, physcians, and scientists. This is predominantly due to the imprecision of the word 'aging'.

Even among aging biology researchers there is a lack of consensus as to what aging refers to.<ref name=":20" /> This remains a significant problem among scientists, and is regarded by some as a barrier to advancing the field into mainstream public consciousness. Yet, there is now consensus among geroscience researchers (the subfield of aging biology concerned with medicine) that aging mechanisms can be targeted to increase human healthspan.

Whether aging is a disease or not is regarded by some researchers as a mere semantic problem. This is as it does not directly interfere with the goals of geroscience. Researchers in the field believe that targeting aging biology will be integral to addressing the ongoing and growing public health crisis of an aging population.

There are various historical examples of prevalent diseases that were once accepted as normal, but have since become thought of as diseases. For example, before effective treatments for tuberculosis were created, the dominant idea within society was that it is natural and to be accepted. Some may argue that if an ailment affects everyone, it should not be classified as a disease, which is a common talking point against calling aging a disease. Atherosclerosis, the hardening of arteries, is near ubiquitous with aging, yet has disease status.<ref name=":22">Head, T., Daunert, S., & Goldschmidt-Clermont, P. J. (2017). The aging risk and atherosclerosis: a fresh look at arterial homeostasis. ''Frontiers in genetics'', ''8'', 216.</ref> Despite prevalence approaching 100% with age, blood pressure and cholesterol medications are widely prescribed to prevent atherosclerosis.<ref name=":22" /> In a paper published by the inventor of statins, Akira Endo comments: "Serious research on the role of cholesterol in human atherosclerosis did not really get underway until the 1940s, due to a prevailing view that the disease was a simple consequence of aging and could not be prevented." A more recent example is sarcopenia, a term referring to the age-related, progressive loss of muscle function. In 2016, sarcopenia was added to the World Health Organization's ICD-10 list of diseases.<ref name=":21">Anker, S. D., Morley, J. E., & von Haehling, S. (2016). Welcome to the ICD‐10 code for sarcopenia.</ref>

Disease definitions in medicine are continually changing, and often depending on whether we have treatments for a given disease or not. This has implications for regulation, such as in considering the scope of the Federal Drug Administration (FDA) in the US. Additionally, classification as a disease spurs further research into developing diagnostics, and also for pharmaceutical companies to develop treatments.<ref name=":21" />

There are growing numbers of aging researchers who are calling on government organizations to classify aging as a disease at a regulatory level, at least in the biological sense of the word as it relates to age-related disease.<ref>Calimport, S. R., Bentley, B. L., Stewart, C. E., Pawelec, G., Scuteri, A., Vinciguerra, M., ... & Church, G. (2019). To help aging populations, classify organismal senescence. ''Science'', ''366''(6465), 576-578.</ref><ref>Zhavoronkov, A., & Bhullar, B. (2015). Classifying aging as a disease in the context of ICD-11. ''Frontiers in genetics'', ''6'', 326.</ref><ref>Bulterijs, S., Hull, R. S., Björk, V. C., & Roy, A. G. (2015). It is time to classify biological aging as a disease. ''Frontiers in genetics'', ''6'', 205.</ref> Others contend that aging cannot be considered a disease, such as because aging affects everyone, and that aging is a natural part of life,<ref>Rattan, S. I. (2014). Aging is not a disease: implications for intervention. ''Aging and disease'', ''5''(3), 196.</ref><ref>Kirkwood, T. B. (2003). The most pressing problem of our age. ''Bmj'', ''326''(7402), 1297-1299.</ref>

==== Citations ====
*
<references />
[[Category:Longevity]]
[[Category:Pillar Articles]]

Handbook:Content Writer Meetings

2021-09-06T14:56:09Z

Schulzm: First preparation notes for first content writer meeting led by Max Schulz

== 07/09/2021 ==

===📓Preparation Notes===
''Max Schulz:''

* '''Proposed Trello board process'''
** Article writing is organized on the Trello board: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]
** Three kind of articles: "Pillar Articles" (Expert Knowledge), "General Articles" (Open to anyone) and "Glossary" (2-3 sentences description from a longevity perspective) | [[Articles]] page will be organised accordingly
*** On Trello: Pillar articles are labeled (as well as the introductory article)
** Trello board organisation:
*** Unsassigned for article ideas
*** Assigned when someone wants to write an article
*** Once working on a draft: In progress
*** When finished with a first draft: Put in Written (merge Edited/Improve and Final Proofread?)
*** When reviewed by at least one other writer in the group: Completed
** Articles are never '''really''' done, as science progresses, so if you want to add something meaningful - please do so and share your idea both on Trello and this meeting!
** Feel free to add ideas about the processes & tools either in these meetings or on the Trello column "Feedback for tooling & organisation"!
** Non-structured contributions: Just get started writing on topics that interest you - the Trello board is to synchronise your efforts with the team and share your work!
* '''Proposed Content writer meeting process'''
** Content writer manager (Max) sharing process & technology updates
** Introductions by new members (short, 1 min / person):
*** Name & where you are based
*** Background & interest in longevity
*** What topics you want to contribute to
** Going through pillar articles updates (content, reviews, contributions)
** Round table: Unblocking writers - suggestions what to write on, asking for reviews etc.
* Regarding share-able Drafts: I think it would be great if we also wrote the drafts directly into the wiki. If the concern is that it shouldn't be made public before ready, we could just have it indicated in the title, e.g. "[DRAFT] Biomarkers of healthspan" until we have a technical solution to mark them accordingly. (Instead of creating local google docs) ''- We can also use categories for this once more visible on the articles page.''
* '''Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021'''
* Kindly ask all writers to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
* Meeting slot not set in stone, will send out a doodle again with more choice after this meeting (with ~10 days response deadline)

=== 🧍 Attending ===

=== 📣 Updates ===

Handbook:Handbook

2021-09-06T13:51:49Z

Schulzm: /* Bi-weekly content creator meetings */ Consistent wording for content writing vs creation

== About the Handbook==
The Longevity Wiki Handbook is the 'source of truth' for the Wiki organisation. It currently contains our mission and strategy, the roles we are looking for, links to our communication platforms and some editing advice. Like the Wiki itself, it's all publicly accessible and transparent and will likely grow and change over time.
== Mission==
Longevity Wiki is an open-access project to create the go-to platform for the science of longevity. The wiki was borne from the need for high quality scientific content on aging and longevity to be freely available and accessible. The Wiki ultimately aims to cover the following topics in detail:

*Longevity drugs and the evidence supporting them
*Personal longevity strategies/advice
*Hallmarks of aging/biology of aging
*Animal models of aging
*Laboratories working in geroscience, and their focus
*Longevity biotech (companies, development pipeline)
*Biology of aging + diseases of aging connection

More information about us can be found on our [[About]] page.

==Strategy==
Instead of producing as much content as possible, we’re going to focus on creating 5 pillar articles written by experts on the topic. These articles will demonstrate the knowledge and quality of our initiative, and then we will build out the wiki from there. These are the pillar articles:

#'''Epigenetic reprogramming'''
#'''Aging and Neurodegeneration'''
#'''Rapamycin'''
#'''Biomarkers of healthspan'''
#'''COVID-19 and Aging'''

In conjunction with these articles, we are going to create a Glossary page of key terms in the longevity space, along with a short (2-3 sentence definition).

== Available Roles and Projects for the Wiki ==
Longevity Wiki is an open access, collaborative project and we invite all volunteers to contribute! The goal of the Wiki is to create a trusted, high quality platform of longevity science content.

This section lists the current projects we are working on, and how you can get involved. If you're interested, please complete our [https://forms.gle/P1huKGcDiPLnRAB17 Volunteer Survey Form] and we will follow up with you by email.

===Pillar article writing===
'''Role: Senior content writer'''

'''Minimum requirements: Masters or PhD training, ideally in a relevant field to content being written'''

We are seeking those with strong scientific backgrounds to help our initial offering of 5 ‘pillar’ articles that will form the initial content on the Wiki.

These articles are designed to be long-form (1.5-2.5k words) articles summarizing the relevant literature as it pertains to aging biology. The style we are aiming for is similar to a literature review, but with a simplified writing style that is accessible to non-specialist readers.

An example is our article on [[Rapamycin]], however, the style and structure of the article may vary by topic.

The following topics have been selected:

*'''Epigenetic reprogramming'''
*'''Aging and Neurodegeneration'''
*'''Rapamycin'''
*'''Biomarkers of healthspan'''
*'''COVID-19 and Aging'''

===Glossary expansion===
'''Role: Junior content writer'''

'''Minimum requirements: High school level biology'''

We are building a glossary of relevant terminology to expand the scope of the Wiki. The glossary will be accessible from an article through the use of so called ‘hovercards’ which makes it possible to display the meaning of a difficult term without leaving the article page.

The list of glossary terms is being populated based on the pillar articles. A full list of glossary terms can be found here (ADD LINK).

To contribute to the glossary, simply choose a term that has not yet been defined, and write a concise, and scientifically accurate definition.

Some guidelines:

*All references should be cited using APA referencing

*All links to internal articles should be linked
*Definitions should be clear and comprehensible to non-specialist audiences
*Definitions can be up to 270 characters in length

An example of a glossary term (ADD LINK).

===Life extension tool database===
'''Role: Researcher'''

'''Minimum requirements: Undergraduate biology, ability to comprehend the longevity data and research'''

We are creating a ‘life extension tool’ that provides an up to date overview of the life extension achieved for different animals with different interventions.

A [https://zpl.io/bePZGJl sample of the tool] can be viewed on our design platform Zeplin.

In order to populate data for the tool, we require assistance in reviewing the literature to identify the lifespan extension associated with different drugs and species, and the original publication in which this was published.

Our current database: [https://docs.google.com/spreadsheets/d/14OLhV4WWSUGomEY-3zko1o8zHHrJwt5YipGbjxhracM/edit?usp=sharing Life Extension Tool Data].

===Software engineering support===
'''Role: Engineer'''

'''Minimum requirements: Interest in software engineering'''

As the wiki grows, we need to ensure that the automation and infrastructure develops. We are especially looking for people with the following abilities:

* AWS reliability engineering/DevOps (people to manage infrastructure and deploy apps)
* PHP
* Front-end development
* Technical product ownership
* A scrum master/iteration manager

===Marketing===
'''Role: Based on experience and performance'''

'''Minimum requirements: Past experience in marketing, splendid communicator and creative individual who is eager to learn'''

Our marketing department is expanding. If you are a creative individual who loves communicating, you could get a lot of significant responsibilities.

=== Graphic design ===
'''Role: Illustrator, data visualization'''

'''Minimum requirements: Experience with graphic design'''

We are looking for individuals with graphic design skills to help us create and re-work pictures, scientific diagrams and graphs to communicate information to non-technical audiences. You will work closely with our content writers to produce high-impact, engaging visuals to accompany the written content.

=== Other roles ===
'''Role: Translator'''

We are looking for individuals with language skills to translate articles into other languages to reach a broader audience - particularly languages spoken commonly around the world. This will be done with the assistance of tools such as Google Translate.

'''Role: UX specialist'''

We are seeking expertise in user experience (UX) to help us design an intuitive and engaging platform. The goal is to create a satisfying experience for our users. You will work with the Head of UX in this role.

== Our communication platforms ==
Besides this Handbook we use a few other platforms for communicating and sharing resources. We're committed to being an open-access platform, and as such, we share all information possible, such as meeting minutes.

=== Discord Server ===
We mostly communicate via the [https://discord.gg/UDKmjcnjye Longevity Wiki Discord Server]. It serves as a day-to-day message board, as well as the host of our meetings. Meetings take place every week at 08:30 GMT.

=== Google Drive ===
Our [https://drive.google.com/drive/folders/19Ol2wcRd2IWUt_gOC5j5Ff7FjSzPVuBf Drive folder] is used for sharing many useful documents, such as draft ideas, spreadsheets, or useful non-wiki resources.

===Organisational weekly meetings===

* Organisanional task management: [https://trello.com/b/0u9pSclR/organisational Trello Board] | [https://trello.com/invite/b/0u9pSclR/0722f6126c69d1341e63765f41d23531/organisational Invitation Link]
* [https://en.longevitywiki.org/wiki/Handbook:Meeting_Minutes Meeting minutes]

The meetings consist of our sprint planning sessions and mid-sprint meetings, which occur on alternating weeks.

=== Bi-weekly content writer meetings ===

* Organisanional task management: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]

The process of synchronising content writing and ideas is just being set up.

===Engineering Team===

*Source code: [https://github.com/longevitywiki Github]
*Task management: [https://longevitywiki.atlassian.net/jira/software/projects/LW/boards/1 Jira]
*Documentation & roadmap: [https://longevitywiki.atlassian.net/wiki/spaces/LW/overview Confluence]

==How to edit the Wiki==
=== Let us know first ===
If you want to edit the wiki, please [[Contact|contact us]] first, so we can help you get started.

=== MediaWiki ===
Longevity Wiki uses the [[mediawikiwiki:MediaWiki|MediaWiki]] platform - the same as Wikipedia. This is the software that makes it possible to store all content, edit articles, track changes and more.
[[File:Account menu.png|thumb|100x100px|The Account menu]]

=== Create an account ===
If you want to edit the wiki, it's a good idea to create an account first. That way it's easier to keep track of your work and you get some extra functionality. To create an account, in the menu click the Account icon on the right (the 'little person') and click '''Create account''' and follow the instructions. Creating an account is not mandatory however for editing.
[[File:Contribute menu.png|thumb|198x198px|The Contribute menu]]

=== Create a page ===
To create a new article on the wiki, go to the menu and click '''Contribute''' and then '''Create new page'''. You will then be prompted to select a title for your article. After that, the Edit toolbar appears at the top and you can start writing. The Edit toolbar provides you with standard edit functions like making headings, bold text, insert links, insert images and much more.

When adding a new page related to longevity to the wiki, please make sure to categorize it as 'Longevity' so that it automatically appears in the [[Articles]] listing. (Save Changes -> Categories)

=== Edit a page ===
To edit an existing article, lookup the article, go to the menu and click '''Contribute''' and then (under 'This page...') click '''Edit'''. Then the Edit toolbar will open at the top, and you can start writing.
[[File:Text editor.png|none|thumb|732x732px|The '''Edit''' toolbar]]

=== Images ===
Often it's a good idea to include images in your article. Just make sure that if you use an image of someone else, you are not violating any copyright. In general, you are free to use images with a [https://creativecommons.org/ Creative Commons] license, but don't forget to use the right [https://creativecommons.org/use-remix/ attribution]. If you need help creating an image yourself, let us know in the Images channel on our [https://discord.gg/jBR5aRcpfV Discord Server], and we can help you create a unique and copyright-free image.

=== Referencing ===
For referencing to external sources (e.g. a journal article), Longevity Wiki uses the [[wikipedia:APA_style|APA referencing style]] - the same as Wikipedia. To create a reference, click '''Cite''' on the Edit toolbar. There are a few useful resources for creating citations, such as [https://zbib.org/ Zoterobib].

=== Writing style ===
The aim of the Wiki is to create '''comprehensive''', '''scientifically accurate''' and '''accessible''' content on longevity. The writing style we are aiming for is essentially the same as Wikipedia, in balancing technical and non-technical content. Here is our '''[[Writing tips for easy reading|writing guide]]''' to help you get started. More information on Wikipedia's writing style can be found in [[wikipedia:Wikipedia:Manual_of_Style|Wikipedia's Manual of Style]].

==Contact information==
See our [[Contact]] page.

Handbook:Meeting Minutes

2021-09-06T09:44:59Z

Schulzm: Add preparation notes chapter for 08/09/21

== 08/09/2021 ==

=== 📓Preparation Notes ===
''Max Schulz:''

* In progress ...

== 01/09/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Ben Wu
* Sharon Wong
* Marc Smeehuijzen
* Andreas Melhede

=== 📣 Updates ===
''Jack Harley''

* Begun ''Aging and Neurodegeneration'' brainstorm and write-up. References and comments welcome.
* Collaborated with Max to create process for content writers (discussed below)
* Kindly ask all Wiki members to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
* [https://agingpharma.org/ ARDD Conference] has begun - good opportunity for Wiki members to learn more about the field - videos should be uploaded to the website for free viewing in the coming weeks.
* Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021

''Sharon Wong''

* Noted that the translation for the Rapamycin article was updating while
* Found it difficult to quickly copy content and formatting to a new page - Bogdan may able to assist with this
* Noted that it's probably not worth translating references
* Recommended deepl.com as the 'gold standard' for translating of articles. Produces more simplistic sentence structures compared to Google Translate.

''Ben Wu''

* Summary of EARD conference - mentioned Tina Woods' talk on lobbying UK government to increase funding towards aging research, and recognising biology of aging as a critical healthcare mission. Also mentioned that emphasis on healthspan seems more effective in communication than emphasis on lifespan.

''Marc''

* Bi-weekly content writers meetings could be structured around a review process whereby writers provide helpful feedback on other writers' articles. Maybe writers with journalistic/editor experience know of an effective review process similar to how people work at a newspaper/magazine/journal.
* We should prevent information being copied across various parts of the website because this makes maintenance harder. E.g. the 'About us' information is now both on the About us page and in the Handbook. He suggests removing the 'About Us' content from the Handbook, and replace it with a link to the 'About us' page.
* The handbook contains much valuable information for contributors but is not that interesting for most wiki visitors who just visit the wiki for longevity related information. He suggests to show only some high level 'how to contribute' information on the 'How to contribute' page so we don't overwhelm visitors (basically just asking people to contact us if they want to help) and then add a prominent link to the Handbook for if they want to dive into all the details. 

Andreas Melhede:

* Discussed Discord Role Management on Discord with Stuart McWhinney.
** It is very close to finished and ready to be implemented on our server.

''Max Schulz:''

* Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
*** Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
*** Using ''Organisational'' board to manage weekly core meetings
*** Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
** ''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
*** Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
*** I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
*** Proposed board usage:
**** Future ideas for clearly far in the future (months)
**** Backlog for tasks to do soon (weeks)
**** Todo for tasks agreed to be done next, or you want to work on next
**** Once task is worked on -> Move to In Progress
**** If you want someone to review -> Move to In Review
**** If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
*** Meaningful task definitions
*** Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
* Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
** Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
** Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
* Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
** Should be filled out by all team members so we have an overview.

== 25/08/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Bogdan Dziewierz
* Marc Smeehuijzen
* Ben Wu
* Andreas Melhede
* Heye Groß
* Max Schons
* Stuart

=== 📣 Updates ===
* Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
* Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
* Max Schons working on risk factors, subjective vs objective measures of health, various major disease
* Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
* Heye planning on engaging with EA community at conferences and talking about the Wiki
* Technical meeting bimonthly with Bogdan, Mac, Stuart
* Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items ===

* Continue working on core articles
*
|}

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Handbook

2021-09-06T08:44:40Z

Schulzm: /* Our communication platforms */ Add information and trello boards for meetings

== About the Handbook==
The Longevity Wiki Handbook is the 'source of truth' for the Wiki organisation. It currently contains our mission and strategy, the roles we are looking for, links to our communication platforms and some editing advice. Like the Wiki itself, it's all publicly accessible and transparent and will likely grow and change over time.
== Mission==
Longevity Wiki is an open-access project to create the go-to platform for the science of longevity. The wiki was borne from the need for high quality scientific content on aging and longevity to be freely available and accessible. The Wiki ultimately aims to cover the following topics in detail:

*Longevity drugs and the evidence supporting them
*Personal longevity strategies/advice
*Hallmarks of aging/biology of aging
*Animal models of aging
*Laboratories working in geroscience, and their focus
*Longevity biotech (companies, development pipeline)
*Biology of aging + diseases of aging connection

More information about us can be found on our [[About]] page.

==Strategy==
Instead of producing as much content as possible, we’re going to focus on creating 5 pillar articles written by experts on the topic. These articles will demonstrate the knowledge and quality of our initiative, and then we will build out the wiki from there. These are the pillar articles:

#'''Epigenetic reprogramming'''
#'''Aging and Neurodegeneration'''
#'''Rapamycin'''
#'''Biomarkers of healthspan'''
#'''COVID-19 and Aging'''

In conjunction with these articles, we are going to create a Glossary page of key terms in the longevity space, along with a short (2-3 sentence definition).

== Available Roles and Projects for the Wiki ==
Longevity Wiki is an open access, collaborative project and we invite all volunteers to contribute! The goal of the Wiki is to create a trusted, high quality platform of longevity science content.

This section lists the current projects we are working on, and how you can get involved. If you're interested, please complete our [https://forms.gle/P1huKGcDiPLnRAB17 Volunteer Survey Form] and we will follow up with you by email.

===Pillar article writing===
'''Role: Senior content writer'''

'''Minimum requirements: Masters or PhD training, ideally in a relevant field to content being written'''

We are seeking those with strong scientific backgrounds to help our initial offering of 5 ‘pillar’ articles that will form the initial content on the Wiki.

These articles are designed to be long-form (1.5-2.5k words) articles summarizing the relevant literature as it pertains to aging biology. The style we are aiming for is similar to a literature review, but with a simplified writing style that is accessible to non-specialist readers.

An example is our article on [[Rapamycin]], however, the style and structure of the article may vary by topic.

The following topics have been selected:

*'''Epigenetic reprogramming'''
*'''Aging and Neurodegeneration'''
*'''Rapamycin'''
*'''Biomarkers of healthspan'''
*'''COVID-19 and Aging'''

===Glossary expansion===
'''Role: Junior content writer'''

'''Minimum requirements: High school level biology'''

We are building a glossary of relevant terminology to expand the scope of the Wiki. The glossary will be accessible from an article through the use of so called ‘hovercards’ which makes it possible to display the meaning of a difficult term without leaving the article page.

The list of glossary terms is being populated based on the pillar articles. A full list of glossary terms can be found here (ADD LINK).

To contribute to the glossary, simply choose a term that has not yet been defined, and write a concise, and scientifically accurate definition.

Some guidelines:

*All references should be cited using APA referencing

*All links to internal articles should be linked
*Definitions should be clear and comprehensible to non-specialist audiences
*Definitions can be up to 270 characters in length

An example of a glossary term (ADD LINK).

===Life extension tool database===
'''Role: Researcher'''

'''Minimum requirements: Undergraduate biology, ability to comprehend the longevity data and research'''

We are creating a ‘life extension tool’ that provides an up to date overview of the life extension achieved for different animals with different interventions.

A [https://zpl.io/bePZGJl sample of the tool] can be viewed on our design platform Zeplin.

In order to populate data for the tool, we require assistance in reviewing the literature to identify the lifespan extension associated with different drugs and species, and the original publication in which this was published.

Our current database: [https://docs.google.com/spreadsheets/d/14OLhV4WWSUGomEY-3zko1o8zHHrJwt5YipGbjxhracM/edit?usp=sharing Life Extension Tool Data].

===Software engineering support===
'''Role: Engineer'''

'''Minimum requirements: Interest in software engineering'''

As the wiki grows, we need to ensure that the automation and infrastructure develops. We are especially looking for people with the following abilities:

* AWS reliability engineering/DevOps (people to manage infrastructure and deploy apps)
* PHP
* Front-end development
* Technical product ownership
* A scrum master/iteration manager

===Marketing===
'''Role: Based on experience and performance'''

'''Minimum requirements: Past experience in marketing, splendid communicator and creative individual who is eager to learn'''

Our marketing department is expanding. If you are a creative individual who loves communicating, you could get a lot of significant responsibilities.

=== Graphic design ===
'''Role: Illustrator, data visualization'''

'''Minimum requirements: Experience with graphic design'''

We are looking for individuals with graphic design skills to help us create and re-work pictures, scientific diagrams and graphs to communicate information to non-technical audiences. You will work closely with our content writers to produce high-impact, engaging visuals to accompany the written content.

=== Other roles ===
'''Role: Translator'''

We are looking for individuals with language skills to translate articles into other languages to reach a broader audience - particularly languages spoken commonly around the world. This will be done with the assistance of tools such as Google Translate.

'''Role: UX specialist'''

We are seeking expertise in user experience (UX) to help us design an intuitive and engaging platform. The goal is to create a satisfying experience for our users. You will work with the Head of UX in this role.

== Our communication platforms ==
Besides this Handbook we use a few other platforms for communicating and sharing resources. We're committed to being an open-access platform, and as such, we share all information possible, such as meeting minutes.

=== Discord Server ===
We mostly communicate via the [https://discord.gg/UDKmjcnjye Longevity Wiki Discord Server]. It serves as a day-to-day message board, as well as the host of our meetings. Meetings take place every week at 08:30 GMT.

=== Google Drive ===
Our [https://drive.google.com/drive/folders/19Ol2wcRd2IWUt_gOC5j5Ff7FjSzPVuBf Drive folder] is used for sharing many useful documents, such as draft ideas, spreadsheets, or useful non-wiki resources.

===Organisational weekly meetings===

* Organisanional task management: [https://trello.com/b/0u9pSclR/organisational Trello Board] | [https://trello.com/invite/b/0u9pSclR/0722f6126c69d1341e63765f41d23531/organisational Invitation Link]
* [https://en.longevitywiki.org/wiki/Handbook:Meeting_Minutes Meeting minutes]

The meetings consist of our sprint planning sessions and mid-sprint meetings, which occur on alternating weeks.

=== Bi-weekly content creator meetings ===

* Organisanional task management: [https://trello.com/b/mfwbyEB6/content-creators Trello Board] | [https://trello.com/invite/b/mfwbyEB6/1ff12fd226e42d2568ac681b858e3342/content-creators Invitation Link]

The process of synchronising content creation and ideas is just being set up.

===Engineering Team===

*Source code: [https://github.com/longevitywiki Github]
*Task management: [https://longevitywiki.atlassian.net/jira/software/projects/LW/boards/1 Jira]
*Documentation & roadmap: [https://longevitywiki.atlassian.net/wiki/spaces/LW/overview Confluence]

==How to edit the Wiki==
=== Let us know first ===
If you want to edit the wiki, please [[Contact|contact us]] first, so we can help you get started.

=== MediaWiki ===
Longevity Wiki uses the [[mediawikiwiki:MediaWiki|MediaWiki]] platform - the same as Wikipedia. This is the software that makes it possible to store all content, edit articles, track changes and more.
[[File:Account menu.png|thumb|100x100px|The Account menu]]

=== Create an account ===
If you want to edit the wiki, it's a good idea to create an account first. That way it's easier to keep track of your work and you get some extra functionality. To create an account, in the menu click the Account icon on the right (the 'little person') and click '''Create account''' and follow the instructions. Creating an account is not mandatory however for editing.
[[File:Contribute menu.png|thumb|198x198px|The Contribute menu]]

=== Create a page ===
To create a new article on the wiki, go to the menu and click '''Contribute''' and then '''Create new page'''. You will then be prompted to select a title for your article. After that, the Edit toolbar appears at the top and you can start writing. The Edit toolbar provides you with standard edit functions like making headings, bold text, insert links, insert images and much more.

When adding a new page related to longevity to the wiki, please make sure to categorize it as 'Longevity' so that it automatically appears in the [[Articles]] listing. (Save Changes -> Categories)

=== Edit a page ===
To edit an existing article, lookup the article, go to the menu and click '''Contribute''' and then (under 'This page...') click '''Edit'''. Then the Edit toolbar will open at the top, and you can start writing.
[[File:Text editor.png|none|thumb|732x732px|The '''Edit''' toolbar]]

=== Images ===
Often it's a good idea to include images in your article. Just make sure that if you use an image of someone else, you are not violating any copyright. In general, you are free to use images with a [https://creativecommons.org/ Creative Commons] license, but don't forget to use the right [https://creativecommons.org/use-remix/ attribution]. If you need help creating an image yourself, let us know in the Images channel on our [https://discord.gg/jBR5aRcpfV Discord Server], and we can help you create a unique and copyright-free image.

=== Referencing ===
For referencing to external sources (e.g. a journal article), Longevity Wiki uses the [[wikipedia:APA_style|APA referencing style]] - the same as Wikipedia. To create a reference, click '''Cite''' on the Edit toolbar. There are a few useful resources for creating citations, such as [https://zbib.org/ Zoterobib].

=== Writing style ===
The aim of the Wiki is to create '''comprehensive''', '''scientifically accurate''' and '''accessible''' content on longevity. The writing style we are aiming for is essentially the same as Wikipedia, in balancing technical and non-technical content. Here is our '''[[Writing tips for easy reading|writing guide]]''' to help you get started. More information on Wikipedia's writing style can be found in [[wikipedia:Wikipedia:Manual_of_Style|Wikipedia's Manual of Style]].

==Contact information==
See our [[Contact]] page.

Handbook:Meeting Minutes

2021-09-01T14:55:18Z

Schulzm: /* 🧍 Attending */ Bulleted list for attendees 01/09

== 01/09/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Ben Wu
* Sharon Wong
* Marc Smeehuijzen
* Andreas Melhede

=== 📓Preparation Notes ===
''Jack Harley''

* Begun ''Aging and Neurodegeneration'' brainstorm and write-up. References and comments welcome.
* Collaborated with Max to create process for content writers (discussed below)
* Kindly ask all Wiki members to complete [https://docs.google.com/forms/d/e/1FAIpQLScnXVdwTutWe_xNt6wJMPoXu_v9QBLb1A7QrBXRXXBifUyESg/viewform?usp=send_form volunteer form] to help keep a record
* [https://agingpharma.org/ ARDD Conference] has begun - good opportunity for Wiki members to learn more about the field - videos should be uploaded to the website for free viewing in the coming weeks.
* Goal is to have 4 pillar articles - by Max, Jack, Ben and the Rapamycin articles - by the end of September 2021

''Sharon Wong''

* Noted that the translation for the Rapamycin article was updating while
* Found it difficult to quickly copy content and formatting to a new page - Bogdan may able to assist with this
* Noted that it's probably not worth translating references
* Recommended deepl.com as the 'gold standard' for translating of articles. Produces more simplistic sentence structures compared to Google Translate.

''Ben Wu''

* Summary of EARD conference - mentioned Tina Woods' talk on lobbying UK government to increase funding towards aging research, and recognising biology of aging as a critical healthcare mission. Also mentioned that emphasis on healthspan seems more effective in communication than emphasis on lifespan.

''Marc''

* Bi-weekly content writers meetings could be structured around a review process whereby writers provide helpful feedback on other writers' articles. Maybe writers with journalistic/editor experience know of an effective review process similar to how people work at a newspaper/magazine/journal.
* We should prevent information being copied across various parts of the website because this makes maintenance harder. E.g. the 'About us' information is now both on the About us page and in the Handbook. He suggests removing the 'About Us' content from the Handbook, and replace it with a link to the 'About us' page.
* The handbook contains much valuable information for contributors but is not that interesting for most wiki visitors who just visit the wiki for longevity related information. He suggests to show only some high level 'how to contribute' information on the 'How to contribute' page so we don't overwhelm visitors (basically just asking people to contact us if they want to help) and then add a prominent link to the Handbook for if they want to dive into all the details. 
''Max Schulz:''

* Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
*** Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
*** Using ''Organisational'' board to manage weekly core meetings
*** Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
** ''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
*** Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
*** I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
*** Proposed board usage:
**** Future ideas for clearly far in the future (months)
**** Backlog for tasks to do soon (weeks)
**** Todo for tasks agreed to be done next, or you want to work on next
**** Once task is worked on -> Move to In Progress
**** If you want someone to review -> Move to In Review
**** If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
*** Meaningful task definitions
*** Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
* Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
** Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
** Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
* Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
** Should be filled out by all team members so we have an overview.

== 25/08/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Bogdan Dziewierz
* Marc Smeehuijzen
* Ben Wu
* Andreas Melhede
* Heye Groß
* Max Schons
* Stuart

=== 📣 Updates ===
* Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
* Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
* Max Schons working on risk factors, subjective vs objective measures of health, various major disease
* Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
* Heye planning on engaging with EA community at conferences and talking about the Wiki
* Technical meeting bimonthly with Bogdan, Mac, Stuart
* Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items ===

* Continue working on core articles
*
|}

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Meeting Minutes

2021-08-31T15:27:49Z

Schulzm: /* 📓Preparation Notes */ Add content writer updates and Jack's survey

== 01/09/2021 ==

=== 🧍 Attending ===
...

=== 📓Preparation Notes ===
''Max Schulz:''

* Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
*** Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
*** Using ''Organisational'' board to manage weekly core meetings
*** Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
** ''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
*** Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
*** I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
*** Proposed board usage:
**** Future ideas for clearly far in the future (months)
**** Backlog for tasks to do soon (weeks)
**** Todo for tasks agreed to be done next, or you want to work on next
**** Once task is worked on -> Move to In Progress
**** If you want someone to review -> Move to In Review
**** If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
*** Meaningful task definitions
*** Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
* Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
** Temporary content writer sheet: [https://docs.google.com/spreadsheets/d/1e9djbjXdMV7m4655yjIISHRoUpB_1mbJcv0O8Zwj1fg/edit#gid=0 link] - will be superseeded by volunteer survey responses (see below)
** Wrote update to content writers [https://docs.google.com/document/d/1FlD9sTf5fPGhBiWYHV9nhzr0ucO6n4CFfEzcdbtnfC0/edit (text link)] with doodle survey for first bi-weekly content meeting after summer (note: should have set a deadlien for doodle ...^^)
**''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
***'''Process for bi-weekly meeting has to be figured out (round-table style?)'''
* Jack created the volunteer survey, ([https://docs.google.com/forms/d/1An8sOTXi_Hne3Elmp1sY1n-3fr6PXwf-bUgPBi8X6e0/edit edit link]) - [https://forms.gle/KHmveeaRSgamtr1D7 shareable link] | answers are linked to the [https://docs.google.com/spreadsheets/d/1FDFYQhQVBdDdHEiGqY1pif0T7sd-suRwOK-0wl7AIXU Google Sheet]
** Should be filled out by all team members so we have an overview.

== 25/08/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Bogdan Dziewierz
* Marc Smeehuijzen
* Ben Wu
* Andreas Melhede
* Heye Groß
* Max Schons
* Stuart

=== 📣 Updates ===
* Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
* Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
* Max Schons working on risk factors, subjective vs objective measures of health, various major disease
* Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
* Heye planning on engaging with EA community at conferences and talking about the Wiki
* Technical meeting bimonthly with Bogdan, Mac, Stuart
* Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items ===

* Continue working on core articles
*
|}

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Meeting Minutes

2021-08-27T15:13:24Z

Schulzm: /* 📓Preparation Notes */ Add info about trello board pricing

== 01/09/2021 ==

=== 🧍 Attending ===
...

=== 📓Preparation Notes ===
''Max Schulz:''

* Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
*** Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
*** Using ''Organisational'' board to manage weekly core meetings
*** Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board? (Should be possible with members instead of guests? [[https://trello.com/en/pricing Pricing Info] | [https://help.trello.com/article/1236-board-guests Board Guests Info]])
** ''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
*** Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
*** I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
*** Proposed board usage:
**** Future ideas for clearly far in the future (months)
**** Backlog for tasks to do soon (weeks)
**** Todo for tasks agreed to be done next, or you want to work on next
**** Once task is worked on -> Move to In Progress
**** If you want someone to review -> Move to In Review
**** If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene we should agree on ([https://mnschulz.medium.com/managing-work-in-a-startup-e80a3d122620 Personal article]), examples:
*** Meaningful task definitions
*** Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
* Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
** ''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
*** '''... Process in progress'''

== 25/08/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Bogdan Dziewierz
* Marc Smeehuijzen
* Ben Wu
* Andreas Melhede
* Heye Groß
* Max Schons
* Stuart

=== 📣 Updates ===
* Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
* Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
* Max Schons working on risk factors, subjective vs objective measures of health, various major disease
* Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
* Heye planning on engaging with EA community at conferences and talking about the Wiki
* Technical meeting bimonthly with Bogdan, Mac, Stuart
* Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items ===

* Continue working on core articles
*
|}

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Meeting Minutes

2021-08-26T15:28:18Z

Schulzm: Add first draft of preparation notes for 01/09/21 meeting

== 01/09/2021 ==

=== 🧍 Attending ===
...

=== 📓Preparation Notes ===
''Max Schulz:''

* Trello Board Set-up & Organization (Tasks on Wiki I would consider once further in development)
** Let's focus only on trello boards that are used, and archive others - I propose:
*** Archiving ''Engineering'' and ''UX'' -> Moving to Jira
*** Merging ''Marketing'' & ''Operations Infrastructure'' into Organisational '''(Please move the tasks you find relevant and archive these)'''
*** Using ''Organisational'' board to manage weekly core meetings
*** Using ''Content creators'' board to manage (to be scheduled) bi-weekly content creators meeting
*** Overall: Can we have one trello group/team with several boards instead of inviting separately for each board?
** ''Organisational'' board (people need to be added):
*** Should be reviewed and kept up to date weekly
*** Action items should be created as tasks, if applicable - I tried to add most of them, sometimes people have to be assigned again
*** I propose even if task is technical (e.g. making handbook more prominent [https://trello.com/c/fOFtXUmy Trello card]) but relevant to the organisational meetings, it should also be tracked on Trello
*** Proposed board usage:
**** Future ideas for clearly far in the future (months)
**** Backlog for tasks to do soon (weeks)
**** Todo for tasks agreed to be done next, or you want to work on next
**** Once task is worked on -> Move to In Progress
**** If you want someone to review -> Move to In Review
**** If task is done -> Move to Done, can then be shared in the next weekly meeting and archived
** Task hygiene (more structured in the future):
*** Descriptions ... kept up to date, etc.
*** Assigned doesn't necessarily mean the person does all the work, but takes (especially on the communication side) responsibility
*** '''... Process in progress'''
** Side-remark: Tipp to see your cards - [https://help.trello.com/article/819-viewing-all-of-your-cards Trello Help]
* Content writer management:
** Low-hanging fruit for article organisation: Instead of just alphabetic ordering in [[Articles]], can we have groups of articles with the first "Category" as the ordering? (Or another mechanism in Mediawiki?) I think it would be important to separate "Pillar Articles", "General Articles" and "Glossary" already for the management of the articles
** ''Content creators'' board:
*** Pillar article label added (also to introductory article, which can be vital as well)
*** '''... Process in progress'''

== 25/08/2021 ==

=== 🧍 Attending ===

* Jack Harley
* Bogdan Dziewierz
* Marc Smeehuijzen
* Ben Wu
* Andreas Melhede
* Heye Groß
* Max Schons
* Stuart

=== 📣 Updates ===
* Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
* Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
* Max Schons working on risk factors, subjective vs objective measures of health, various major disease
* Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
* Heye planning on engaging with EA community at conferences and talking about the Wiki
* Technical meeting bimonthly with Bogdan, Mac, Stuart
* Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items ===

* Continue working on core articles
*
|}

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Meeting Minutes

2021-08-26T08:01:51Z

Schulzm: Updates header for 25/08 Meeting

= 25/08/2021 =

=== 🧍 Attending ===

* Jack Harley
* Bogdan Dziewierz
* Marc Smeehuijzen
* Ben Wu
* Andreas Melhede
* Heye Groß
* Max Schons
* Stuart

=== 📣 Updates ===
* Considering scoring of new participants to determine level of understanding, also as filtering for determining what level they might contribute at
* Thinking about providing a list of articles/content etc for Wiki contributors to obtain a better overview of the field
* Database of interests of participants, time zones etc.
* Max Schons working on risk factors, subjective vs objective measures of health, various major disease
* Considering submitting core articles to professional proofreading agencies, or reaching out to undergrad/postgrad students
* Heye planning on engaging with EA community at conferences and talking about the Wiki
* Technical meeting bimonthly with Bogdan, Mac, Stuart
* Considering merging Max's medium article with Ben's intro article

{| class="wikitable"
|
=== ✅ Action Items ===

* Continue working on core articles
*
|}

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed whether Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you currently navigate the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}

Handbook:Handbook

2021-08-18T13:00:52Z

Schulzm: Delete unused, empty paragraphs

''Should be merged with the About page: [[About]] (Note: Should be an editable wiki-page)''

== Organizational Mission==
Being the go-to platform on all scientific areas related to longevity:

*Personal longevity strategies/advice
*Hallmarks of aging/biology of aging
*Longevity drugs
*Animal models of aging
*Laboratories working in geroscience, and their focus
*Longevity biotech (companies, development pipeline)
*Biology of aging + diseases of aging connectio

==How to edit the Wiki==
The complete technical guide to editing the Wiki can be found [[How to contribute|here]].

==Strategy==
Instead of producing as much content as possible, we’re going to focus on creating 5 pillar articles written by experts on the topic. These articles will demonstrate the knowledge and quality of our initiative, and then we will build out the wiki from there.

As for the 5 pillar articles, if you have a post-grad (MSc, PhD, MD) in a related area to one of the articles below, please rech

#'''Epigenetic reprogramming'''
#'''Aging and Neurodegeneration'''
#'''Rapamycin'''
#'''Biomarkers of healthspan'''
#'''COVID-19 and Aging'''

In conjunction with these articles, we are going to create a Glossary page of key terms in the longevity space, along with a short (2-3 sentence definition). This Glossary is the major area where we will need help from any interested content writers. We also will need people to help with marketing, and with the administration/organization of the wiki.

==Organization==

===General===

*Communications: Organizational discord server can be found [https://discord.gg/UDKmjcnjye here].
*Weekly Meetings, 10:30 a.m. (CET) on the Discord Server ''(TODO: other meetings, public calendar links for people to add?)''

*This wiki (Handbook namespace) as the source of truth for the organiyation
*Trello for Content Writers Task Management (In the future could be the Wiki itself): [https://trello.com/b/mfwbyEB6/content-creators Content creator board]
* Google Drive for presentations and unordered thoughts to share: [https://drive.google.com/drive/folders/19Ol2wcRd2IWUt_gOC5j5Ff7FjSzPVuBf Drive Link (public)]

===Engineering Team===

*Source code: [https://github.com/longevitywiki Github]
*Task management: [https://longevitywiki.atlassian.net/jira/software/projects/LW/boards/1 Jira]
*Documentation & roadmap: [https://longevitywiki.atlassian.net/wiki/spaces/LW/overview Confluence]

==Available Roles and Projects for the Wiki==
Longevity Wiki is an open access, collaborative project and we invite all volunteers to contribute! The goal of the Wiki is to create a trusted, high quality platform of longevity science content.

This chapter lists the current projects we are working on, and how you can get involved.

===Pillar article writing===
'''Role: Senior content writer'''

'''Minimum requirements: Masters or PhD training, ideally in a relevant field to content being written'''

We are seeking those with strong scientific backgrounds to help our initial offering of 20 ‘pillar’ articles that will form the initial content on the Wiki.

These articles are designed to be long-form (1.5-2.5k words) articles summarising the relevant literature as it pertains to aging biology. The style we are aiming for is similar to a literature review, but with a simplified writing style that is accessible to non-specialist readers.

An example article is [[Rapamycin|here]], however, the style and structure of the article may vary by topic.

The following topics have been selected:

*Biomarkers of Healthspan
*Brain aging and neurodegeneration

If you are interested in volunteering to help research or write these articles, please contact Jack Harley at [[Mailto:jtt.harley@gmail.com|jtt.harley@gmail.com]] or Max Schons at [[Mailto:Maxxsschons@gmail.com|Mxschons@gmail.com]].

===Glossary expansion===
'''Role: Junior content writer'''

'''Minimum requirements: High school level biology'''

We are building a glossary of relevant terminology to expand the scope of the Wiki. This will be used to allow users to use the ‘hovercard’ feature to define any words they are unfamiliar with.

The list of glossary terms is being populated based on the pillar articles. A full list of glossary terms can be found here.

To contribute to the glossary, simply choose a term that has not yet been defined, and write a concise, and scientifically accurate definition.

*All references should be cited using APA referencing

*All links to internal articles should be linked
*Technical advice on how to edit the Wiki can be found [[Contribute|here]]
*Definitions are clear and comprehensible to non-specialist audiences.
*Definitions are up to 270 characters in length

An example of a glossary term can be found here.

===Life extension tool database===
'''Role: Researcher'''

'''Minimum requirements: Undergraduate biology, ability to comprehend data and research'''

We are creating a ‘life extension tool’ that allows the lifespan extension of certain drugs on various model organisms to be visualised.

A sample of the tool can be viewed here. In order to populate data for the tool, we require assistance in reviewing the literature to identify the lifespan extension associated with different drugs, and the original publication in which this was published.

The current database of life-extension data can be viewed and edited here.

===Software engineering support===
'''Role: Engineer'''

'''Minimum requirements: Interest in software Engineering'''

T.B.D

===Marketing===
'''Role: Based on experience and performance'''

'''Minimum requirements: Past experience in marketing, splendid communicator and creative individual who is eager to learn.'''

Our marketing department is expanding. If you are a creative individual who loves communicating, you could get a lot of significant responsibilities.

As our platform expands, our marketing efforts must do the same. Are you are eager to learn and would love to help us grow as quick as humanly possible?

Then, let’s talk: andreasdmelhede@gmail.com

==Meeting minutes==
All meeting minutes can be viewed [https://en.longevitywiki.org/wiki/Handbook:Meeting_Minutes?venotify=created here].

==Organisational Constitution==

Handbook:Meeting Minutes

2021-08-18T12:44:10Z

Schulzm: /* 📣 Updates Roundtable */ Small update to India Times article

== 18/08/2021 ==

=== 🧍 Attending ===
* Jack Harley
* Bogdan Dziewierz
* Max Schulz
* Andreas Melhede
* Sam Voigt
* Marc Smeehujizen
* Heye Groß

=== 📣 Updates Roundtable ===
Jack Harley

* India times article is being finalised, to be released next week or week after. New co-author [https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/ Brian Kennedy] joined

* More contributors interested to join the project. There is a need for people to help with on-boarding new contributors

* Gave a talk in EA group in Melbourne. This was followed up with an invitation to the medical conference in Melbourne.

* Handbook work is progressing'''.''' We need to make it more prominent and visible in the menu.

''Bogdan Dziewierz''

* Custom namespace "Handbook" created on the Wiki
* Engineering iteration meeting needs to be scheduled. Created new #engineering channel in Discord to help with coordination of such activities.
* Slowly progressing on Life Extension tool

''Heye Groß''

* Will get more involved in Longevity Wiki over next weeks. More clear on working hours.
* Discussed weather Longevity is a topic that is / should be on the agenda for EA compared to other existential risks and how EA can be used as spread-the-word or funding platform for Longevity effectively.
* Open Philantropy: Donates to the most effective areas but have a pessimistic view of longevity research. We think their evaluation is limited because they haven’t done cost / benefits calculation of investing into geroscience. Can be low-hanging fruit for donations, provided cost / benefit calculation is done for them.

''Jack Harley''

* Let’s try to organise symposium or conference once we get funding. EA could be convinced to fund this initiative.

''Max Schulz''

* Meeting Organization in general: I also like the process of always having a pre-created meeting topics from participants file for the next meeting
** Every participant plan can add his points already (I personally like to do this), then the meeting owner already has an idea in advance what people want to talk about and how to potentially structure it (Jack Harley in this case?)
* Updated the about page with pillar articles and ongoing projects suggestion ([[Handbook:Handbook]]). Some open points on my side (see page)
** 5 or 20 pillar articles to start with? Saw conflicting information
** Content should be merged with: [[About]], [[How to contribute]] (Especially "Other Roles")
** In the visual editor, there are quite some "paragraphs" that I can't delete, they don't show up in the source editor ...?
** Open calendar links for meetings would be good (also are there other meetings to know of...?)
* How do you navigate currently the articles on the wiki? For example, how do you find the handbook article? (Any ongoing efforts on the navigation side?)
* There are article drafts shared on Discord with Google Docs, we should encourage everybody to directly write to the Wiki so this work doesn't get lost (e.g. [https://docs.google.com/document/d/1gSJjEJbP_A1Qs_uewoWjkSFUhsyfN1IUNUYIVuxDb7E/edit link]) (The "core articles" that we want to work on should just be categorized accordingly IMHO)
** Similarly, with the glossary suggestion - better if it would be already added to the wiki instead: [https://docs.google.com/document/d/1q2dlsLK76bAXyU3ZPZ_eWn_oI3UFQEtie_8D2nRH5cQ/edit#heading=h.lhdrp4ijtcd2 google docs]
* What is the status of the vision and action plan? ([https://docs.google.com/presentation/d/1rlPZyncQGRW6koCunM23msQyVWEQ0CVyGMnMAUSaE8U/edit#slide=id.g655cbd83be_0_18 Google Slides])
* Idea to try get some funding from the upcoming Gitcoin round from VitaDAO? I know that the high quality articles would make the case stronger, on the other hand they explicitly want to also go for early projects and "open science": [https://docs.google.com/document/d/13rjnkgxCdQ63V1M69cE-moeY6ktRfo5XIF8E9nwaeIU/edit Quadratic Funding Round Document]
* Last week, the process of registering a non-profit was quickly discussed but it's not in the minutes (I don't remember what was discussed)

''Heye Groß / Jack Harley / Bogdan Dziewierz''

* There is need to think about what we need money for so that we can start participating in funding rounds / grants / etc.

''Andres Melhede''

* Waiting for India article so that it can be used as a source for more content to be used on Social Media

{| class="wikitable"
|
=== ✅ Action Items ===

* Jack: There is a need for volunteers to help with on-boarding new contributors

* Bogdan: We need to make it more prominent and visible in the menu
* Bogdan: How to contribute menu item needs to be replaced with Handbook
* Jack: We need to brainstorm and document what we need the funds for so that we can start participating in funding rounds / grants / etc.
* Jack: Let’s try to organise symposium or conference once we get funding.
* Max: Max to follow up with VitaDAO to find out if we can participate in their Gitcoin round.
|}

== 11/08/2021 ==

=== Purpose ===
Regular weekly meeting

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Max Schons, Content Writer
* Max Schulz, Engineering Team Member and Organisational Consultant
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing
* Sharon Wong, Content Translator

=== 📣 Updates Roundtable ===

# Name: Max Schulz
## Discussed benefits of the ‘handbook-first’ approach, such as convenience in onboarding new volunteers to the organisation, and having a centralized knowledge base for strategy and roadmap documents. Brought up the need for a central landing page upon which organisational links are easily accessible.
## Discussed platforms for hosting the Handbook, such as Confluence.
# Name Bogdan
## Suggested using the Wiki itself as the ‘Handbook’, and Confluence for the engineering activities. The rest of the team agreed. Offered to create a namespace using MediaWiki for the handbook and landing page.
## Life extension tool is a work in progress.
# Name Jack
## Discussed the role of content writer manager, and suggested Max Schulz be introduced to this role.
## Once content writers are on board with the new content writing strategy, those with a biology background can be tasked with adding data to the life extension tool.
# ‍Name Max Schons
## Outlined briefly the content strategy of creating a few high quality articles then seeking the endorsement of experts in the field, to attract more high quality contributors.
## Provided example of meeting minutes layouts in a handbook: <nowiki>https://github.com/mermaid-js/mermaid/releases</nowiki>
# Name Ben
## Provided update on the Times of India article, which will be published in the coming 1-2 weeks. The article will mention Longevity Wiki in the authors’ biographies section.
# Name Sharon
## Offered to review meeting minutes, and provided suggestions for the minutes - including key references and links at the beginning of the minutes.
# Name Andreas
## Provided updates on social media accounts.
## Did several edits and suggestions for the Aging Article for the Indian News Site.

{| class="wikitable"
|
=== ✅ Action Items ===

* Bogdan to create namespace for Handbook, and Handbook landing page
* Jack follow up on Max’s organizational wiki suggestions
* Jack to follow up with Max Schulz regarding content writers management
* Jack to assign organizational document writing to other members
* Bogdan to organize an Engineering team spring meeting
* Jack to create and share a document of organizational processes
* Max Schulz to forward exemplary handbook to Jack
* Max Schons to continue working on Biomarkers of Healthspan article
* Ben Wu to continue working on Aging Epigenetics article
|}

== 04/08/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Bogdan Dziewierz, Co-founder & Head of Engineering
* Marc Smeehuijzen, Head of UX
* Ben Wu, Head of Content
* Andreas Melhede, Head of Marketing

=== 📣 Updates Roundtable ===

# Name: Bogdan
## Had the kick-off engineering meeting 30 July 2021 with Sam Voigt, Maximilian Schulz and Mark Whitlock. He setup Jira and Confluence. (These are popular project management tools in IT development). The engineering cards on Trello will be moved to Jira. For more details on this meeting, see the minutes on Confluence. (If you don’t have access to Confluence, ask Bogdan).
## Suggestion: split weekly meetings per department (so engineering, marketing, content, etc. all have their own weekly meeting instead of everybody in the same meeting).
## Suggestion: we could move the draft articles that we’re working on from Google Docs to the wiki itself. This way visitors can see the wiki is alive and check recent changes of the articles.
## Continue working on the Life Extension Tool and a glossary extension for the wiki, among other things. We might develop other tools in the future. Jack for instance suggested an interactive roadmap for longevity laboratories in the world.
# Name Ben
## There is a little delay in writing the India Times article on longevity. But it’s 90% done. He will see if we can get a famous professor as co author (e.g. David Sinclair). On Google Docs there’s a draft of the article and members of the team are welcome to provide feedback
# Name Jack
## Talked to Maximillian Schulz who made a number of interesting organizational suggestions for the wiki (see Jack’s email from 4 Aug. 2021). There is a need for organizational docs to be made transparently accessible on the Wiki, and we proposed this be in the form of pages on the Wiki categorized accordingly.
## New marketing expert is interested in joining the project, could work alongside Andreas
## Plan to reach out to expert in Rapamycin (Mikhail Blagosklonny) to seek a review/endorsement for this article on the Wiki.
## Looking for someone who can manage the content writers.
# ‍Name Marc
## Updated the design for the Life Extension Tool. There are now two modes: 1. you can see per species what % life extension has been achieved per intervention and 2. you can see per intervention what % life extension has been achieved per species. The designs can be found on Zeplin. (If you don’t have access to Zeplin, please send Marc your email address so he can add you). He also posted some screenshots of the designs in the UX channel on our Discord server.
## Made English to Dutch translations of the interface elements of the wiki (document is on Google Drive).
# Name Andreas
## Made some social media posts on the 5 key articles that we’re working on.
## Engagement and sharing relevant content on the various social media platforms (especially focused on Twitter)

{| class="wikitable"
|
=== ✅ Action Items ===

* Ben looks for famous professor as co author for India Times article
* Jack follow up on Maximillian’s organizational wiki suggestions
* Jack looks for someone to manage the content writers
* Jack to assign organizational document writing to other members
* Marc joins the engineering team and moves his Trello cards to Jira
|}

== 29/07/2021 ==

=== 🧍 Attending ===

* Jack Harley, Co-Founder
* Andreas Melhede, Head of Marketing
* Ben Wu, Head of Content

=== 🙌 Celebrate wins ===

* New software developer, Mark Whitlock, will join the IT team to help develop the technical side
* Database for the Life Extension Tool (the UX design for which can be viewed here) has been created

=== 💬 Discussion Topics ===

* Who are we trying to target with content? Discussed the need for content that appeals to the masses to fill a gap in content in this space. While we hope to create content that scientists will read, and for credibility most will likely stick with reading review articles so we should bear in mind our target audience of non-specialists.

=== 📣 Updates Roundtable ===

# Name: Jack
## A new contributor, Max Schultz, who has written blog posts about knowledge databases has provided a report on the state of the Wiki, offering avenues for expanding the Wiki. The notes for his meeting agenda with me are attached below this document.
## We have created an excel spreadsheet of data for the Life extension tool, and are encouraging contributors to help expand the data.
## Have created a new folder in the Google Drive called ‘Weekly Meetings’ wherein this Meeting Minutes and future minutes can be saved.
## Discussed the need to update content writers with a new approach of creating a glossary for pillar articles.
# Name Ben
## Joao Pedro’s database contains an extensive list of drugs and their life extension effects, which we can draw from for our own tool. <nowiki>https://genomics.senescence.info/drugs/browse.php</nowiki>

<nowiki>https://genomics.senescence.info/drugs/</nowiki>

We should aim to create a more user-friendly, and simplified version for our tool, focusing on ~20 key drugs that are most relevant to today’s life extension protocols.

# We should focus on data from the ITP (NIA’s Intervention Testing Program) as this is a rigorous and reliable test.

# Name Andreas
## Clarifying the target audience as primarily those who are non-specialists
## Clarified the style of social media posts, as evidence-based and reliable, as advised by Ben.

‍
{| class="wikitable"
|
=== ✅ Action Items ===

* Jack meeting with Max Shulz to discuss further collaboration ideas
* Ben to add list of drugs of interest to lifespan extension tool database
* Ben to add relevant sources to the database for content writers - E.g. ITP
* Assign content writers / other team members with science background to assist with completing data for the life extension tool
* Andreas to create Discord channel for meeting minutes
* Communicate to content writers the new deliverables of expanding the glossary associated with the ‘pillar’ articles
|}